(54) Title: POLYNUCLEOTIDES, POLYPEPTIDES EXPRESSED BY THE POLYNUCLEOTIDES AND METHODS FOR THEIR USE

(57) Abstract: Novel polynucleotides including partial and extended sequences, and open reading frames, are provided, together with probes and primers, DNA constructs comprising the polynucleotides, biological materials and organisms incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for using the polynucleotides and polypeptides.

POLYNUCLEOTIDES, POLYPEPTIDES EXPRESSED BY THE
POLYNUCLEOTIDES AND METHODS FOR THEIR USE

5 Technical Field of the Invention

This invention relates to polynucleotides believed to be novel, including partial, extended and full length sequences, as well as probes and primers, genetic constructs comprising the polynucleotides, biological materials incorporating the polynucleotides, polypeptides expressed by the polynucleotides, and methods for

10 using the polynucleotides and polypeptides.

Background of the Invention

Sequencing of the genomes, or portions of the genomes, of numerous biological materials, including humans, animals, microorganisms and various

15 plant varieties, has been and is being carried out on a large scale. Polynucleotides identified using sequencing techniques may be partial or full-length genes, and may contain open reading frames, or portions of open reading frames, that encode polypeptides. Putative polypeptides may be determined based on polynucleotide sequences. The sequencing data relating to polynucleotides thus represents

20 valuable and useful information.

Polynucleotides may be analyzed for various degrees of novelty by comparing identified sequences to sequences published in various public domain databases, such as EMBL. Newly identified polynucleotides and putative polypeptides may also be compared to polynucleotides and polypeptides

25 contained in public domain information to ascertain homology to known polynucleotides and polypeptides. In this way, the degree of similarity, identity or homology of polynucleotides and polypeptides of unknown function may be determined relative to polynucleotides and polypeptides having known functions.

Information relating to the sequences of isolated polynucleotides may be

30 used in a variety of ways. Specified polynucleotides having a particular sequence may be isolated, or synthesized, for use in *in vivo* or *in vitro* experimentation as

probes or primers. Alternatively, collections of sequences of isolated polynucleotides may be stored using magnetic or optical storage medium, and analyzed or manipulated using computer hardware and software, as well as other types of tools.

5

Summary of the Invention

The present invention relates to polynucleotide sequences identified in the attached Sequence Listing as SEQ ID NOS: 1-35, variants of those sequences, extended sequences comprising the sequences set out in SEQ ID NOS: 1-35 and

10   their variants, probes and primers corresponding to the sequences set out in SEQ ID NOS: 1-35 and their variants, polynucleotides comprising at least a specified number of contiguous residues of any of the polynucleotides identified as SEQ ID NOS: 1-35 (x-mers), and extended sequences comprising portions of the sequences set out in SEQ ID NOS: 1-35, all of which are referred to herein,

15   collectively, as "polynucleotides of the present invention."

The polynucleotide sequences identified as SEQ ID NOS: 1-35 were derived from mammalian sources, namely, from mouse airways induced eosinophilia, rat dermal papilla and mouse stromal cells. Some of the polynucleotides of the present invention are "partial" sequences, in that they do

20   not represent a full-length gene encoding a full-length polypeptide. Such partial sequences may be extended by further analyzing and sequencing the EST clones from which the sequences were obtained, or by analyzing and sequencing various DNA libraries (e.g. cDNA or genomic) using primers and/or probes and well known hybridization and/or PCR techniques. The partial sequences identified as

25   SEQ ID NOS: 1-35 may thus be extended until an open reading frame encoding a polypeptide, a full-length polynucleotide and/or gene capable of expressing a polypeptide, or another useful portion of the genome is identified. Such extended sequences, including full-length polynucleotides and genes, are described as "corresponding to" a sequence identified as one of the sequences of SEQ ID NOS:

30   1-35 or a variant thereof, or a portion of one of the sequences of SEQ ID NOS: 1-35 or a variant thereof, when the extended polynucleotide comprises an identified

sequence or its variant, or an identified contiguous portion (x-mer) of one of the sequences of SEQ ID NOS: 1-35 or a variant thereof.

The polynucleotides identified as SEQ ID NOS: 1-35 were isolated from mouse and rat cDNA clones and represent sequences that are expressed in the tissue from which the cDNA was prepared. The sequence information may be used to isolate or synthesize expressible DNA molecules, such as open reading frames or full-length genes, that can then be used as expressible or otherwise functional DNA in transgenic mammals and other organisms. Similarly, RNA sequences, reverse sequences, complementary sequences, anti-sense sequences and the like, corresponding to the polynucleotides of the present invention, may be routinely ascertained and obtained using the cDNA sequences identified as SEQ ID NOS: 1-35.

In a first aspect, the present invention provides isolated polynucleotide sequences comprising a polynucleotide selected from the group consisting of: (a) sequences recited in SEQ ID NO: 1-35; (b) complements of the sequences recited in SEQ ID NO: 1-35; (c) reverse complements of the sequences recited in SEQ ID NO: 1-35; (d) reverse sequences of the sequences recited in SEQ ID NO: 1-35; (e) sequences having either 40%, 60%, 75% or 90% identical nucleotides, as defined herein, to a sequence of (a) – (d); probes and primers corresponding to the sequences set out in SEQ ID NO: 1-35; polynucleotides comprising at least a specified number of contiguous residues of any of the polynucleotides identified as SEQ ID NO: 1-35; and extended sequences comprising portions of the sequences set out in SEQ ID NO: 1-35; all of which are referred to herein as "polynucleotides of the present invention". The present invention also provides isolated polypeptide sequences identified in the attached Sequence Listing as SEQ. ID NO: 36-65; polypeptide variants of those sequences; and polypeptides comprising the isolated polypeptide sequences and variants of those sequences.

In another aspect, the present invention provides genetic constructs comprising a polynucleotide of the present invention, either alone, or in combination with one or more additional polynucleotides of the present invention,

or in combination with one or more known polynucleotides, together with cells and target organisms comprising such constructs.

The polynucleotides identified as SEQ ID NOS: 1-35 may contain open reading frames ("ORFs") or partial open reading frames encoding polypeptides.
5   Additionally, open reading frames encoding polypeptides may be identified in extended or full-length sequences corresponding to the sequences set out as SEQ ID NOS: 1-35. Open reading frames may be identified using techniques that are well known in the art. These techniques include, for example, analysis for the location of known start and stop codons, most likely reading frame identification
10   based on codon frequencies, etc. Suitable tools and software for ORF analysis are available, for example, on the Internet at http://www.ncbi.nlm.nih.gov/gorf/gorf.html. Open reading frames and portions of open reading frames may be identified in the polynucleotides of the present invention. Once a partial open reading frame is identified, the polynucleotide may
15   be extended in the area of the partial open reading frame using techniques that are well known in the art until the polynucleotide for the full open reading frame is identified. Thus, polynucleotides and open reading frames encoding polypeptides may be identified using the polynucleotides of the present invention.

Once open reading frames are identified in the polynucleotides of the
20   present invention, the open reading frames may be isolated and/or synthesized. Expressible DNA constructs may then be constructed that comprise the open reading frames and suitable promoters, initiators, terminators, etc., which are well known in the art. Such DNA constructs may be introduced into a host cell to express the polypeptide encoded by the open reading frame. Suitable host cells
25   may include various prokaryotic and eukaryotic cells.

Polypeptides encoded by the polynucleotides of the present invention may be expressed and used in various assays to determine their biological activity. Such polypeptides may be used to raise antibodies, to isolate corresponding interacting proteins or other compounds, and to quantitatively determine levels of
30   interacting proteins or other compounds.

In another aspect, the present invention provides isolated polypeptides encoded, or partially encoded, by the above polynucleotides. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins, wherein the amino acid residues are linked by covalent peptide

5   bonds. The term "polypeptide encoded by a polynucleotide" as used herein, includes polypeptides encoded by a polynucleotide that comprises an isolated polynucleotide sequence or variant provided herein. Polypeptides of the present invention may be naturally purified products, or may be produced partially or wholly using recombinant techniques. Such polypeptides may be glycosylated

10   with bacterial, fungal, mammalian or other eukaryotic carbohydrates or may be non-glycosylated. In specific embodiments, the inventive polypeptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 36-65.

Polypeptides of the present invention may be produced recombinantly by inserting a polynucleotide sequence that encodes the polypeptide into a genetic

15   construct and expressing the polypeptide in an appropriate host. Any of a variety of genetic constructs known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with a genetic construct containing a polynucleotide that encodes a recombinant polypeptide. Suitable host cells include prokaryotes,

20   yeast, and higher eukaryotic cells. Preferably, the host cells employed are *Escherichia coli*, insect, yeast, or a mammalian cell line such as COS or CHO. The polynucleotide sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof.

25   In a related aspect, polypeptides are provided that comprise at least a functional portion of a polypeptide having an amino acid sequence encoded by a polynucleotide of the present invention. As used herein, the "functional portion" of a polypeptide is that portion which contains the active site essential for affecting the function of the polypeptide, for example, the portion of the molecule

30   that is capable of binding one or more reactants. The active site may be made up

of separate portions present on one or more polypeptide chains and will generally exhibit high binding affinity.

Functional portions of a polypeptide may be identified by first preparing fragments of the polypeptide by either chemical or enzymatic digestion of the polypeptide, or by mutation analysis of the polynucleotide that encodes the polypeptide and subsequent expression of the resulting mutant polypeptides. The polypeptide fragments or mutant polypeptides are then tested to determine which portions retain biological activity, using, for example, the representative assays provided below.

Portions and other variants of the inventive polypeptides may also be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase. synthesis method, where amino acids are sequentially added to a growing amino acid chain. *See* Merrifield, *J. Am. Chem. Soc.* 85:2149-2154, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems, Inc. (Foster City, California), and may be operated according to the manufacturer's instructions. Variants of a native polypeptide may be prepared using standard mutagenesis techniques, such as oligonucleotide-directed, site-specific mutagenesis (Kunkel, *Proc. Natl. Acad. Sci. USA* 82:488-492, 1985). Sections of polynucleotide sequence may also be removed using standard techniques to permit preparation of truncated polypeptides.

In general, the polypeptides disclosed herein are prepared in an isolated, substantially pure, form. Preferably, the polypeptides are at least about 80% pure, more preferably at least about 90% pure, and most preferably at least about 99%. pure. In certain embodiments, described in detail below, the isolated polypeptides are incorporated into pharmaceutical compositions or vaccines.

The present invention also contemplates methods for modulating the polynucleotide and/or polypeptide content and composition of an organism, such methods involving stably incorporating into the genome of the organism a construct containing DNA of the present invention. In one embodiment, the target organism is a mammal, preferably a human, for example for human gene therapy. In a related aspect, a method for producing an organism having an altered genotype or phenotype is provided, the method comprising transforming a cell with a DNA construct of the present invention to provide a transgenic cell, and cultivating the transgenic cell under conditions conducive to regeneration and mature organism growth.

The isolated polynucleotides of the present invention have utility in genome mapping, in physical mapping, and in positional cloning of genes. Additionally, the polynucleotide sequences identified as SEQ ID NOS: 1-35 and their variants may be used to design oligonucleotide probes and primers. Oligonucleotide probes and primers have sequences that are substantially complementary to the polynucleotide of interest over a certain portion of the polynucleotide. Oligonucleotide probes designed using the polynucleotides of the present invention may be used to detect the presence and examine the expression patterns of genes in any organism having sufficiently similar DNA and RNA sequences in their cells using techniques that are well known in the art, such as slot blot DNA hybridization techniques. Oligonucleotide primers designed using the polynucleotides of the present invention may be used for PCR amplifications. Oligonucleotide probes and primers designed using the polynucleotides of the present invention may also be used in connection with various microarray technologies, including the microarray technology of Affymetrix (Santa Clara, CA).

The polynucleotides of the present invention may also be used to tag or identify an organism or reproductive material therefrom. Such tagging may be accomplished, for example, by stably introducing a non-disruptive non-functional heterologous polynucleotide identifier into an organism, the polynucleotide comprising one of the polynucleotides of the present invention.

<u>Detailed Description</u>

Polynucleotides were isolated by high throughput sequencing of cDNA libraries prepared from mouse airway-induced eosinophilia, rat dermal papilla and mouse stromal cells as described below, in Example 1. Isolated polynucleotides

5   of the present invention include the polynucleotides identified as SEQ ID NOS: 1-. 35; isolated polynucleotides comprising a polynucleotide sequence selected from the group consisting of SEQ ID NOS: 1-35; isolated polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of the polynucleotides identified as SEQ ID NOS: 1-35; polynucleotides complementary

10   to any of the above polynucleotides; anti-sense sequences corresponding to any of the above polynucleotides; and variants of any of the above polynucleotides, as that term is described in this specification. The present invention also provides isolated polypeptide sequences identified in the attached Sequence Listing as SEQ ID NO: 36-65; polypeptide variants of those sequences; and polypeptides

15   comprising the isolated polypeptide sequences and variants of those sequences.

The correspondence of isolated polynucleotides encoding isolated polypeptides of the present invention, and the functionality of the polypeptides, are shown, below, in Table 1.

20   <u>Table 1</u>

SEQ ID NO Poly-nucleotides	SEQ ID NO Poly-peptides	Activity Category	Functionality
1	36.	Secretory molecule	Hypothetical 131.1 kDa protein
2	37	Secretory molecule/cytokine/ cell signaling	ZCYTO7 belongs to a family of IL-17-related cytokines differing in patterns of expression and proinflammatory responses that may be transduced through a cognate set of cell surface receptors. IL-17 is a T cell-derived cytokine that may play an important role in the initiation or maintenance of the proinflammatory response. Whereas expression of IL-17 is restricted to activated T cells, the IL-17 receptor is found to be

			widely expressed, a finding consistent with the pleiotropic activities of IL-17.
3	38	Secretory molecule	Novel
4	39	Receptor/cytokine/ cell signaling	Tumor endothelial marker 1 precursor
5	40	Secretory molecule	ERO1-L (ERO1-like protein) is involved in oxidative endoplasmic reticulum (ER) protein folding in mammalian cells. Oxidizing conditions must be maintained in the ER to allow the formation of disulfide bonds in secretory proteins. A family of conserved genes, termed ERO for ER oxidoreductins, plays a key role in this process. ERO1-L is a type II integral membrane protein.
6	41	Secretory molecule	Novel
7	42	Receptor/transcriptio n factor	EMR2 is an EGF-like module that is part of the epidermal growth factor (EGF)-TM7 proteins, which also include EMR1, (EGF-like molecule containing mucin-like hormone receptor 1) F4/80, and CD97. These proteins constitute a recently defined class B GPCR subfamily and are predominantly expressed on leukocytes. These molecules possess N-terminal EGF-like domains coupled to a seven-span transmembrane (7TM) moiety via a mucin-like spacer domain. EMR2 contains a total of five tandem EGF-like domains and expresses similar protein isoforms consisting of various numbers of EGF-like domains as a result of alternative RNA splicing. EMR2 share many characteristics with CD97, including highly homologous EGF-like domains and identical gene organization, indicating that both genes are the products of a recent gene duplication event. Both EMR2 and CD97 are highly expressed in immune tissues; however, unlike

			CD97, which is ubiquitously expressed in most cell types, EMR2 expression is restricted to monocytes, macrophages
8	43	Secretory molecule/ cell structure/motility, extracellular matrix	Bone/cartilage proteoglycan I (BGN) is also known as biglycan or PG-S1. BGN is found in the extracellular matrices of several connective tissues, especially in articular cartilages. The two glycosaminoglycan chains attached to BGN can be either chondroitin sulfate or dermatan sulfate. BGN belongs to the small interstitial proteoglycans family. BGN is a small leucine-rich proteoglycan and is a nonfibrillar extracellular matrix component with functions that include the positive regulation of bone formation. It is synthesized as a precursor with an NH(2)-terminal propeptide that is cleaved to yield the mature form found in vertebrate tissues. Bone morphogenetic protein-1 (BMP-1) cleaves proBGN at a single site, removing the propeptide and producing BGN. Soluble BGN purified from rat thymic myoid cells had hemopoietic activity capable of inducing preferential growth and differentiation of monocytic lineage cells from various hemopoietic sources, including brain microglial cells. The haemopoietic BGN plays an important role in generating brain-specific circumstances for development of microglial/monocytic cells
9	44	Secretory molecule	Tubulointerstitial nephritis antigen (TIN-ag) is a basement membrane glycoprotein reactive with autoantibodies in some forms of immunologically mediated human tubulointerstitial nephritis. TIN1 and TIN2 are alternatively spliced products of the TIN-Ag gene. The

			open reading frames of TIN1 and TIN2 indicates the presence of a signal peptide and putative pre-propeptide and both forms contain putative calcium-binding sites. TIN1 additionally contains a characteristic laminin-like epidermal growth factor (EGF) motif and significant homology within the carboxy terminus with the cysteine proteinase family of enzymes. The EGF motif bears important similarities in the positions of cysteines with two motifs in the propeptide of von Willebrand factor. The EGF motif and part of the region that is homologous with the cysteine proteinase family are removed from the TIN2 cDNA. The rest of the TIN1 and TIN2 sequences are identical. TIN-ag is expressed mainly in the kidney and in the intestinal epithelium.
10		Receptor-like molecule	Novel
11	45	Secretory molecule/ gene/protein expression, RNA synthesis, transcription factors	Toso is a cell surface, specific regulator of Fas-induced apoptosis in T cells. Fas is a surface receptor that can transmit signals for apoptosis. Toso is expressed in lymphoid cells and expression is enhanced after cell-specific activation processes in T cells. Toso appeared limited to inhibition of apoptosis mediated by members of the TNF receptor family and was capable of inhibiting T cell self-killing induced by TCR activation processes that up-regulate Fas ligand. Toso inhibits caspase-8 processing, the most upstream caspase activity in Fas-mediated signaling, potentially through activation of cFLIP. Toso therefore serves as a novel regulator of Fas-mediated apoptosis and may act as a regulator of cell fate in T cells and

| 12 | 46 | Secretory molecule/ gene/protein expression, RNA synthesis, transcription factors | Surface glycoprotein CD59 is a phosphatidyl-inositol-glycan-anchored glycoprotein involved in T-cell activation and restriction of complement-mediated lysis. It is also known as protectin, and is ubiquitously expressed on benign and malignant cells. CD59 inhibits complement (C)-mediated lysis of target cells by preventing the formation of the membrane attack complex, in the terminal step of C-ctivation. Recent experimental evidence demonstrates that CD59 is the main restriction factor of C-mediated lysis of malignant cells of different histotypes. Additionally, a soluble form of CD59, that retains its anchoring ability and functional properties, has been identified in body fluids and in culture supernatants of different malignant cells. CD59 may protect neoplastic cells from C-mediated lysis, contributing to their escape from innate C-control and to tumor progression. The expression of CD59 by neoplastic cells may contribute to impair the therapeutic efficacy of C-activating monoclonal antibodies (mAb) directed to tumor-associated antigens. CD59 can be utilized to improve the therapeutic efficacy of clinical approaches of humoral immunotherapy with C-activating mAb in human malignancies. |
| 13 | 47 | Secretory molecules/cell or organism defense, homeostasis, detoxification | Cytochrome B561 (cyb561) is a secretory vesicle-specific electron transport protein unique to neuroendocrine secretory vesicles. It binds two heme groups non-covalently and is an integral membrane protein. It acts as an electron channel and mediates |

(top of table, continued) other hematopoietic lineages.

			equilibration of ascorbate-semidehydroascorbate inside the secretory vesicle with the ascorbate redox pair in the cytoplasm. The role for this function is to regenerate ascorbate inside the secretory vesicle for use by monooxygenases. The secretory vesicles contain catecholamines and amidated peptides. Cyb561 belongs to the eukaryotic b561 family.
14	48	Secretory molecule	Novel
15	49	Receptor-like molecule/ gene or protein expression, RNA synthesis, transcription factor	High affinity immunoglobulin epsilon receptor beta-subunit (FCER1) is also known as IgE Fc receptor, beta-subunit, FCER1b or FCE1b. FCER1 binds to the Fc region of immunoglobulins epsilon and is a high affinity receptor. FCER1 plays a role in initiating the allergic response where binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators, such as histamine. FCER1 is responsible for the manifestations of allergy and induces the secretion of important lymphokines. It functions as a tetramer consisting of an alpha chain, a beta chain, and two disulfide-linked gamma chains and is an integral membrane protein. Variants of the FCER1B gene have been identified, which are associated with an increased risk of developing atopy and bronchial asthma. Atopic dermatitis is a common skin disease frequently associated with allergic disorders such as allergic rhinitis and asthma.
16	50	Receptor-like molecule	Hypothetical 10.3 kDa protein
17	51	Secretory molecule/antigen processing	Lysosomal thiol reductase IP30 catalyzes disulfide bond reduction both *in vitro* and *in vivo* and is optimally active at acidic pH. IP30

● ●

			is important in disulfide bond reduction of proteins delivered to MHC class II-containing compartments and consequently in antigen processing. IP30 can be mediated by multiple lysosomal proteases. Proteins internalized into the endocytic pathway are usually degraded. Efficient proteolysis requires denaturation, induced by acidic conditions within lysosomes, and reduction of inter- and intrachain disulfide bonds. The active site, determined by mutagenesis, consists of a pair of cysteine residues separated by two amino acids, similar to other enzymes of the thioredoxin family.
18		Receptor-like molecule	RNA binding protein.
19	52	Secretory molecule/cellular	Notch4-like protein (ZNEU1) is part of the NOTCH4 family that encodes receptors responsible for cell fate decisions during development. These Notch receptors and their ligands, Delta and Jagged, have been implicated in several diseases. When truncated, constitutively active mutant forms of the Notch receptor appear to be involved in T-cell leukemia, mammary carcinomas and a tumorous germline phenotype. Notch4 genes are expressed specifically in endothelial cells.
20	53	Secretory molecule	Novel
21	54	Secretory molecule/transporter	Serotransferrin (siderophilin) (Tf) or beta-1-metal binding globulin is part of the transferrin family. Transferrins are iron binding transport proteins which can bind two atoms of ferric iron in association with the binding of an anion, usually bicarbonate. Tf is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and

			utilization. Serum transferrin also has a further role in stimulating cell proliferation. Tf gene expression is modulated by vitamin A, testosterone, and peptide hormones.
22	55	Secretory molecule/ gene or protein expression, RNA synthesis, transcription factor	Insulin-like growth factor binding protein 5 protease (IGFBP-5) modulates the effects of insulin growth factors (IGFs) on cells. IGFBP-5 is synthesized by smooth muxcle cells and binds to the extracellular matrix. It is also secreted into conditioned medium of cultured cells and is cleaved into fragments by a concomitantly produced protease. These fragments have reduced affinity for the IGFs. IGFBP-5 protease belongs to a family of serine-metallo proteases.
23	56	Secretory molecule/cellular development	Major epididymis-specific protein E4 is also known as epididymal protein BE-20. It belongs to WAP-type 'four-disulfide core' family and plays a role in the maturation of spermatozoa during its movement through the epididymis and the capacity of sperm to fertilize ova. Expression of E4 was located to the epithelial cells of the cauda epididymis and proximal segment of the ductus deferens by in situ hybridization. No expression was found in sections of the corpus and caput epididymis, testis, and liver.
24		Secretory molecule/cell signaling	TNFR-related death receptor-6 DR6 contains an extracellular region containing varying numbers of cysteine-rich domains and an intracellular region that contains the death domain. Death receptors are activated in a ligand-dependent or independent manner and transduce apoptotic signals via their respective intracellular death domains.
25	57	Receptor-like molecule	Novel

26	58	Secretory molecule/regulation	Channel inducing factor precursor (CHIF) or corticosteroid-induced protein induces a potassium channel when expressed in *Xenopus* oocytes and activates endogenous oocyte transport proteins. It is a type I membrane protein selectively present in the distal parts of the nephron (medullary and papillary collecting ducts and end portions of cortical collecting tubule) and in the epithelial cells of the distal colon. No expression is found in renal proximal tubule, loop of Henle and distal tubule, proximal colon, small intestine, lung, choroid plexus, salivary glands, or brain. CHIF belongs to the ATP1G1 /PLM / Mat-8 family and exhibits significant homologies with proteins that are putatively regulatory (phospholemman, gamma-subunit of Na(+)-K(+)-ATPase, Mat-8).
27	59	Secretory molecule	Hepatocellular carcinoma-associated antigen 112.
28	60	Receptor-like molecule/homeostasis	Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is a major receptor for hyaluronan (HA) on the lymph vessel wall molecule that binds both soluble and immobilized HA. LYVE-1 plays a role in the control of the HA pathway. The extracellular matrix glycosaminoglycan hyaluronan (HA) is an abundant component of skin and mesenchymal tissues where it facilitates cell migration during wound healing, inflammation, and embryonic morphogenesis. Both during normal tissue homeostasis and particularly after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver. LYVE-1 is similar to the

			CD44 HA receptor, but in contrast to CD44, LYVE-1 colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels.
29	61	Receptor-like molecule/cell signaling	G protein-coupled receptor GPR35 is an integral membrane protein that belongs to family 1 of G-protein coupled receptors (GPRC). The GPCR family shares a structural motif of seven transmembrane segments with large numbers of conserved residues in those regions.
30	62	Receptor-like molecule	Tumor-associated glycoprotein E4 is also known as Taa1 or Tage4 and belongs to the immunoglobulin superfamily. This family contains cell adhesion molecules which have wide-ranging functions and mediate a variety of homotypic and heterotypic cellular interactions playing a general role in cell surface recognition. The Tage4 gene product is closely related to the hepatocellular carcinoma antigen TuAg.1. Tage4 is a glycoprotein expressed at the surface of colon carcinoma cell lines, but at a very low level in normal adult colon and lung tissue and not in normal tissues tested.
31	63	Secretory molecule	Hypothetical 28.6 kDa protein is also known as plunc, for palate, lung, and nasal epithelium clone. Expression of plunc is associated with the palate, nasal septum, and nasal conchae. It is also expressed strongly in the trachea and bronchi of the adult lung. No significant homologies with known genes were observed at the nucleotide level and limited amino acid homology with two salivary gland-specific proteins was noted. The amino acid sequence revealed consensus sequences for N-glycosylation, protein kinase C and

			casein kinase phosphorylation, as well as a leucine zipper. In addition, an unique amino acid sequence repeat sequence is located near the amino-terminal portion of the protein.
32	64	Secretory molecule	Claudin-18 (Cldn18) is a component of tight junction (TJ) strands and belongs to the claudin family. Claudins are integral membrane protein component of tight junctions, a structure controlling cell-to-cell adhesion and, consequently, regulating paracellular and transcellular transport of solutes across epithelia and endothelia. The claudin family also includes occludin and 17 other distinct claudins. Claudin family members are tetra-span transmembrane proteins that are localized in cell-specific TJs. In multicellular organisms, various compositionally distinct fluid compartments are established by epithelial and endothelial cellular sheets. For these cells to function as barriers, TJs are considered to create a primary barrier for the diffusion of solutes through the paracellular pathway. Claudins are therefore responsible for TJ-specific obliteration of the intercellular space.
33		Secretory molecule	Glutamine repeat protein 1 (GRP-1) contains simple tandem repeats of the trinucleotide sequence CAG that encode homopolymeric stretches of glutamine. Although polyglutamine has been identified in diverse proteins, it is present predominantly in transcription factors. Greater than two-thirds of GRP-1 are only two amino acids, namely glutamine (50%) and histidine (18%). There are four polyglutamine motifs interspersed with histidine-rich regions. There is also a putative

			nuclear localization signal flanked by sites for possible serine phosphorylation. GRP-1 mRNA was expressed constitutively in some macrophage cell lines and B and T cell lines. Interferon-gamma or lipopolysaccharide augmented GRP-1 mRNA expression in the mouse macrophage cell line ANA-1. Because polyglutamine motifs can cause protein oligomerization and can function as transcriptional activation domains, GRP-1 is a transcription factor associated with interferon-gamma- or lipopolysaccharide-induced activation of macrophages.
34		Secretory molecule	Alpha-1 collagen
35	65	Receptor-like molecule/Cell signaling	Gdnf family receptor alpha 4, transmembrane isoform (Gfra4) is a members of the Gdnf protein family that signal through receptors consisting of a GPI-linked GFRalpha subunit and the transmembrane tyrosine kinase Ret. Gfra4 is expressed in many tissues, including nervous system, in which intron retention leads to a putative intracellular or secreted GFRalpha4 protein. Efficient splicing occurs only in thyroid, parathyroid, and pituitary and less in adrenal glands. A splice form that leads to a GPI-linked GFRalpha4 receptor is expressed in juvenile thyroid and parathyroid glands. In newborn and mature thyroid as well as in parathyroid and pituitary glands major transcripts encode for a putative transmembrane isoform of GFRalpha4. GFRalpha4 expression may restrict the inherited cancer syndrome multiple endocrine neoplasia type 2, associated with mutations in RET, to these cells.

The word "polynucleotide(s)," as used herein, means a polymeric collection of nucleotides and includes DNA and corresponding RNA molecules and both single and double stranded molecules, including HnRNA and mRNA molecules, sense and anti-sense strands of DNA and RNA molecules, and

5   comprehends cDNA, genomic DNA, and wholly or partially synthesized polynucleotides. An HnRNA molecule contains introns and "corresponds to" a DNA molecule in a generally one-to-one manner. An mRNA molecule "corresponds to" an HnRNA and DNA molecule from which the introns have been excised. A polynucleotide of the present invention may be an entire gene, or

10 any portion thereof. A gene is a DNA sequence which codes for a functional protein or RNA molecule. Operable anti-sense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all operable anti-sense fragments. Anti-sense polynucleotides and techniques involving anti-sense polynucleotides are well

15 known in the art and are described, for example, in Robinson-Benion et al., Methods in Enzymol. 254(23): 363-375, 1995 and Kawasaki et al., Artific. Organs 20 (8): 836-848, 1996.

Identification of genomic DNA and heterologous species DNA can be accomplished by standard DNA/DNA hybridization techniques, under

20 appropriately stringent conditions, using all or part of a cDNA sequence as a probe to screen an appropriate library. Alternatively, PCR techniques using oligonucleotide primers that are designed based on known genomic DNA, cDNA and/or protein sequences can be used to amplify and identify genomic and cDNA sequences. Synthetic DNA corresponding to the identified sequences and variants

25 may be produced by conventional synthesis methods. All of the polynucleotides described herein are isolated and purified, as those terms are commonly used in the art.

As used herein, the term "oligonucleotide" refers to a relatively short segment of a polynucleotide sequence, generally comprising between 6 and 60

30 nucleotides, and comprehends both probes for use in hybridization assays and primers for use in the amplification of DNA by polymerase chain reaction.

As used herein, the term "*x*-mer," with reference to a specific value of "*x*," refers to a polynucleotide comprising at least a specified number ("*x*") of contiguous residues of any of the polynucleotides identified as SEQ ID NOS: 1-35. The value of *x* may be from about 20 to about 600, depending upon the specific sequence.

As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins, wherein amino acid residues are linked by covalent peptide bonds. Polypeptides of the present invention may be naturally purified products, or may be produced partially or wholly using recombinant techniques. Such polypeptides may be glycosylated with mammalian or other eukaryotic carbohydrates or may be non-glycosylated.

According to one embodiment, "variants" of the polynucleotides of the present invention, including the polynucleotides set forth as SEQ ID NOS: 1-35, as that term is used herein, comprehends polynucleotides producing an "E" value of 0.01 or less, as described below, or having at least a specified percentage identity to a polynucleotide of the present invention, as described below. Polynucleotide variants of the present invention may be naturally occurring allelic variants, or non-naturally occurring variants.

Polynucleotide and polypeptide sequences may be aligned, and percentages of identical residues in a specified region may be determined against another polynucleotide or polypeptide, using computer algorithms that are publicly available. Two exemplary algorithms for aligning and identifying the similarity of polynucleotide sequences are the BLASTN and FASTA algorithms. Polynucleotides may also be analyzed using the BLASTX algorithm, which compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database. The percentage identity of polypeptide sequences may be examined using the BLASTP algorithm. The BLASTN, BLASTP and BLASTX algorithms are available on the NCBI anonymous FTP server (ftp://ncbi.nlm.nih.gov) under /blast/executables/ and are available from the National Center for Biotechnology Information (NCBI), National Library of Medicine, Building 38A, Room 8N805, Bethesda, MD 20894,

USA. The BLASTN algorithm Version 2.0.11 [Jan-20-2000], set to the parameters described below, is preferred for use in the determination of polynucleotide variants according to the present invention. The BLASTP algorithm, set to the parameters described below, is preferred for use in the determination of polypeptide variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN, BLASTP and BLASTX, is described at NCBI's website at URL http://www.ncbi.nlm.nih.gov/BLAST/newblast.html and in the publication of Altschul, *et al., Nucleic Acids Res.* 25: 3389-3402, 1997.

The FASTA and FASTX algorithms are available on the Internet at the ftp site ftp://ftp.virginia.edu/pub/, and from the University of Virginia by contacting David Hudson, Vice Provost for Research, University of Virginia, P.O. Box 9025, Charlottesville, VA 22906-9025, USA. The FASTA algorithm, set to the default parameters described in the documentation and distributed with the algorithm, may be used in the determination of polynucleotide variants. The readme files for FASTA and FASTX Version 1.0x that are distributed with the algorithms describe the use of the algorithms and describe the default parameters. The use of the FASTA and FASTX algorithms is described in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444-2448, 1988; and Pearson, *Methods in Enzymol.* 183:63-98, 1990. The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity: Unix running command with default parameter values thus: blastall -p blastn -d embldb -e 10 -G 0 -E 0 -r 1 -v 30 -b 30 -i queryseq –o results; the Parameters are : -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -r Reward for a nucleotide match (BLASTN only) [Integer]; -v Number of one-line descriptions (V) [Integer]; -b Number of alignments to show (B) [Integer]; -i Query File [File In]; -o BLAST report Output File [File Out] Optional.

The "hits" to one or more database sequences by a queried sequence produced by BLASTN or FASTA or a similar algorithm align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally

5   represent an overlap over only a fraction of the sequence length of the queried sequence.

The BLASTN and FASTA algorithms produce "Expect" values for alignments. The Expect value (E) indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a

10   database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database, such as the preferred EMBL database, indicates true similarity. For example, an E value of 0.1 assigned to a hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a

15   similar score simply by chance. The aligned and matched portions of the sequences, then, have a probability of 90% of being the same by this criterion. For sequences having an E value of 0.01 or less over aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN or FASTA algorithm.

20   According to one embodiment, "variant" polynucleotides, with reference to each of the polynucleotides of the present invention, preferably comprise sequences having the same number or fewer nucleic acids than each of the polynucleotides of the present invention and producing an E value of 0.01 or less when compared to the polynucleotide of the present invention. That is, a variant

25   polynucleotide is any sequence that has at least a 99% probability of being the same as the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters. According to a preferred embodiment, a variant polynucleotide is a sequence having the same number or fewer nucleic acids than a polynucleotide of

30   the present invention that has at least a 99% probability of being the same as the

polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the default parameters.

Alternatively, variant polynucleotides of the present invention may comprise a sequence exhibiting at least about 40%, more preferably at least about 60%, more preferably yet at least about 75%, and most preferably at least about 90% similarity to a polynucleotide of the present invention, determined as described below. The percentage similarity is determined by aligning sequences using one of the BLASTN or FASTA algorithms, set at default parameters, and identifying the number of identical nucleic acids over the best aligned portion; dividing the number of identical nucleic acids by the total number of nucleic acids of the polynucleotide of the present invention; and then multiplying by 100 to determine the percentage similarity. For example, a polynucleotide of the present invention having 220 nucleic acids has a hit to a polynucleotide sequence in the EMBL database having 520 nucleic acids over a stretch of 23 nucleotides in the alignment produced by the BLASTN algorithm using the default parameters. The 23 nucleotide hit includes 21 identical nucleotides, one gap and one different nucleotide. The percentage similarity of the polynucleotide of the present invention to the hit in the EMBL library is thus 21/220 times 100, or 9.5%. The polynucleotide sequence in the EMBL database is thus not a variant of a polynucleotide of the present invention.

Alternatively, variant polynucleotides of the present invention hybridize to a polynucleotide of the present invention under stringent hybridization conditions. As used herein, "stringent conditions" mean prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65°C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1X SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65°C.

The present invention also encompasses allelic variants of the disclosed sequences, together with DNA sequences that differ from the disclosed sequences but which, due to the degeneracy of the genetic code, encode a polypeptide which is the same as that encoded by a DNA sequence disclosed herein. Thus, polynucleotides comprising sequences that differ from the polynucleotide

sequences recited in SEQ ID NOS: 1-35, or complements, reverse sequences, or reverse complements of those sequences as a result of conservative substitutions are contemplated by and encompassed within the present invention. Additionally, polynucleotides comprising sequences that differ from the polynucleotide sequences recited in SEQ ID NOS: 1-35, or complements, reverse complements, or reverse sequences as a result of deletions and/or insertions totaling less than 10% of the total sequence length are also contemplated by and encompassed within the present invention.

The polynucleotides of the present invention may be isolated from various DNA libraries, or may be synthesized using techniques that are well known in the art. The polynucleotides may be synthesized, for example, using automated oligonucleotide synthesizers (e.g. Beckman Oligo 1000M DNA Synthesizer) to obtain polynucleotide segments of up to 50 or more nucleic acids. A plurality of such polynucleotide segments may then be ligated using standard DNA manipulation techniques that are well known in the art of molecular biology. One conventional and exemplary polynucleotide synthesis technique involves synthesis of a single stranded polynucleotide segment having, for example, 80 nucleic acids, and hybridizing that segment to a synthesized complementary 85 nucleic acid segment to produce a 5-nucleotide overhang. The next segment may then be synthesized in a similar fashion, with a 5-nucleotide overhang on the opposite strand. The "sticky" ends ensure proper ligation when the two portions are hybridized. In this way, a complete polynucleotide of the present invention may be synthesized entirely *in vitro*.

SEQ ID NOS: 2, 3, 5, 7-9, 11, 12, 14, 15, 17, 19-21, 23, 26, 28 and 30-32 are full-length sequences. The remaining polynucleotides are referred to as "partial" sequences, in that they may not represent the full coding portion of a gene encoding a naturally occurring polypeptide. The partial polynucleotide sequences disclosed herein may be employed to obtain the corresponding full-length genes for various species and organisms by, for example, screening DNA expression libraries using hybridization probes based on the polynucleotides of the present invention, or using PCR amplification with primers based upon the

polynucleotides of the present invention. In this way one can, using methods well known in the art, extend a polynucleotide of the present invention upstream and downstream of the corresponding mRNA, as well as identify the corresponding genomic DNA, including the promoter and enhancer regions, of the complete

5   gene.   The present invention thus comprehends isolated polynucleotides comprising a sequence identified in SEQ ID NOS: 1-35, or a variant of one of the specified sequences, that encode a functional polypeptide, including full-length genes. Such extended polynucleotides may have a length of from about 50 to about 4,000 nucleic acids or base pairs, and preferably have a length of less than

10   about 4,000 nucleic acids or base pairs, more preferably yet a length of less than about 3,000 nucleic acids or base pairs, more preferably yet a length of less than about 2,000 nucleic acids or base pairs.   Under some circumstances, extended polynucleotides of the present invention may have a length of less than about 1,800 nucleic acids or base pairs, preferably less than about 1,600 nucleic acids or

15   base pairs, more preferably less than about 1,400 nucleic acids or base pairs, more preferably yet less than about 1,200 nucleic acids or base pairs, and most preferably less than about 1,000 nucleic acids or base pairs.

Polynucleotides of the present invention comprehend polynucleotides comprising at least a specified number of contiguous residues (x-mers) of any of

20   the polynucleotides identified as SEQ ID NOS: 1-35 or their variants. According to preferred embodiments, the value of x is preferably at least 20, more preferably at least 40, more preferably yet at least 60, and most preferably at least 80. Thus, polynucleotides of the present invention include polynucleotides comprising a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer,

25   a 220-mer a 250-mer, or a 300-mer, 400-mer, 500-mer or 600-mer of a polynucleotide identified as SEQ ID NOS: 1-35 or a variant of one of the polynucleotides identified as SEQ ID NOS: 1-35.

Polynucleotide   probes   and   primers   complementary   to   and/or. corresponding to SEQ ID NOS: 1-35, and variants of those sequences, are also

30   comprehended by the present invention. Such oligonucleotide probes and primers are substantially complementary to the polynucleotide of interest.   An

oligonucleotide probe or primer is described as "corresponding to" a polynucleotide of the present invention, including one of the sequences set out as SEQ ID NOS: 1-35 or a variant, if the oligonucleotide probe or primer, or its complement, is contained within one of the sequences set out as SEQ ID NOS: 1-

5   35 or a variant of one of the specified sequences.

Two single stranded sequences are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared using, for example, the BLAST algorithm as described above, with the appropriate nucleotide insertions and/or deletions, pair with at least 80%, preferably at least

10   90% to 95%, and more preferably at least 98% to 100%, of the nucleotides of the other strand. Alternatively, substantial complementarity exists when a first DNA strand will selectively hybridize to a second DNA strand under stringent hybridization conditions. Stringent hybridization conditions for determining complementarity include salt conditions of less than about 1 M, more usually less

15   than about 500 mM and preferably less than about 200 mM. Hybridization temperatures can be as low as 5°C, but are generally greater than about 22°C, more preferably greater than about 30°C and most preferably greater than about 37°C. Longer DNA fragments may require higher hybridization temperatures for specific hybridization. Since the stringency of hybridization may be affected by

20   other factors such as probe composition, presence of organic solvents and extent of base mismatching, the combination of parameters is more important than the absolute measure of any one alone. The DNA from plants or samples or products containing plant material can be either genomic DNA or DNA derived by preparing cDNA from the RNA present in the sample.

25   In addition to DNA-DNA hybridization, DNA-RNA or RNA-RNA hybridization assays are also possible. In the case of DNA-RNA hybridization, the mRNA from expressed genes would then be detected instead of genomic DNA or cDNA derived from mRNA of the sample. In the case of RNA-RNA hybridization, RNA probes could be used. In addition, artificial analogs of DNA

30   hybridizing specifically to target sequences could also be employed.

In specific embodiments, the oligonucleotide probes and/or primers comprise at least about 6 contiguous residues, more preferably at least about 10 contiguous residues, and most preferably at least about 20 contiguous residues complementary to a polynucleotide sequence of the present invention. Probes and

5   primers of the present invention may be from about 8 to 100 base pairs in length or, preferably from about 10 to 50 base pairs in length or, more preferably from about 15 to 40 base pairs in length. The probes can be easily selected using procedures well known in the art, taking into account DNA-DNA hybridization stringencies, annealing and melting temperatures, potential for formation of loops

10   and other factors, which are well known in the art. Tools and software suitable for designing probes, and especially suitable for designing PCR primers, are available on the Internet, for example, URL http://www.horizonpress.com/pcr/. Preferred techniques for designing PCR primers are also disclosed in Dieffenbach and Dyksler, *PCR primer: a laboratory manual*. Cold Spring Harbor Laboratory

15   Press, Cold Spring Harbor, NY, 1995.

A plurality of oligonucleotide probes or primers corresponding to a polynucleotide of the present invention may be provided in a kit form. Such kits generally comprise multiple DNA or oligonucleotide probes, each probe being specific for a polynucleotide sequence. Kits of the present invention may

20   comprise one or more probes or primers corresponding to a polynucleotide of the present invention, including a polynucleotide sequence identified in SEQ ID NOS: 1-35.

In one embodiment useful for high-throughput assays, the oligonucleotide probe kits of the present invention comprise multiple probes in an array format,

25   wherein each probe is immobilized in a predefined, spatially addressable location on the surface of a solid substrate. Array formats which may be usefully employed in the present invention are disclosed, for example, in U.S. Patents No. 5,412,087, 5,545,531, and PCT Publication No. WO 95/00530, the disclosures of which are hereby incorporated by reference.

30   Oligonucleotide probes for use in the present invention may be constructed synthetically prior to immobilization on an array, using techniques well known in

the art (see, for example, *Oligonucleotide Synthesis: A Practical Approach*, Gait, ed., IRL Press, Oxford, 1984). Automated equipment for the synthesis of oligonucleotides is available commercially from such companies as Perkin Elmer/Applied Biosystems Division (Foster City, CA) and may be operated

5   according to the manufacturer's instructions. Alternatively, the probes may be constructed directly on the surface of the array using techniques taught, for example, in PCT Publication No. WO 95/00530.

The solid substrate and the surface thereof preferably form a rigid support and are generally formed from the same material. Examples of materials from

10   which the solid substrate may be constructed include polymers, plastics, resins, membranes, polysaccharides, silica or silica-based materials, carbon, metals and inorganic glasses. Synthetically prepared probes may be immobilized on the surface of the solid substrate using techniques well known in the art, such as those disclosed in U.S. Patent No. 5,412,087.

15   In one such technique, compounds having protected functional groups, such as thiols protected with photochemically removable protecting groups, are attached to the surface of the substrate. Selected regions of the surface are then irradiated with a light source, preferably a laser, to provide reactive thiol groups. This irradiation step is generally performed using a mask having apertures at

20   predefined locations using photolithographic techniques well known in the art of semiconductors. The reactive thiol groups are then incubated with the oligonucleotide probe to be immobilized. The precise conditions for incubation, such as temperature, time and pH, depend on the specific probe and can be easily determined by one of skill in the art. The surface of the substrate is washed free of

25   unbound probe and the irradiation step is repeated using a second mask having a different pattern of apertures. The surface is subsequently incubated with a second, different, probe. Each oligonucleotide probe is typically immobilized in a discrete area of less than about 1 mm^2. Preferably each discrete area is less than about 10,000 mm^2, more preferably less than about 100 mm^2. In this manner, a

30   multitude of oligonucleotide probes may be immobilized at predefined locations on the array.

The resulting array may be employed to screen for differences in organisms or samples or products containing genetic material as follows. Genomic or cDNA libraries are prepared using techniques well known in the art. The resulting target DNA is then labeled with a suitable marker, such as a

5   radiolabel, chromophore, fluorophore or chemiluminescent agent, using protocols well known for those skilled in the art. A solution of the labeled target DNA is contacted with the surface of the array and incubated for a suitable period of time.

The surface of the array is then washed free of unbound target DNA and the probes to which the target DNA hybridized are determined by identifying

10   those regions of the array to which the markers are attached. When the marker is a radiolabel, such as ^{32}P, autoradiography is employed as the detection method. In one embodiment, the marker is a fluorophore, such as fluorescein, and the location of bound target DNA is determined by means of fluorescence spectroscopy. Automated equipment for use in fluorescence scanning of oligonucleotide probe

15   arrays is available from Affymetrix, Inc. (Santa Clara, CA) and may be operated according to the manufacturer's instructions. Such equipment may be employed to determine the intensity of fluorescence at each predefined location on the array, thereby providing a measure of the amount of target DNA bound at each location. Such an assay would be able to indicate not only the absence and presence of the

20   marker probe in the target, but also the quantitative amount as well.

In this manner, oligonucleotide probe kits of the present invention may be employed to examine the presence/absence (or relative amounts in case of mixtures) of polynucleotides in different samples or products containing different materials rapidly and in a cost-effective manner.

25   Another aspect of the present invention involves collections of a plurality of polynucleotides of the present invention. A collection of a plurality of the polynucleotides of the present invention, particularly the polynucleotides identified as SEQ ID NOS: 1-35, may be recorded and/or stored on a storage medium and subsequently accessed for purposes of analysis, comparison, etc.

30   One utility for such sets of sequences is the analysis of the set, either alone or together with other sequences sets, for single nucleotide polymorphisms (SNPs)

between sequences from different tissues and/or individuals for genetic studies, mapping and fingerprinting purposes. Suitable storage media include magnetic media such as magnetic diskettes, magnetic tapes, CD-ROM storage media, optical storage media, and the like. Suitable storage media and methods for

5   recording and storing information, as well as accessing information such as polynucleotide sequences recorded on such media, are well known in the art. The polynucleotide information stored on the storage medium is preferably computer-readable and may be used for analysis and comparison of the polynucleotide information.

10   Another aspect of the present invention thus involves storage medium on which are recorded a collection of the polynucleotides of the present invention, particularly a collection of the polynucleotides identified as SEQ ID NOS: 1-35. According to one embodiment, the storage medium includes a collection of at least 20, preferably at least 50, more preferably at least 100, and most preferably

15   at least 200 of the polynucleotides of the present invention, preferably the polynucleotides identified as SEQ ID NOS: 1-35, or variants of those polynucleotides.

       Another aspect of the present invention involves a combination of polynucleotides, the combination containing at least 5, preferably at least 10, more

20   preferably at least 20, and most preferably at least 50 different polynucleotides of the present invention, including polynucleotides selected from SEQ ID NOS: 1-35, or variants of these polynucleotides.

       In another aspect, the present invention provides DNA constructs comprising, in the 5'-3' direction, a gene promoter sequence; an open reading

25   frame coding for at least a functional portion of a polypeptide encoded by a polynucleotide of the present invention; and a gene termination sequence. The open reading frame may be orientated in either a sense or antisense direction. DNA constructs comprising a non-coding region of a gene coding for an enzyme encoded by the above DNA sequences or a nucleotide sequence complementary to

30   a non-coding region, together with a gene promoter sequence and a gene termination sequence, are also provided. Preferably, the gene promoter and

termination sequences are functional in a host cell. More preferably, the gene promoter and termination sequences are common to those of the polynucleotide being introduced. Other promoter and termination sequences generally used in the art, such as the Cauliflower Mosaic Virus (CMV) promoter, with or without

5   enhancers, such as the Kozak sequence or Omega enhancer, and *Agrobacterium tumefaciens* nopalin synthase terminator may be usefully employed in the present invention. Tissue-specific promoters may be employed in order to target expression to one or more desired tissues. The DNA construct may further include a marker for the identification of transformed cells.

10   Techniques for operatively linking the components of the DNA constructs are well known in the art and include the use of synthetic linkers containing one or more restriction endonuclease sites as described, for example, by Sambrook *et al.*, *Molecular Cloning: a laboratory manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. The DNA constructs of the present invention

15   may be linked to a vector having at least one replication system, for example, *Escherichia coli*, whereby after each manipulation, the resulting construct can be cloned and sequenced and the correctness of the manipulation determined.

          Transgenic cells comprising the DNA constructs of the present invention are provided, together with organisms comprising such transgenic cells.

20   Techniques for stably incorporating DNA constructs into the genome of target organisms, such as mammals, are well known in the art and include electroporation, protoplast fusion, injection into reproductive organs, injection into immature embryos, high velocity projectile introduction and the like. The choice of technique will depend upon the target organism to be transformed. In

25   one embodiment, naked DNA is injected or delivered orally. Once the cells are transformed, cells having the DNA construct incorporated in their genome are selected. Transgenic cells may then be cultured in an appropriate medium, using techniques well known in the art.

          In yet a further aspect, the present invention provides methods for

30   modifying the level (concentration) or activity of a polypeptide in a host organism, comprising stably incorporating into the genome of the organism a

DNA construct of the present invention. The DNA constructs of the present invention may be used to transform a variety of organisms, including mammals, for example to make experimental gene knock out or transgenic animals.

Further, the polynucleotides of the present invention have particular application for use as non-disruptive tags for marking organisms, including commercially valuable animals, fish, bacteria and yeasts. DNA constructs comprising polynucleotides of the present invention may be stably introduced into an organism as heterologous, non-functional, non-disruptive tags. It is then possible to identify the origin or source of the organism at a later date by determining the presence or absence of the tag(s) in a sample of material.

Detection of the tag(s) may be accomplished using a variety of conventional techniques, and will generally involve the use of nucleic acid probes. Sensitivity in assaying the presence of probe can be usefully increased by using branched oligonucleotides, as described by Horn *et al.*, *Nucleic Acids Res.* 25(23):4842-4849, 1997, enabling to detect as few as 50 DNA molecules in the sample.

In particular, the polynucleotides of the present invention encode polypeptides that have important roles in processes such as induction of growth, differentiation of tissue-specific cells, cell migration, cell proliferation, and cell-cell interaction. These polypeptides are important in the maintenance of tissue integrity, and thus are important in processes such as wound healing. Some of these polypeptides act as modulators of immune responses, such as immunologically active polypeptides for the benefit of offspring. In addition, many polypeptides are immunologically active, making them important therapeutic targets in a whole range of disease states. Antibodies to the polypeptides of the present invention and small molecule inhibitors related to the polypeptides of the present invention may also be used for modulating immune responses and for treatment of diseases according to the present invention.

SEQ ID NOS: 1; 2; 4; 5; 6; 8; 9; 11; 12; 14; 17; 19-24; 26; 27; 31-34 encode secreted polypeptides. SEQ ID NOS: 10; 15; 16; 18; 25; 28; 30; and 35 encode polypeptides acting as receptors. SEQ ID NOS: 2; 4; 24; 29 and 35

encode polypeptides with cell signaling activity, which may be either intracellular or extracellular. Kinase genes, for example, encode polypeptides that phosphorylate specific substrates during cell-to-cell signaling. While some kinases are involved in normal metabolism and nucleotide production, others are

5 significant for altering the activity of many cellular processes through the phosphorylation of specific proteins. Polypeptides encoded by these genes are important in the transmission of intracellular signals resulting from the binding of extracellular ligands such as hormones, growth factors or cytokines to membrane-bound receptors. The utility of polynucleotides encoding kinases resides in the

10 manipulation of their signaling activities and downstream effects for the diagnosis and treatment of mammalian diseases that may be a consequence of inappropriate expression of these kinase genes.

SEQ ID NOS: 2 and 4 encode polypeptides with cytokine activity. Cytokine or growth factor polynucleotides encode polypeptides involved in

15 intercellular signaling and represent another important class of molecules. Polynucleotides encoding such genes have utility in the diagnosis and treatment of disease.

SEQ ID NOS: 7; 11; 12; 15 and 22 encode polypeptides with transcription factor activity. These polynucleotides encode polypeptides required for the control

20 of synthesis of proteins in tissue specific manner and have utility for the modification of protein synthesis for the control of disease.

SEQ ID NOS: 8 encode polypeptides acting in the extracellular matrix.

SEQ ID NOS: 11; 12; 15 and 22 encode polypeptides with RNA synthesis activities.

25 SEQ ID NO: 12 encodes a polypeptide having CD antigen activity. Such polynucleotides have utility as modulators of the composition, expression level and class of CD antigen expressed, which influence immune responses to self-antigens, neo-antigens and infectious agents.

Further exemplary specific utilities, for exemplary polynucleotides of the

30 present invention, are specified in the Table below.

SEQ ID NO:	UTILITY
2	Promoting immune response as part of a vaccine or anti-cancer treatment. Inhibitors of this molecule can be useful as anti-inflammatory treatment, e.g. for autoimmune diseases or allergies.
11; 19	Utility as a target for cancer treatment and as an immunoregulatory and anti-inflammatory molecule
12	Diagnostic for specific types of cancer and for development of an anti-cancer treatment.
15	As a target for antagonists in the treatment of diseases such as asthma and allergy.
22	Useful to inhibit or enhance the activity of the soluble molecule that binds this protein.
28	Useful to promote or block cell trafficking and therefore in the treatment as anti-inflammatory and/or vaccine adjuvant where it can promoter inflammation.
35	Useful for tissue and neural regeneration.

The following examples are offered by way of illustration and not by way of limitation.

5   Example 1

ISOLATION OF CDNA SEQUENCES FROM MAMMALIAN EXPRESSION LIBRARIES

The cDNA sequences of the present invention were obtained by high-throughput sequencing of cDNA expression libraries constructed mouse airways-
10   induced eosinophilia, rat dermal papilla and mouse stromal cells. The cDNA libraries were prepared as follows.

cDNA Library from Dermal Papilla (DEPA)

Dermal papilla cells from rat hair vibrissae (whiskers) were grown in
15   culture and the total RNA extracted from these cells using established protocols. Total RNA, isolated using TRIzol Reagent (BRL Life Technologies, Gaithersburg, MD), was used to obtain mRNA using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA), according to the manufacturer's

specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit (Stratagene).

5 *cDNA library from mouse airway-induced eosinophilia (MALA)*

Airway eosinophilia were induced in BALB/cByJ mice by administering 2 µg ovalbumin in 2 mg alum adjuvant intraperitoneally on day 0 and day 14, and subsequently 100 µg ovalbumin in 50 µl phosphate buffered saline (PBS) intranasally route on day 28. The accumulated eosinophils in the lungs were

10 detected by washing the airways of the anesthetized mice with saline, collecting the washings (broncheolar lavage or BAL), and counting the numbers of eosinophils. The mice were sacrificed and total RNA was isolated from whole lung tissue using TRIzol Reagent (BRL Life Technologies). mRNA was isolated by using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA),

15 according to the manufacturer's specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit (Stratagene).

cDNA Expression Library from Peripheral Lymph Node Stromal Cells (MLSA)

20 The peripheral axillary and brachial lymph nodes of BALB/cByJ mice with the flaky skin (*fsn*) mutation (Jackson Laboratories, Bar Harbour, MN) were dissected out. Single cell suspensions were obtained from the lymph nodes and cultured in tissue culture flasks at 10^7 cells /ml in 20% fetal calf serum and Dulbecco's Minimum Essential Medium. After 2 days the non-adherent cells were

25 removed. The adherent cells were cultured for a further 2 days and then treated with 0.25 g/100ml Trypsin (ICN, Aurora, OH) and re-cultured. After a further 4 days, non-adherent cells were discarded and adherent cells removed by trypsinization. Remaining adherent cells were physically removed by scraping with a rubber policeman. All adherent stromal cells were pooled.

30

cDNA Expression Library from Flaky skin lymph node stromal cells in pBK-CMV (MLSA)

Stromal cells from Flaky skin mice lymph nodes were grown in culture and the total RNA extracted from these cells using established protocols. Total

5   RNA, isolated using TRIzol Reagent (BRL Life Technologies, Gaithersburg, MD), was used to obtain mRNA using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA), according to the manufacturer's specifications. A cDNA expression library was then prepared from the mRNA by reverse transcriptase synthesis using a Lambda ZAP cDNA library synthesis kit

10   (Stratagene).

cDNA sequences were obtained by high-throughput sequencing of the cDNA libraries described above using a Prism 377 sequencer (Perkin Elmer/Applied Biosystems Division, Foster City CA), and are provided in SEQ ID NO: 1-35, with corresponding polypeptide sequences in SEQ ID NOS: 36-65.

15

EXAMPLE 2

Analysis of cDNA sequences using BLAST algorithms

BLASTN Polynucleotide analysis

20   The isolated cDNA sequences were compared to sequences in the EMBL DNA database using the computer algorithm BLASTN. Comparisons of DNA sequences provided in SEQ ID NOS: 1-35, to sequences in the EMBL DNA database (using BLASTN) were made as of November, 2000, using Version 2.0.11 [Jan-20-2000], and the following Unix running command: blastall –p

25   blastn –d embldb –e 10 –G0 –E0 –r 1 –v 30 –b 30 –i queryseq –o.

The sequences of SEQ ID NOS: 1, 3, 4, 6-11, 13, 18, 21, 22, 24, 25, 28-30, 33 and 34 were determined to have less than 50% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above. The sequences of SEQ ID NOS: 2, 12,

30   14-16, 20 and 35 were determined to have less than 75% identity, determined as described above, to sequences in the EMBL database using the computer

algorithm BLASTN, as described above. The sequences of SEQ ID NOS: 17, 19, 23 and 27 were determined to have less than 90% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above. Finally, the sequences of SEQ ID NOS: 5, 26 and 32 were determined to have less than 98% identity, determined as described above, to sequences in the EMBL database using the computer algorithm BLASTN, as described above.

BLASTP Polypeptide analysis

The sequences of SEQ ID NOS: 37, 41, 42, 44, 46-50, 55, 56 and 59 were determined to have less than 50% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. The sequences of SEQ ID NOS: 36, 38, 43, 45 and 60 were determined to have less than 75% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. The sequences of SEQ ID NOS: 39, 54 and 58 were determined to have less than 90% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above. Finally, the sequences of SEQ ID NOS: 53, 57, 62 and 65 were determined to have less than 98% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTP, as described above.

BLASTX Polynucleotide Analysis

The sequences of SEQ ID NOS: 2-4, 6-16, 18, 22-24, 26-30 and 33-35 were determined to have less than 50% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTX, as described above. The sequences of SEQ ID NOS: 1, 19, 20, 25 and 32 were determined to have less than 75% identity, determined as described above, to sequences in the SwissProt database using the computer algorithm BLASTX, as described above. Finally, the sequences of SEQ ID NOS: 5, 17, 21 and 31 were determined to have less than 90% identity, determined as described above, to

sequences in the SwissProt database using the computer algorithm BLASTX, as described above.

5   Example 2

ISOLATION AND CHARACTERIZATION OF THE HUMAN HOMOLOG OF MUKS1

This example demonstrates that an isolated cDNA may be used to isolate its homologue from a different species, the corresponding polypeptide may be

10   expressed and the function of the polypeptide can be determined, starting the whole process from an isolated cDNA obtained as described above.

Analysis of RNA transcripts by Northern Blotting

Northern analysis to determine the size and distribution of mRNA for the

15   clone muKS1 (SEQ ID NO: 66; isolated from a mouse keratinocyte stem cell cDNA library using high-throughput sequencing as described above) was performed by probing murine tissue mRNA blots with a probe consisting of nucleotides 268-499 of muKS1, radioactively labeled with $[\alpha^{32}P]$-dCTP. Prehybridization, hybridization, washing and probe labeling were performed as

20   described in Sambrook *et al.*, *Ibid.* mRNA for muKS1 was 1.6 kb in size and was observed to be most abundant in brain, lung, muscle and heart. Expression could also be detected in lower intestine, skin and kidney. No detectable signal was found in testis, spleen, liver, thymus and stomach.

25   *Human homologue of muKS1*

MuKS1 (SEQ ID NO: 66) was used to search the EMBL database (Release 50 plus updates to June, 1998) to identify human EST homologues. The top three homologies were to the following ESTs: accession numbers AA643952, HS1301003 and AA865643. These showed 92.63% identity over 285

30   nucleotides, 93.64% over 283 nucleotides and 94.035% over 285 nucleotides, respectively. Frame shifts were identified in AA643952 and HS1301003 when

translated. Combination of all three ESTs identified the human homologue huKS1 (SEQ ID NO: 67) and translated polypeptide SEQ ID NO: 67. Alignment of muKS1 and huKS1 polypeptides indicated 95% identity over 96 amino acids.

5   *Bacterial expression and purification of muKS1 and huKS1*

Polynucleotides 269-502 of muKS1 (SEQ ID NO: 69), encoding amino acids 23-99 of polypeptide muKS1 (SEQ ID NO: 70), and polynucleotides 55-288. of huKS1 (SEQ ID NO: 71), encoding amino acids 19-95 of polypeptide huKS1 (SEQ ID NO: 72), were cloned into the bacterial expression vector pET-16b

10   (Novagen, Madison, WI), which contains a bacterial leader sequence and N-terminal 6xHistidine tag. These constructs were transformed into competent *E. coli* BL21(DE3) (Novagen) as described in Sambrook *et al., Ibid.*

Starter cultures of recombinant *E. coli* BL21(DE3) (Novagen) transformed with bacterial expression vector pET16b containing SEQ ID NO: 69 (muKS1a)

15   and SEQ ID NO: 71 (huKS1a) were grown in NZY broth containing 100 µg/ml ampicillin (Gibco-BRL Life Technologies) at 37°C. Cultures were spun down and used to inoculate 800 ml of NZY broth and 100 µg/ml ampicillin. Cultures were grown until the OD_{595} of the cells was between 0.4 and 0.8. Bacterial expression was induced for 3 hours with 1 mM IPTG. Bacterial expression produced an

20   induced band of approximately 15 kDa for muKS1a and huKS1a.

MuKS1a and huKS1a were expressed in insoluble inclusion bodies. In order to purify the polypeptides, bacterial cell pellets were re-suspended in lysis buffer (20 mM Tris-HCl pH 8.0, 10 mM β–Mercaptoethanol, 1 mM PMSF). To the lysed cells, 1% NP-40 was added and the mix incubated on ice for 10 minutes.

25   Lysates were further disrupted by sonication on ice at 95 W for 4 x 15 seconds and then centrifuged for 10 minutes at 18,000 rpm to pellet the inclusion bodies.

The pellet containing the inclusion bodies was re-suspended in lysis buffer containing 0.5% w/v CHAPS and sonicated for 5-10 seconds. This mix was stored on ice for 1 hour, centrifuged at 14,000 rpm for 15 minutes at 4°C and the

30   supernatant discarded. The pellet was once more re-suspended in lysis buffer

containing 0.5% w/v CHAPS, sonicated, centrifuged and the supernatant removed as before. The pellet was re-suspended in solubilizing buffer (6 M guanidine HCl, 0.5 M NaCl, 20 mM Tris-HCl pH 8.0), sonicated at 95 W for 4 x 15 sec and centrifuged for 10 minutes at 18,000 rpm and 4°C to remove debris. The supernatant was stored at 4°C. MuKS1a and huKS1a were purified by virtue of the N-terminal 6x histidine tag contained within the bacterial leader sequence, using a Nickel-Chelating sepharose column (Amersham Pharmacia, Uppsala, Sweden) and following the manufacturer's protocol. Proteins were purified twice over the column to reduce endotoxin contamination. In order to re-fold the proteins once purified, the protein solution was dialysed in a 4 M-2 M urea gradient in 20 mM Tris-HCl pH 7.5 containing 10% glycerol overnight at 4°C. The protein was then further dialysed 2x against 2 litres of 20 mM Tris-HCl pH 7.5 containing 10% glycerol.

Injection of bacterially expressed muKS1a into nude mice

Two nude mice were anaesthetised intraperitoneally with 75 µl of 1/10 dilution of Hypnorm (Janssen Pharmaceuticals, Buckinghamshire, England) in phosphate buffered saline. 20 µg of bacterially expressed muKS1a (SEQ ID NO: 70) was injected subcutaneously in the left hind foot, ear and left hand side of the back. The same volume of phosphate buffered saline was injected in the same sites but on the right hand side of the same animal. Mice were left for 18 hours and then examined for inflammation. Both mice showed a red swelling in the ear and foot sites injected with the bacterially expressed protein. No obvious inflammation could be identified in either back site. Mice were culled and biopsies taken from the ear, back and foot sites and fixed in 3.7% formol saline. Biopsies were embedded, sectioned and stained with Haemotoxylin and eosin. Sites injected with muKS1a had a marked increase in polymorphonuclear granulocytes, whereas sites injected with phosphate buffered saline had a low background infiltrate of polymorphonuclear granulocytes.

Chemokines are a large superfamily of highly basic secreted proteins with a broad number of functions (Baggiolini *et al.*, *Annu. Rev. Immunol.* 15:675-705, 1997; Ward *et al.*, *Immunity* 9:1-11, 1998; Horuk, *Nature* 393:524-525, 1998). The polypeptide sequences of muKS1 and huKS1 have similarity to CXC

5   chemokines, suggesting that this protein will act like other CXC chemokines. The *in vivo* data from nude mice supports this hypothesis. This chemokine-like protein may therefore be expected to stimulate leukocyte, epithelial, stromal and neuronal cell migration, promote angiogenesis and vascular development, promote neuronal patterning, hematopoietic stem cell mobilization, keratinocyte

10   and epithelial stem cell patterning and development, activation and proliferation of leukocytes, and promotion of migration in wound healing events. It has recently been shown that receptors to chemokines act as co-receptors for HIV-1 infection of CD4+ cells (Cairns *et al.*, *Nature Medicine* 4:563-568, 1998) and that high circulating levels of chemokines can render a degree of immunity to

15   those exposed to the HIV virus (Zagury *et al.*, *Proc. Natl. Acad. Sci. USA* 95:3857-3861, 1998). This novel gene and its encoded protein may thus be usefully employed as regulators of epithelial, lymphoid, myeloid, stromal and neuronal cells migration and cancers; as agents for the treatment of cancers, neuro-degenerative diseases, inflammatory autoimmune diseases such as

20   psoriasis, asthma and Crohns disease; for use in wound healing; and as agents for the prevention of HIV-1 binding and infection of leukocytes.

SEQ ID NOS: 1-72 are set out in the attached Sequence Listing. The codes for nucleotide sequences used in the attached Sequence Listing, including the symbol "n," conform to WIPO Standard ST.25 (1998), Appendix 2, Table 1.

25   All references cited herein, including patent references and non-patent publications, are hereby incorporated by reference in their entireties.

While in the foregoing specification this invention has been described in relation to certain preferred embodiments, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the

30   invention is susceptible to additional embodiments and that certain of the details

described herein may be varied considerably without departing from the basic principles of the invention.

5

We claim:

1.   An isolated polynucleotide comprising a sequence selected from the group consisting of: (1) sequences recited in SEQ ID NOS: 1-35; (2) complements of the sequences recited in SEQ ID NOS: 1-35; (3) reverse

5   complements of the sequences recited in SEQ ID NOS: 1-35; (4) reverse sequences of the sequences recited in SEQ ID NOS: 1-35 (5) sequences having at least a 99% probability of being the same as a sequence recited in (1) – (4) above as determined using computer algorithm BLASTN; (6) sequences having at least 50% identity to a nucleotide sequence recited in (1) – (4) above determined using

10   computer algorithm BLASTN; (7) sequences having at least 75% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm BLASTN; (8) sequences having at least 90% identity to a nucleotide sequence recited in (1) – (4) above determined using computer algorithm. BLASTN; (9) sequences having at least 95% identity to a nucleotide sequence

15   recited in (1) – (4) above determined using computer algorithm BLASTN; (10) nucleotide sequences that hybridize to a sequence recited in (1) – (4) above under stringent hybridization conditions; (11) nucleotide sequences that are 200-mers of a sequence recited in (1) – (4) above; (12) nucleotide sequences that are 100-mers of a sequence recited in (1) – (4) above; (13) nucleotide sequences that are 40-

20   mers of a sequence recited in (1) – (4) above; (14) nucleotide sequences that are 20-mers of a sequence recited in (1) – (4) above; and (15) nucleotide sequences that are degeneratively equivalent to a sequence recited in (1) – (4) above.

2.   An oligonucleotide comprising at least 10 contiguous residues

25   complementary to 10 contiguous residues of a nucleotide sequence recited in claim 1.

3.   A genetic construct comprising an isolated polynucleotide of claim 1.

30

4.   A host cell transformed with a genetic construct of claim 3.

5.   An isolated polypeptide encoded by a polynucleotide of claim 1.

5   6.   An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOS: 36-65; (b) sequences having at least a 99% probability of being the same as a sequence of SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (c) sequences having at least 50% identity to a sequence provided in
10   SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (d) sequences having at least 75% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (e) sequences having at least 90% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; and (f) sequences having at
15   least 95% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP.

7.   An isolated polynucleotide encoding a polypeptide of claim 6.

20   8.   An isolated polypeptide comprising at least a functional portion of a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) sequences provided in SEQ ID NOS: 36-65; (b) sequences having at least a 99% probability of being the same as a sequence of SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (c) sequences
25   having at least 50% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (d) sequences having at least 75% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP; (e) sequences having at least 90% identity to a sequence provided in SEQ ID NOS: 36-65, as determined using the computer
30   algorithm BLASTP and (f) sequences having at least 95% identity to a sequence

46

provided in SEQ ID NOS: 36-65, as determined using the computer algorithm BLASTP.

9.   A composition comprising a polypeptide according to any one of
5   claims 6 and 8 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

10.   A composition comprising a polynucleotide according to claim 1 and at least one component selected from the group consisting of
10   pharmaceutically acceptable carriers and immunostimulants.

11.   A method for treating a disorder in a mammal comprising administering a composition according to claim 9.

15   12.   A method for treating a disorder in a mammal comprising. administering a composition according to claim 10.

13.   A diagnostic kit comprising at least one oligonucleotide according to claim 2.

20

14.   An organism comprising a host cell according to claim 4.

SEQUENCE LISTING

<110> Watson, James D
      Murison, James G

<120> Polynucleotides, polypeptides expressed
  by the polynucleotides and methods for their use.

<130> 1050U1PCT

<160> 74

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 2401
<212> DNA
<213> Rat

<400> 1
```
gaggccacag ttatcaccac ggagaagaga gagaggccag cgcccctag agagctcctg      60
gtacccagg cagaagtgac agcacgtagc ctccggctcc agtgggtccc tggcagcgat     120
ggggcctccc cgatccggta ctttaccgtg caggtgcgag agctgccggg tggagaatgg     180
cagacctact cctcgtctat cagccacgag gccacactct gtgctgttga aaggctgagg     240
ccttttcacct cctacaagct gcgcctgaag gccaccaacg acattgggga cagtgacttc     300
agtgcagaaa cagaggctgt gaccacactg caagatgttc caggagagcc accaggatct     360
gtctcagcca caccgcacac cacgtcctca gttctgatcc agtggcagcc tccccgggat     420
gagagcttga atggccttct gcaaggctac aggatctact accgtgagct ggagtccgag     480
acaggcctga gccctgaacc caagacactc aagagcccct ctgccttacg tgctgaactc     540
acggctcaaa gcagcttcaa gaccgtgaac agcagctcca cattaacgac ctatgaatta     600
acacatctga agaagtaccg gcgctatgaa gtcatcatga ctgcctataa catcattggt     660
gagagcccag ccagtgtacc agtggaggtc ttcgttggtg aggctgcccc agcaatggcc     720
ccacagaaca tccaggtgac cccactcaca gccagccagc tggaggtcac atgggacccg     780
ccaccccag agagccagaa tgggaacatc caaggttaca aggtttacta ctgggaggca     840
gacagtcgta atgagacgga gaaaatgaag gtcctctttc tccctgagcc tgtggtaaag     900
attaaggatc tcaccagcca cacaaagtac ctggtcagca tctcagcctt caacgctgct     960
ggtgacgggc ccagaagtga cccatgccag ggacgcacac accaggcagc tccagggccc    1020
ccaagcttct tggaattctc agaaataaca tctaccacac tcaacgtatc ctggggggag    1080
ccatcggcag ccaacggcat cctacagggc tatcgagtgg tgtatgaacc cttagcacca    1140
gtgcaaggcg tgagcaaggt ggtgaccgtg gatgtgaaag gaactggca acggtggctg    1200
aaggtgcggg acctcaccaa gggagtgacc tatttcttcc gtgttcaggc gcgaaccatc    1260
gcctacgggc cagaactcca agccaatgtc actgcagggc cagccgaggg gtccccagga    1320
tctccaagaa atgtccttgt caccaaatct gcctctgagc tgacccttca gtggacagaa    1380
gggaacacag gaacacacc cactacaggc tacgtcatag aagccagacc atcagatgaa    1440
ggcttatggg acatgtttgc aaaggacatt cccaggagtg ctacgtcata caccgtgggt    1500
ctggacaagc tgcggcaagg ggtgacctac gagttccggg tggtggccgt gaacaaggca    1560
ggctttgggg aacccagccg cccttccatt gcagtgtcag cacaagctga agccccgttc    1620
tatgaggagt ggtggttcct gctggtgata gcgctctcca gcctcctcct cgtcctcctg    1680
gtggtcttcg tgctggtcct gcatgggcaa agcaagaagt acaagaactg ggctcaggt    1740
aagggcatct ccaacatgga ggagacagtg accctggata tggagggtt tgccgccttg    1800
gaactcaaca gtcgtcacct caatgtcaag agcaccttct caaagaagaa cggaaccaga    1860
tccccacccc gaccaagccc cggaggtctg cactactctg acgaagacat ctgcaacaaa    1920
tacaacggtg cggtgctgac agagagtgtg aacctcaagg agaaatcggt ggatgggtcg    1980
gaatcggagg cttctgactc agactacgag gaagccctgc ccaagcactc ctttgtcaac    2040
cactacatga gcgaccccac ctactacaac ttttggaagc ggcgtccccc tgccgcagca    2100
```

```
ccgcacaggt acgaggcggt ggcaggggcc gaagctggcc cgcacctgca cacagtcatc     2160
accacacaga gcgcgggcgg agtttacaca ccagctggcc ccggagcccg ggcccccctc     2220
accggcttct cctccttcgt gtgacgtcac gcctccatca gggtagacgg gtgcagaact     2280
tctggagtct attttttgtta agacaatcaa ctccgataac tgagctgaat ttttttttgtt     2340
taaaaaaata ataataattt tgataagcga aaaaaaaaaa aaaaaaaaaa aaaaaaaaa     2400
a                                                                    2401


<210> 2
<211> 1258
<212> DNA
<213> Mouse

<400> 2
cacacgcccc gcgtgtgcgg agcccttatt tacttcgcag aagagccttc agaccccctc      60
ctaacaagtg tggaaagcat cacggcgacg cgatgttggg gacactggtc tggatgctcg     120
cggtcggctt cctgctggca ctggcgccgg gccgcgcggc gggcgcgctg aggaccggga     180
ggcgcccggc gcggccgcgg gactgcgcgg accggccgga ggagctcctg gagcagctgt     240
acgggcggct ggcggccggc gtgctcagcg ccttccacca cacgctgcag ctcgggccgc     300
gcgagcaggc gcgcaatgcc agctgcccgg ccggggggcag ggccgccgac cgccgcttcc     360
ggccacccac caacctgcgc agcgtgtcgc cctgggcgta caggatttcc tacgaccctg     420
ctcgctttcc gaggtacctg cccgaagcct actgcctgtg ccgaggctgc ctgaccgggc     480
tctacgggga ggaggacttc cgctttcgca gcacacccgt cttctctcca gccgtggtgc     540
tgcggcgcac agcggcctgc gcgggcggcc gctctgtgta cgccgaacac tacatcacca     600
tcccggtggg ctgcacctgc gtgcccgagc cggacaagtc cgcggacagt gcgaactcca     660
gcatggacaa gctgctgctg gggcccgccg acaggcctgc ggggcgctga tgccggggac     720
tgcccgccat ggcccagctt cctgcatgca tcaggtcccc tggccctgac aaaacccacc     780
ccatgatccc tggccgctgc ctaattttc caaaaggaca gctacataag ctttaaatat     840
attttttcaaa gtagacacta catatctaca actattttga atagtggcag aaactatttt     900
catattagta atttagagca agcatgttgt ttttaaactt ctttgatata caagcacatc     960
acacacatcc cgttttcctc tagtaggatt cttgagtgca taattgtagt gctcagatga    1020
acttccttct gctgcactgt gccctgtccc tgagtctctc ctgtggccca agcttactaa    1080
ggtgataatg agtgctccgg atctgggcac ctaaggtctc caggtccctg gagagggagg    1140
gatgtggggg ggctaggaac caagcgcccc tttgttcttt agcttatgga tggtcttaac    1200
tttataaaga ttaaagtttt tggtgttatt ctttcaaaaa aaaaaaaaaa aaaaaaa     1258


<210> 3
<211> 3043
<212> DNA
<213> Mouse

<400> 3
cgcgtctccc gccgcaccca cccgtcgctg tatcaagcaa aagcgaaagg aagccgagcg      60
gtcccgcgtg gcgtggcgtg ggcggggagg tggctgcgcg ctctagctcc gcgggaccag     120
gctgccgctt tgtgacttca ccggtttcgc aacaagccag gaccgcccgc gccccaccca     180
cccggctgcc cgtccgccct ccgccctcgg gtctctgagc gcttccctcc ctccggggct     240
gggcctgtcc cggccgtccc ggagtctctg tcccgccgcg ccgttagctg tctgtgtctt     300
ggccaccgcc tccaggcagt ccgcagcaag ccagcttctt ggtccgacga gctcagcgcc     360
ctctcaccgc gatgctgtgc ttcctcaggg gaatggcttt cgtcccttc ctcctggtga     420
cttggtcgtc cgcagccttc atcatctcct acgtggtcgc ggtgctctct gggcacgtca    480
acccctttct ccctatatc agtgacacag gaacaactcc tccagagagt ggtatttttg     540
gattcatgat aaacttctct gcatttcttg gcgcagctac gatgtacaca agatacaaga    600
tagtggagaa gcagaatgag acctgctact tcagcactcc cgtttttaac ttggtgtcct     660
tggcgcttgg attggtggga tgcatcggaa tgggcatcgt agccaacttc caggagttag     720
ccgtgcctgt ggtccatgat ggcggtgcgc ttctggcttt cgtctgcggg gtggtgtaca     780
cgctcctgca atcgatcatc tcctacaaat cctgtcccca gtggaacagt ctcaccacgt     840
gccatgtcag gatggccatc tccgctgttt cgtgcgcagc tgtcgtcccc atgattgcct     900
gtgcttcact catttctata accaagctgg aatggaatcc aaaagaaaag gattatatat     960
```

```
atcacgtggt gagcgccatc tgtgagtgga ccgtggcttt tggttttatt ttctatttcc    1020
taacattcat ccaagatttc cagagtgtca ctctaaggat atccacagaa atcaatgacg    1080
acttttgaaa gatcgagaat cctgtctcat tcagggagtg tcgcagacag tttctggaag    1140
tggacagagg acggacgggc ttggatgtca ccctgatggg gactttatct gtggcacatc    1200
cgggacttga atttcattaa gagttcctag tagttcaatt tacaaaggta tgtttccctg    1260
gaggatggat agcaccaacg acactgtagc aatattttta tattttctaa aacaatcttt    1320
tatgaacaaa ttcatatgca aagaagacga ggcattgcag aaaggggagg attattcttg    1380
tatagattct ttagactttt tatgtaataa tgatttatga aaatacacta agagaaaaaa    1440
atgttaagtt tagtactttt tattaaagaa gccaaatcag ggcatattca ctttaaaatt    1500
tcatttttta aatacagtga cctgcataca ttttcatcac aagagcactt atacaattca    1560
attcatagtg attatatacc ctaatggtat agatttaggt aataaacgaa cactttaaag    1620
cactctgaat tttcagtgca ttaaacaaat gctttttatag tgaaggactc aaaaccattt    1680
acagtgcaca ttaaccagcg aatgtggaag acctcggttc gaaaatttag cccctcatt     1740
tacttctcca agggacccac agctttactg ccgctgttaa tggtgggccc gggaactaat    1800
tccaggtagg atgggctcat caggccagct tagaaatgat caaactgccc ttctctgtga    1860
ccgggcagca caagttcaat tcacttctca gtttccctgt aagccaaaga gaatgcagat    1920
ccaagtcagg gagaaaggag agcgctcata gaaacttcca gatgtgggct gctgcctatc    1980
tgctcctatc aatgcctgtg ggccactata agggagtcag gccctttccg aagcaaggcc    2040
tggagactct accttttcatg cagttcacca atggcaaaga aacgccagct gttgtggagg    2100
aagaagtgga taacaagacc ccccagtctg ggccagtagg agctgcccca agggcacgtt    2160
ccaaggacag agaccatttg gacagcctta gtgaaagggt acctggcgat gaaggggcac    2220
acagcagtgc ctcctttggc tgctaagtga agggtgctgc tcagcaggca cttctgccat    2280
gacatcctgt gtcttcttcc tcagtgtgca gtggtggcaa ccaacgtcca tttctgagtc    2340
ccctgtaact tttcacagta ccgaacatgc ccattgtaac actggaacag aaagacagtg    2400
gctgtcattc tgatgagtga gagaggagtc gatacatttc ctgtggaagc tggggcggac    2460
tgaatgcatg ctgttctttg cttttgagcgg gagccttggt tgatgccttc ccagaatgca    2520
cttggctctc ttcgcttcca ctggagaccc gaccacgtgc ctttacccat agtggaacac    2580
agtgccttgt ggcatgcaat aggtgcttaa taaatactca ttgaatgtat gcacgcataa    2640
atggatgaac aagtaacgac tagggatgtt tgaggtgcta agggtttttt ttactctagt    2700
tcacgggtat tctaaggtca acagctagtc tgtgccaatt agtaatgttg tctgttttgc    2760
tttgtgaact attctcgttt ccacctgttc cagctgtgtg agcttcatga ttgtgtgaca    2820
actctctcct ggacagatag cacagaaatt gttacatggg ctaaacctgt cttggcaaac    2880
cgaggaggcc cccaaatcac actctgcaga ttccatgcga cttctagttt tatccctgtt    2940
ttggtgttat ttttaatttc tacaaatatg tatttccttg gactttgtac ccgagaaagt    3000
aaaataaaat atttctttat tttaaaaaaa aaaaaaaaa aaa                        3043
```

<210> 4
<211> 2515
<212> DNA
<213> Mouse

<400> 4
```
gctgcgcctg ctgctggcct gggtggccgc ggtgcccgca ctgggccagg tcccctggac     60
gccggagcct cgagccgcgt gcggccccag cagctgctac gcgctctttc cccggcgccg    120
cacattcctg gaagcttggc gggcgtgccg cgaattgggg ggcaacctgg ccacaccgcg    180
gaccccagag gaggcccagc gtgtggacag cctggtgggg gtcgggccgg ccaacgggct    240
gctatggatt gggttgcagc ggcaggctag gcaatgccag ccgcagcgcc cactgcgggg    300
cttcatatgg accacgggag accaggacac cgccttcacc aactgggccc agccggctac    360
ggaaggaccc tgcccagccc agcgctgtgc agcccttgag gccagcggag agcatcgctg    420
gctcgaaggc tcgtgcacac tggctgtcga cggctacctc tgccagtttg gttttgaggg    480
tgcctgccct gccttgccgc ttgaggtggg tcaggccggt cccgctgtct acaccacacc    540
cttcaacctg gtttccagcg agttcgaatg gctgcccttt ggctccgtgg cagctgtgca    600
gtgccaagct ggcaggggag cttctctgct gtgcgtgaaa cagccttcag gtggcgtggg    660
ctggtcccag actggcccgc tgtgcccagg gactggctgt ggtcctgaca atggggggttg    720
cgaacatgag tgtgtggaag aggtggacgg tgctgtgtcc tgccgctgca gtgaaggctt    780
ccgtctagca gcagatgggc acagttgtga agaccccgt gcccaggccc cctgtgagca     840
gcagtgtgaa cctggagggc acaaggcta tagctgccac tgtcgccttg gcttccggcc    900
```

```
agctgaggat gatccacacc gctgcgtgga cacggatgag tgccagattg ctggtgtgtg      960
ccagcagatg tgtgtcaact atgttggtgg ctttgagtgt tactgcagcg agggtcacga     1020
gcttgaggca gatggtatca gctgtagccc tgcaggagcc atgggtgccc aggcttccca     1080
ggatctcaga gatgagttgc tggatgatgg agaagaaggg gaggatgaag aggagccctg     1140
ggaggacttt gatggcacct ggacagagga acaggggatc ctatggctgg cacctacaca     1200
tccacctgac tttggcctgc cctataggcc caacttccca caggatggag agcctcagag     1260
attgcacctg gagcctacct ggccaccccc acttaaggcc cccaagggcc cccaacaacc     1320
cccaaggggg gccgccaaaa cgcccaaggg gaaccccgcc aacccaaccc acactacctt     1380
ctgcccacaa gacctctgtt atttcagcta cacgcccacc cctgagccct gtccacccac     1440
ctgccatggc ccctgccaca cctccagctg tgttctctga gcaccagatc cccaaaatca     1500
aggccaatta tccagacctg ccttttggcc acaagcctgg gataacctcg gccactcacc     1560
cagcacggcc tcctccgtac cagcccccca ttatctcaac caactatccc caagtcttcc     1620
ctccccacca ggcccctatg tctccagata cccacactat cacttatttg cctccagtcc     1680
cccctcacct tgatcctggg gataccactt ctaaagccca tcaacaccct ttgctcccag     1740
atgctccagg tatcagaacc caggcccccc agctttctgt ctcagctctc cagcccctc      1800
ttcctaccaa ctccaggtct tctgtccatg aaactcctgt gcctgctgcc aaccagcccc     1860
cagccttccc ttcttctccc ctcccccctc agaggcccac taaccagacc tcatctatca     1920
gccctacaca ttcctattcc agagccctc tagtcccaag ggaaggagtt cccagtccca     1980
aatcagtgcc acagctgccc tcggtgccct ccacagcagc tccaacagcc ctggcagagt     2040
caggtcttgc aggccaaagc caaagggatg accgctggct gctggtggca ctcctggtgc     2100
caacatgtgt cttcttggtg gtgctgcttg ccctgggcat tgtgtactgc actcgctgtg     2160
gctcccacgc acccaacaag cggatcacgg actgctatcg ctgggtcaca catgctggga     2220
acaagagctc aacagaaccc atgccccca gaggcagcct tacaggggta cagacctgta     2280
gaaccagtgt gtgatggggt gcagatgccc ctttgtggga tagaagaaaa ggacttgctt     2340
tggacacatg gctgagacca caccaaggac ttatgggggc tgcccagctg acagaggagg     2400
ttctgttctt tgagcccagc atccatggca aaggacacac caggactcca ggacctcaag     2460
gggtgggtgc tgggatcttc tccaataaat ggggtgccaa cctctaaaaa aaaaa           2515
```

```
<210> 5
<211> 1587
<212> DNA
<213> Mouse

<400> 5
gcggcgcggg tagagggcgg tgggcggcga gcggcgatgg gccgcgcctg gggcttgctc       60
gttggactcc tgggcgtcgt gtggctgctg cgcttgggcc acggcgagga gcggcggccg      120
gagacagcgg cacagcgctg cttctgccag gttagtggtt acctggacga ctgtacctgt      180
gatgtcgaga ccatcgataa gtttaataac tacagacttt tcccaagact acaaaagctt      240
cttgaaagtg actactttag atattacaag gtgaacttga agaagccttg tcctttctgg      300
aatgacatca accagtgtgg aagaagagac tgtgccgtca accctgcca ttctgatgaa       360
gttcctgatg gaattaagtc tgcgagctac aagtattctg aggaagccaa ccgcattgaa      420
gaatgtgagc aagctgagcg acttggagcc gtggatgagt ctctgagtga ggagacccag      480
aaagctgtac ttcagtggac caagcatgat gattcgtcag acagcttctg cgaaattgac      540
gatatacagt cccccgatgc tgagtatgtg gacttactcc ttaaccctga gcgctacaca      600
ggctacaagg ggccagacgc ttggaggata tggagtgtca tctatgaaga aaactgtttt      660
aagccacaga caattcaaag gcctttggct tctgggcgag gaaaaagtaa agagaacaca      720
ttttacaact ggctagaagg cctctgtgta gaaaagagag cattctacag acttatatct      780
ggcctgcacg caagcattaa tgtgcatttg agtgcaaggt atcttttaca agatacttgg      840
ctggaaaaga aatggggtca caatgtcaca gagttccagc agcgctttga tgggattctg      900
actgaaggag aaggcccacg aaggctgagg aacttgtact tcctgtacct gatagagtta      960
agggctctct ccaaagtgct tccatttttt gagcgtccag attttcagct cttcactggg     1020
aataaagttc aggatgcaga aaacaaagcg ttacttctgg agatacttca tgaaatcaag     1080
tcatttcctt tgcacttcga tgagaattct ttttttgctg gggataaaaa cgaagcacat     1140
aaactaaagg aggacttccg gctacacttt aggaacattt caagaatcat ggactgtgtt     1200
ggctgcttca agtgccgcct gtggggcaag cttcagacgc aggggctggg cactgctctg     1260
aagatcttgt tttccgaaaa actgatcgca aatatgccgg aaagcggacc aagttatgag     1320
ttccagctaa ccagacaaga aatagtatca ctgtttaatg catttggaag gatttccaca     1380
```

```
agtgtgagag aactagagaa cttcaggcac ttgttacaga atgttcactg aggaggacgg    1440
ttggaatgtg cctgtttctg cacaggggaa tttgaagggc aaaatctctt ttagccccat    1500
ggttgcaatg tactgtccta agcccaacgt ttatataaac ctgcttttgt taaagaaaaa    1560
aaaaaaaaaa aaaaaaaaaa aaaaaaa                                         1587
```

```
<210> 6
<211> 2494
<212> DNA
<213> Rat
```

```
<400> 6
acttgaactg gcagataaaa aagtatgaca ccaaggcagc ttactgccag agcaagttgg     60
ctgttgtcct cttcaccaag gagctgagtc gccggctgca aggcactggt gtgactgtca    120
atgcgctgca ccctggcgtg gccaggacgg agctggggcg acatacaggc atgcacaact    180
ctgcgttctc tggcttcatg cttgggccct tcttctggct gctgttcaag agtccccagc    240
tggcggccca gcccagcaca tacctggctg tggcagagga actggagagt gtctctggga    300
agtactttga tggactcaga gagaaggctc catctcctga ggctgaagat gaggaagtag    360
cccggaggct ttggactgaa agtgcccatt tggtgggctt ggacatggct catgggtcct    420
ctgggagagg acattccatc tccagataac cttcagaaat ccagatggag cctcatcatc    480
ctctaggggc agtgttggta ttgttagaat ctcaagactg tggatgttgg ctgccatgac    540
cctcatcatc tctctaggagc agtgttgtac tactcgaact gaagactgtg gatgctggct    600
gccatcctct gggtggctgt gttggtccta gcattattgt tagctggctg ctttggtttg    660
gaccacggga tggcaggcac atgtactctt ttggttactg gggagatagt ccattggtgc    720
ctcctacagg aatctaaaag cggggaagct gatggaggag tcagtcactc tagttatggg    780
cagtgtccaa agacagtgga caccaaagct gcagtagtgg actgattgat ccactgtgaa    840
agagcaagta atcagacaaa tatggctgta gagctttgtg ggcccttgca catgtctgcc    900
tcctctctga cttggctgtt gttctagttt gcttctgtt gctgtgataa ataccatgac    960
caaaatcaac ttggggagga aaagggctta tttaacttac aggttatagt ttaccatgga   1020
agagggaaac cagggaagga actcaggaca agaacttgaa gcagatacca gatacaacgg   1080
aggtttgctc ccaggcatac atcagatacc tttattttat ttttattatt gttatttttt   1140
tatagagagg gtctcacttt gtaaccctgg cctccctgga acttgctatg tagatcaggc   1200
tggcctcaaa ctcacagaga cctgccttct gggattaaag gcttgaatta ttaggcttgg   1260
cccaggtacc agtgcagcct acctgcccag ggatggcacc atctgcagtg gggttctacc   1320
tcccatatca actagcaatc aagaaaatgc tccacaaaca ttccctcagg gcagtctggt   1380
ctaagcagtt cttcaggcga gggtctgtct gtctatcttc taggtatgcc aggttgacaa   1440
acaaatgaac cagacggctc ttgattgcaa actgcaaagg gtgtctgcta cctcaggat    1500
ggtgtgggcc tgaagctctt gcccaactca gtaaaggca gctgtggaca cttgtgtact   1560
ggacactggc tgaggggctg ggatccagtg gaaaccctgg cctttgttag ccctgaagta   1620
atcaggacag aatggagtga aaagctgcta gctgctgcct cagaaaatga gtgtgacctg   1680
ggatcacgat ctctccagtt cctgtgtaat tttaacctta gcctctcaag catgttgttt   1740
gattataata acaagctaga tagaggtagt ggcacacttc agtagctcca gcacttaaga   1800
gggagaggca ggagtatcaa aagtccaagg tcatccgagg ccagcctggg ctatatgaga   1860
ttctgccgaa acaaagcaaa acggtgagat ctccaaatgg ctgattcata gatttaaaat   1920
aaagacatac atttagtgtg cgagtgtgta tactatgtgt gtgtatgtgt acgggtatgt   1980
gcacgtgccc ttgtatgtgc attacatgat ggaggtcaga ggacaacctg tgggaatcag   2040
ttctctcttc gtgaatcccg aggatccaac tcagtttgtc aggcttggtg caagggcct    2100
tcacctctga accatagtgc cagccctgag tcatagggtt ttttttatc ctttctgtat   2160
gggatttatt ccacatacaa cttattcttt attccttta agaaactaag acattcaatt   2220
gttgacaaga caatgatttt ccaacaactc cctcgtattt ctcatctatc ctgttctgct   2280
taaattaggc tagatcaact tccccttcc cccctttctt tgttttgaga cagagtttca   2340
ctctatagat caggctaaac ttgggctctc aggctccttg tctaagcctc tggagtccag   2400
agatgacggg tctgccacac cctgcgttta caatcagtgt ttacaatcaa ataaatggaa   2460
ataaacattt ctatcaaaaa aaaaaaaaa aaaa                                 2494
```

```
<210> 7
<211> 1859
<212> DNA
```

<213> Mouse

<400> 7

```
gctcaaagtg gccaactaca gcaactcagg cagattcaag aagaggttca tgtatcctgt      60
aggatatggg cttcctgctt ttattgttgc tgcatgctgc aatagctggc cacaagaatt     120
atggaacaca caaccactgc tggctcagcc ttcatcgagg attcatctgg agcttcttgg     180
ggccagcggc agccattatc ttgataaacc tggtgttcta ctttctaata atatggattt     240
tgagaagcaa actttcttct ctcaataaag aagtttctac acttcaagac acaaaggtta     300
tgacatttaa agccattgtc cagttatttg tgttgggatg ttcttggggc attggcttgt     360
ttattttcat tgaagttggg aagacagtga gactgatcgt tgcctatctg ttcaccatca     420
tcaatgtcct gcagggtgtt ttgatattta tggtacattg tctgcttaat cgccaggtgc     480
ggatggaata taagaagtgg tttcatagac tgcggaagga agttgaaagt gaaagcactg     540
aagtgtctca ttctactact cacacaaaaa tgggtctttc tctgaacctg gaaaatttct     600
gcccaacagg aaacctccat gatccttctg actccatcct tccaagtact gaagtagcag     660
gtgtatatct aagcacaccc aggtctcaca tgggtgctga ggatgtgaac tcaggtactc     720
acgcttactg gagcagaact attagtgatt gaatcagctc cttcccccaa gcctcttaca     780
gtacatttta acttgtactg tgccatgcac atgaagctat aattgctagt ctggtaaaac     840
aactgttgca tattccatga tcatttcatt ttatctctac ttgcaaagt tagctttctt      900
tttatatcat tttattct ctttctttttg tttatatata gcttcagttg agtgggtttc     960
tagtcttaat gttctagatc actatttctt tttcagttaa cctttattgg tatttagttc    1020
ctgtgtagtg tataccactg gaatatttt atttctttaa ttttgaggtt aaaatatagt     1080
tacatcattt ttccttttt tctttcccac aatcctcctg tatactttt ccctggtgtc      1140
tattttattg tttctacatg catatatatt ttatgcaaaa catatatatg tataaaatata   1200
aatatatatt cttatatgca tgaaaaccat ctacttcatc caaataatgt tccttctatg    1260
tatgttttca ggacagggac aacaatagct atggtagcat ggcaggggaa agcccacagg    1320
acctcagcct tatacaaaga atcagaggca actgaggagt gctgagttga aggaattgtc    1380
ttacccaggg gagggcacat taattggtta tctaatacaa aatgttcagc cccaaaactg    1440
ttaagataaa agcctatatg catcttagga agtatctacc ttgatacacc tttattggaa    1500
tatcatccac atgtttattg tgtgttctga agagggtctg ttgaatttct aagggttgat    1560
cagtttaatt gtgccatttt atattcaggg tgtttggctt tgttgtagtg aataatgcta    1620
tatttccctg tatgtgtcat ctttgactgt tatttttttcc tggcaatact ttattcaaca   1680
agaacctaga gccttggttt attactttt cttccataga aaaactattt gtcttccagg     1740
attagatatg atcaatattt cttatatgca tgtatcaaat atcatgatga aatatattac    1800
tgtgtataat taataactgg caataaagtc caagggaaaa ggaaaaaaaa aaaaaaaaa     1859
```

<210> 8
<211> 2305
<212> DNA
<213> Mouse

<400> 8

```
gaatctgtgg aagcagttta ttccagtatc acccaggagc agccacacag aggctggtag      60
gagggctgga ttttttgttct cttttttttct tttctttaaa tgtaacactt ctttatttt     120
tcttcttgaa gagtcttgag gatacttaca ttgcagttaa gtagtacagg gtggataaat      180
tctactttga agaaaacttc tctcctctga caaggttgga cttgtacaca ggccagcatg       240
aaggagtatg tgatgctact gctttttggct gtgtgctctg ccaaacccctt ctttagccct     300
tcccacacag cactgaagaa tatgatgttg aaggatatgg aagacacaga tgatgacgat       360
aacgatgatg acgacaactc tcttttttcca acgaaagagc cagtgaaccc ttttttttcct    420
ttcgatttgt ttccaacatg tccatttggg tgccaatgtt actctcgagt tgttcactgc       480
tctgatctag gtctgacatc ggttccaaac aacattccat ttgatactcg aatggttgac       540
cttcaaaata ataaaatcaa ggaaattaaa gaaaatgact ttaaaggact cacttcactt       600
tatgctctga ttctgaacaa caacaagcta acaaagattc acccaaaaac ctttctaacc       660
acaaagaaat tgagaaggct atatttatcc cacaaccaac taagtgaaat tccacttaat       720
cttcccaaat cattagcaga actcagaatt catgataata aagttaagaa gatacaaaag       780
gacacgttca agggaatgaa tgctttacat gttttggaaa tgagtgcaaa ccctcttgag       840
aacaacggga tagaaccagg ggcatttgaa ggggtgacag tattccatat caggatcgct       900
gaagcaaaac taacctcaat tccaaaaggc ctaccaccaa ctttgctgga gcttcatta       960
```

```
caggctggcg gaagccccca gatatcacag ccggaactgg gaagggccct gtttggaaac      1680.
tgcagggagt atagacagat tccaggtccc tggtcagcca ggccaagacc acaggagcta      1740
agacacccca acctcatcac cctcctaccc accctctctc tcatcttctt tttgatgaat      1800
tctgtccatc tccctagcct ccattttggt tgtacctttc cattctcagt actgctttct      1860
tattctttaa agatatttat ttttcttttc attaaaataa aaccaaagta ttgataaaaa      1920
aaaaaaaaaa                                                              1930      .
```

<210> 10
<211> 2617
<212> DNA
<213> Mouse

<400> 10
```
ggcggcggga agatgcggtt gcggctccta gcgctggcgg cggccgtgct gctgggtccg       60
gccccggaag tctgtggtgc tctcaatgtc acggtgtccc caggacctgt ggtggactac      120
ttggaagggg aaaatgccac cctcctctgc cacgtctccc agaagagacg gaaggacagc      180
tgctggccgt gcgctggttc ttcgcccctg acggctccca ggaggccttg atggtgaaga      240
tgacgaagct ccggataatt cagtactatg ggaacttcag ccggactgcc aaccagcaga      300
ggctacgcct gctcgaggag cgtcgagggg tgctgtacag gctgtctgtc ctgacgctcc      360
ggcccacaga tcaagggcag tatgtctgca aagtgcaaga aatcagcaag caccgcaaca      420
agtggacagc ctggtccaat ggctcctcgg cgacggaaat gagagtgatc tccctcaaag      480
ctggcgaaga ttcatcattt gagaaaaaga aggtgacttg ggcatttttt gaagatctct      540
atgtgtacgc tgtccttgtg tgctgcgtgg ggatcctcag tgttctgctc ttcaccctgg      600
tcattgcctg cagtctgtgt ttcacaagag gaaatcaaga gtgagacatt atttggtgaa      660
gtgccctcag aacagctcag gggagactgt caccagtgtg accagcttgg ccccactgca      720
gccacagaag ggtaagaggc agaagaagaa ggtagatgtt ccacctgcag tccctgccaa      780
agcgccgata gccaccactt tccacaaacc aaagctgctg aaaccacaga ggaaagtcgc      840
cctgcccaag atcaccgagg aaaacttgac ctatgccgag ctggagctga tcaaaccaca      900
cagggctgcc aaaggcgtcc ccaccagcac cgtgtatgca cagatcctct tcgaggagaa      960
ccagctgtag cgatacctcc tctctggctg tcatgtgttc tcccagttgt ttatgacact     1020
cagaaacaaa ctccctagtt ttgtattttc acccgtgcct tcagtgtgat ggggagcccc     1080
ttcccacagc gttctgatgt cttctaagag gtacacactt cccagaagag aagggaccag     1140
ctcttggcca tgcctcccaa gataagaggc ccctggcctg attctgagca caaggactct     1200
gcttctgaga gcattgctga gccaaccgta ccaacttctc ctcttcttaa gccttaaagt     1260
tttgagggaa aaatcaaatc ttaattttaa tcagcccccc ttgttctgta taacaagcat     1320
ccagtttata gccacaggaa atgctgtaaa ggtcacagag agaaatggga tatatggact     1380
gacaagttct ctaaggctct gggacaccca ggacagagca aacccctgga ggtggtggca     1440
ggagccactt atgatgacat ccattgcttt taatagatgc tctgaaactg gccatgtgag     1500
.ggcagagatg ctgatggttg aaagccggag atctggctca gaaaattctg gtcttatgtc     1560
tttagagcca tacttcacca gggctgtaga tctacaagaa cacccttgta aagtgtttgt     1620
ccccctttag cagaatggac ctagagagac atattgttct ctctttccaa aagacttgag     1680
tatggctcca gtgggtacat cgggtaagtg agcaaagcat gcaagctcag tcaactccat     1740
tcaagataga gtggagcctt tcaccattcc ctcagcagag aaatgaaagc acaaggcatg     1800
ccgggaaact atgtccagga ggactcaacc cttggcaagt gctttgaccg tctcaatctt     1860
ggatgagaac catgattgcc ttgggtggat gtcaggggac catgggacat aagtccgtgg     1920
ggaagtgact ctgtggacct aaacaatgta caaaaatgtc agacttaatg gaagtaagag     1980
agtcaccttg atttccgcag tgctattgat gcttcttgat gtatactctg gtggccactt     2040
actgcacttt ataaacattg tctggctttg taattttaca atgtatatat gataaattat     2100
ctattttaaa cacagctagg gtgtgcattg tgccctctgt ctcactgtgg gacttgagtt     2160
ttttattacc ttaacttgga tcacagctac acaagttgtg ggaatggggg aacccactga     2220
acattgcctt ttaatgggga atagaagcct cacagcatcc ctgccgagct tgtctctctg     2280
acttttttcaa agggaaaccg cagcagcacc ctcagagcag ggacaatgag cagtttgtac     2340
ctggtgcttg tttgaagtaa catattttgg ggttcttgat cagaaaatgt gtctagtcgc     2400
tcttccttta ccacatagac cactaaccgt gaattgacat ttctgaagct aagtgaggag     2460
aagcatccat catctggaaa gtgcaaaggg ttcttcttgc gacaaggcat caataggagc     2520
ggtgatgtaa tcactgagta gttccccaaa tggacagctg cttccagtgt tccatgcaat     2580
taaagcaagc atgacctcaa aaaaagaaaa aaaaaa                                2617
```

```
gattttaata aaatttcaac ggtggaactt gaagatctta aacggtacag ggaactgcaa      1020
aggctgggtc ttggaaacaa cagaatcaca gatattgaaa atggaacttt tgctaatata      1080
ccacgtgtga gagagataca cttggaacac aataaactaa aaaaaatccc ttcaggatta      1140
caggagttga aatacctcca gataatcttc cttcattata attcaattgc aaaagtggga      1200
gtgaatgact tctgtccaac agtgccaaag atgaagaaat ctttatacag tgcaataagt      1260
ttattcaaca acccaatgaa gtactgggaa atacaacctg caacatttcg ttgtgttctt      1320
ggcagaatga gtgttcagct tgggaatgtt ggaaaataat tcatgacatc cattaaatat      1380
aaaattcaaa aatgtataca tttggaatac ttgaactgtc ctagtaatgg tagtattata      1440
cacataagca aaattctatt ctatatggtc aatgacaaaa aatttcaaca gaattttgcc      1500
taattattga tgctcagaat aaatttctat tgcagtgtcc ttctgcacat gaatgattct      1560
tgcgtaaatc ttttgcttga acattctttt tttcggcaaa aaaagatatt tagtatttaa      1620
cccttcatta tcaagtcagt caaacagaat tgtactgtaa acagaatgct tgacttagta      1680
acatttgtgt catatctttg ctgttagaaa aacaaaactg gcaagaacag cattttgaag      1740
agtacatata tttttagtag ttttttaaaa aaaacttgga cagtactgta atgtttccaa      1800
taatgttgga atacatatag tttgacagaa tcaaaattct caactcataa taaagcttca      1860
agtattcaca gataatattc atcagagttg gtttgggcta taacacatga atatcttttt      1920
taaattatta actggctata aaattgtaaa aatataatga ctgctaatat aaaatctata      1980
atgtgcattt tatgatcagt tatataagct ttgaagaaca cagtaactgt taggttacat      2040
agtgttatta cttcaactag gaatatttca ggatatccct ttggaacagt atggacgcca      2100
atcaatttta tatcaactta tctcttcaaa tatgcacatt gggtaatgcc tggaaacata      2160
gctaaggtga caaaaactga aaactgaaca aaacttaata gtactttcat gtgtttttt      2220
taaactgata ttcattatga attaagtaaa aagtgacaat aaggaaaaca ttaaatactg      2280
gttttcaata aaaaaaaaaa aaaaa                                           2305
```

<210> 9
<211> 1930
<212> DNA
<213> Mouse

<400> 9
```
gcggaggcgc gcagggcagc ctgggtccag cccacacccc tcaccaggag gcaccatgtg       60
gggatgttgg ctggggctgc tcttgctgct gctggctggc caggctgccc tggaggcccg      120
gcggagtcgt tggcgcaggg agctggcgcc agggctgcac ctgcggggca tccgggacgc      180
cggtggcaga tactgccaag agcaggacat gtgctgtcga ggccgtgctg acgagtgtgc      240
cctgccctac ctgggagcca cctgttactg tgacctcttc tgcaaccgca ccgtctctga      300
ctgctgcccc gacttctggg acttctgcct cgggattcca ccccccttcc ctcccgtcca      360
agggtgcatg catgggggcc ggatctaccc agtcttcgga acctactggg acaactgcaa      420
tcgatgcacc tgccatgagg gagggcattg ggagtgcgac caggagccgt gtctagtgga      480
cccagacatg attaaagcca tcaaccgagg caactacggg tggcaggctg gaaccacag      540
tgccttctgg ggcatgaccc tggatgaggg cattcgctac cgcctgggca caatccgccc      600
atcctccact gtcatgaata tgaatgagat ttatacggtg ctgggccaag gggaagtgct      660
acccactgcc tttgaagctt cagagaagtg gcccaacctg atccacgagc cattggacca      720
gggcaattgt gcaggttcct gggctttctc cacagcagct gtcgcatctg atcgcgtctc      780
tatccattct ttgggacaca tgacacccat cctatcaccg caaaacctgc tgtcctgtga      840
tacccaccac cagcagggct gccgaggtgg gcgtcttgat ggcgcttggt ggttcctgcg      900
gcgccgcggg gtggtgtctg acaactgtta cccattctcc ggccgtgagc agaacgaggc      960
cagccccact cctcgttgta tgatgcacag ccgcgccatg gggcggggca gcgccaagc      1020
cacttcccgc tgccccaatg gtcaggttga ttccaacgac atctaccagg tcacgcctgc      1080
ctaccgcctg ggctctgatg agaaggagat catgaaggag ctaatggaaa acggccctgt      1140
tcaagcactc atggaagtac acgaggactt cttcttgtac cagcgtggca tctacagcca      1200
cacacctgta agccagggga ggccggagca gtaccgcaga catgggactc actcagtcaa      1260
gatcactggg tggggagaag agacgctgcc agacggaagg accattaagt actggactgc      1320
tgccaactcg tggggcccat ggtggggtga aggggccac ttccggatcg tgcgtggcac      1380
caacgagtgc gacatcgaga ccttcgtgct gggcgtctgg ggtcgcgtgg gaatggagga      1440
catggggcac cactgagtct cagccactag gcgaggtggg atccacagcc acagaagagg      1500
ccttgggggc catgcccgat gaagccttgt gtgcacttcg ggaccaggtg ctaatctcta      1560
cagactcaga tccgcgcgtg cgcgctaagg cagaatccca cctaggagac aaagatgcac      1620
```

```
<210> 11
<211> 1480
<212> DNA
<213> Mouse

<400> 11
gggctcccag gtgatcggtg tgtgtcagcc tcactccagg gcctccaggg aaccatggac        60
ttttggcttt ggttacttta cttcctgcca gtgtctgggg ccctgagagt cctcccagaa       120
gtacagctga atgtagagtg gggtggatcc attatcatcg aatgcccact ccctcaacta       180
cacgtaagga tgtatctgtg tcggcagatg gccaaacctg ggatatgctc cactgtggtg       240
tccaacacct ttgtcaagaa ggaatatgaa aggcgagtca ccctgacgcc atgcttggat       300
aagaagctat cctagtgga gatgacacag ctgacggaaa atgacgatgg aatctatgcc        360
tgtggtgtgg gcatgaagac agacaaaggc aagacccaga aaatcaccct gaatgtccat       420
aatgaatacc cagaaccatt ctgggaagat gaatggacct ctgagcggcc aagatggttg       480
cacagatttc tgcagcacca gatgccctgg ctccacggga gtgaacatcc cagctcttct       540
ggagtcatag ccaaagttac cacgccagct tcaaagactg aggcccctcc ggttcaccag       600
ccctccagca tcacttcagt aacccaacat cccagagttt acagagcatt ttctgtgtca       660
gctaccaagt cccccagcgct cctgccagca accacagcct caaagacttc cactcagcaa       720
gcaatcaggc ccctagaggc cagctacagc caccacacca gacttcatga gcaaaggaca       780
cgccaccatg gcccacacta tgggagagaa gaccgagggc ttcacatccc catcccagaa       840
tttcacatcc tgattccgac cttcctgggc tttctcttgc tggttctttt gggactggtg       900
gtaaaaagag ccattcaaag gaggagagcc tcctccagac gtgcgggccg actggcgatg       960
aggaggcgag gccggggggc ttcccgcccg ttccccacac agcgccggga tgccccgcag      1020
aggccgcgct cgcagaacaa cgtctacagc gcctgcccccc ggcgcgcacg gggaccagac      1080
agcttgggtc cagcggaggc tccgctcctc aacgccccag cctcagcgtc ccccgcttct      1140
ccgcaggtac ttgaagctcc ttggccccac accccatctc tgaagatgag ctgtgaatac      1200
gtgagcttgg gctaccagcc tgctgtcaac ctggaagacc ctgattcaga tgattacatc      1260
aatattcctg acccatctca tctccctagc tatgccccag ggcccagatc ttcatgccaa      1320
tgagttctgc ctgtttgctg atgtctagca cgttttcctt ataggatccc tgtcatggcg      1380
tatgtcctat accctaagtc gactctcacc tgactatctg aatgccttga gaatgatcaa      1440
ttacaggcta attttcacc ccaaaaaaaa aaaaaaaaa                             1480

<210> 12
<211> 802
<212> DNA
<213> Mouse

<400> 12
gctgagccag gatgaaggct ctcagggctg tcctcctgat cttgctacta agtggacagc        60
caggggtgg ctgggcacaa gaagatggt atgcggaccc ggagccagag aactacaact       120
acgatgatga cgatgatgaa gaggaagagg aggagaccaa catgatccct ggaagcaggg       180
acagagcacc tctacaatgc tacttctgtc aagtgcttca gcgggggag agctgcaatc       240
agacacagag ctgctccagc agcaaaccct tctgcatcac gctcgtctcc cacagcggaa       300
ccgacaaagg ttacctgact acctactcca tgtggtgtac tgatacctgc cagcccatca       360
tcaagacagt gggaggcacc cagatgactc agacctgttg ccagtccaca ctgtgcaata       420
ttccaccctg gcagaacccc caagtccaga accctctggg tggccgggca gacagccccc       480
tggaaagtgg gactagacat cctcagggtg gcaagtttag ccaccccag gttgtcaagg       540
ctgctcatcc tcagagcgat ggggctaact tgcctaagag tggcaaggct aaccagcccc       600
agggaagtgg ggcaggatac ccttcaggct ggaccaaatt tggtaatata gccctcctgc       660
tcagcttctt cacttgtctg tgggcgtcag gggcctgaag acccgttctc ctccaaccag       720
gacgccctgg cctctccttc ctgacaacca gcttcagaga ataaacttga atgtcgtttg       780
ccatctaaaa aaaaaaaaaa aa                                               802

<210> 13
<211> 2112
<212> DNA
```

<213> Mouse

<400> 13
```
gggtgctcag acggtgaaaa tcagagatca ggccaccttt ctgtgagcct tcagctgagt        60
ctaaaggtgt tattgatcag aatggcttca ggatggtttt acctgtcctg catggtgctg       120
ggatcgctgg gatcgatgtg catcctcttc actgcctact ggatgcagta ctggcgcggt       180
ggctttgcct gggatggcac ggtgctcatg tttaactggc acccagtgct catggttgcc       240
ggcatggtgg tgctctatgg agctgcctca ctggtgtacc gcctgccttc atcgtgggtg       300
gggcccaggc tgccctggaa agttctccat gcagcactgc acctgctggc cttcacctgc       360
actgtggtgg ggctgattgc cgtctttcgg tttcacaacc actcgagaat cgcacacctc       420
tactccctgc acagctggct gggtatcacc actgtagtcc tcttcgcctg ccagtggttc       480
ctgggctttg ctgtcttcct cctgccctgg gcatcccagt ggctgcgaag cctcctgaaa       540
cctctgcatg tattctttgg agcctgcatc ctttccctgt ccatcacatc tgttatttcc       600
ggcatcaatg agaagctttt ctttgttttg aaaaatgcca ccaagcccta ctccagcctg       660
cctggtgagg ctgtctttgc caacagcaca gggctcttgg tggtggcttt tggcttgctg       720
gttctctatg ttcttctggc ttcatcatgg aagcgtccag atccaggagc tctgactgat       780
agacagcccc tgttgcatga cagggaatga agcgggcagg ggctcctggg aacggtcagc       840
gatgcggtct ctgctccctc agaagttctg ctgtactggg gctcctggct ggtttcagca       900
acagacttct cttgggccag agacccaacc ttgctactcc agttgcaggc tctcgctgtc       960
cagccactag ctgttcctct gcttttcttg tggctttggc ttattgccgt ttttttctgg      1020
tcctccattg gcacaaagac cttcttgcct tggtcacaca tgtctcttct gctggtctgc      1080
agatttgggc tgctttcctt accactccta gggatgtggg agaagccaaa gctggggttc      1140
aaatgcagtc tacacgtgta aaatacaaag tctgctctct gtgggagcat ttgtcttagt      1200
taggtatgct tccccctctg ctctgtcctg gatgtgtatt tgggtgggca gttgcattga      1260
ggggtcattc atgggacagt ggcagccgga gaagcctctg ctgtaaagtc aggtgcccag      1320
tactctgctc ttttcacttt gatgtgctgt attgtgtgga ttgtgacctt gtgattcccc      1380
ctcttctagc tgctgctcca gctgcttcct ggatcccgcc ctttccctgt gacttacatg      1440
cctgttcccc tcaggtagca tgacgagccg ttaaacagtt ctcccaagaa cacatgtcct      1500
gtccctagag tccctcccag tgatgagtct gaggtttctt tggccttcct ttctgtccct      1560
ttgtgggtat gggctttcct gcctcctcta gttatgctct ccctgacag ggccccagcc       1620
cactatgaaa ttgaaaccag cattatgaag caatttgctg ggagccattc actgctgctg      1680
ccttcagaga tgttccttag tgagtagtgg gtgcttctgt ccccaaaag gtcactcagc       1740
taccctctat gctataccag aatgtgagct ttgctcttct gaatagaaac tgggtagaga      1800
gggaggagtc ttgccccact cctttgtgtt agccctgcca ggtccctcaa caggcaggca      1860
ggcaggcaag caggcagaca ggcaggcaga gttgggttcc tgaactctct gcagacagtg      1920
gccaggctgc cagacgttgg gaggagggct ggcatggatt tgctgactaa atggaagcct      1980
gaacacatag cgatgactct tggcacccac atgaacatct cctggttca ctcatgagtg       2040
ggtattttac ttcatgaatc ttatttttat taaatatgtt tttaaacatc agaaaaaaaa      2100
aaaaaaaaaa aa                                                          2112
```

<210> 14
<211> 915
<212> DNA
<213> Mouse

<400> 14
```
ggaagtaagt tcagaggcca tgagactgcc tctgccactg ttgctactgt tcgggtgcag        60
ggctatcctg gggagcgccg gggatagggt ttccctctcg gcttcggctc ccacactgga       120
tgatgaagag aagtactcgg ctcatatgcc ggctcacctg cgctgcgatg cctgccgggc       180
tgtggccttc cagatggggc aacgtctggc gaaagcagag gctaaatctc acactccaga       240
cgccagtgga ttgcaggagc tgagtgaatc cacgtacaca gatgtcctgg accagacctg       300
ctctcagaac tggcagtcct atggagttca tgaagtgaac cagatgaagc gtctcacggg       360
cccaggactt agcaaggggc cagagccaag aatcagcgtg atgatttctg ggggtccctg       420
gcccaatagg ctctccaaga cgtgtttcca ctacctgggt gagtttggag aggaccagat       480
ctatgaagcc taccgccaag gccaagcgaa tctggaggcg ctgctctgtg ggggcaccca       540
tgggccctgc tcacaggaga tcctggccca gagagaagag ctttagtcca acctgctgca       600
cttctggatc ttctctaatt ttattattat taatggctga ttagaggcag gctctcatca       660
```

```
tgtaggccag gctggcctta aacttgtcat cctgctcagc ctcgaaagtg ctgcatttaa    720
gtcctgagcc tttttgtgct tgaccctcct atataatttt ttcaactgtg gtggtgggga    780
ggggacaggg aagcctgact ctagctgtca atcttctccc tccacctctc gatggggtac    840
tgggactgag gctgcctttc tactttcaaa taaagctttg aaagacaaaa aaaaaaaaa    900
aaaaaaaaaa aaaaa                                                     915
```

<210> 15
<211> 1308
<212> DNA
<213> Mouse

<400> 15
```
gtgagagctc agctggaagt gactgggtga caaggcgcac aggctcagcc gtggaagctc     60
catcatgatt ccacaagtag tgaccagtga gactgtcaca gtgatttcac caaatggaat    120
cagctttccc caaacagaca aaccccagcc ttcccaccag agccaagaca gactgaagaa    180
acatctaaag gctgagatca aagtgatggc ggcaatccag atcatgtgtg ctgtgatggt    240
gttgagtctg ggaatcattt tggcatctgt tccctccaat ctacacttta cctcagtgtt    300
ttccatcctg ttagaatctg ctacccatt tgtaggagct ttgttttttg ccatctctgg    360
aattctgtct attgtcacag agaaaaagat gactaagcct ttggttcaca gcagcctagc    420
cctgagcatc ctgagtgtcc tctctgctct tacaggcatc gctattctct ctgtcagttt    480
ggctgcttta gagcctgcct tgcagcaatg taagctggct ttcacacaac tagacacaac    540
ccaagacgct tatcatttct ttagccctga gccattaaac agctgcttcg tggccaaagc    600
tgctctgact ggagtctttt cactgatgct aatcagcagt gtgttggagc ttggcctggc    660
tgtcctcact gccacactgt ggtggaaaca gagctcctct gctttctctg gaatgtgat    720
tttcctgtct cagaactcaa agaataaatc cagtgtatct tcagagtcac tttgtaaccc    780
tacatatgaa aacatattga cttcataaga attaagtaga ggttatatag cagaaaaatc    840
tgtctttaac atgatttaga aaagccattt actgtgtgac aacaatgctt aatatcttaa    900
tatcttaatg tgtgtattgg ttaatcagca accatgaaaa acatactaac tggctgggtt    960
cagtagcacg ctcttgattt ggcgtcagtc aaaacacaga cctgtaaatt ccaatttatg   1020
tagtggtcaa agagccccaa ttattttctc aaaaaactgg aagaatgttt cataggatca   1080
tggtggagcc aatgggcaac agttcttctt atccttgtca cttggctgca ggaggtactg   1140
actagggcct gagatcatat tctgtgtgcg tggcatggac ttcatggcat ctattttatt   1200
cataagcaca tgaaaacaag tcatctctta tgaagtctca aagagcataa aaaagttagc   1260
ctccaaataa agtctttatg taatcccaaa aaaaaaaaaa aaaaaaa                 1308
```

<210> 16
<211> 1288
<212> DNA
<213> Mouse

<400> 16
```
gctccagctc ctccatcctg tagtttacag ggtgtaccct atgtcgggac caatgtgacc     60
ctgaactgca agtccccaag gagtaaacct actgctcagt accagtggga gaggctggcc    120
ccatcctccc aggtcttctt tggaccagcc ttagatgctg ttcgtggatc tttaaagctc    180
actaaccttt ccattgccat gtctggagtc tatgtctgca aggctcaaaa cagagtgggc    240
tttgccaagt gcaacgtgac cttggacgtg atgacaggtc agtaagggg tccaaggctg    300
cagtggtcgc tggagcagtt gtgggcactt ttgttgggtt ggtgctgata gctggctgg    360
tcctgttgta ccagcgccgg agcaagacct tggaagagct ggccaatgat atcaaggaag    420
atgccattgc tccccggacc ttgccttgga ccaaaggctc agacacaatc tccaagaatg    480
ggacactttc ttcggtcacc tcagcacgag ctctgcggcc acccaaggct gctcctccaa    540
gacctggcac atttactccc acacccagtg tctctagcca ggccctgtcc tcaccaagac    600
tgcccagggt agatgaaccc ccacctcagg cagtgtccct gaccccaggt ggggtttctt    660
cttctgctct gagccgcatg ggtgctgtgc ctgtgatggt gcctgcacag agtcaggctg    720
ggtctcttgt gtgatagccc aggcactcat tagctacatc tggtatctga cctttctgta    780
aaggtctcct tgtggcacag aggactcaat cttgggagga tgcccacatt ctagacctcc    840
agtcctttgc tcctacctcc ttctattgtt ggaatactgg gcctcagtaa gactaaaatc    900
tgggtcaaag gacaaaagga ggaaatggac ctgaggtagg gggttgggag tgaggaggct    960
```

```
tcacttcctc cctgcttctc cctgaagcca gatgaatgct gcggaagatc ggctaccctc      1020
caagggctct ggaggagact gccagtcagt gatgcccctg gctctgtgat ctgtacaaca      1080
cccttatcta atgctgtcct ttgccgttcg ctccatctcc ctgtattaat ataacctgtc      1140
ctgctggctt ggctgggttt tgttgtagca gggggatagg aaagacattt taaaatctga      1200
cttgaaattg atgttttgt ttttattttg caaattccaa taaagataca tcgcatttgc      1260
atggccaaaa aaaaaaaaa aaaaaaa                                          1288
```

<210> 17
<211> 999
<212> DNA
<213> Mouse

<400> 17
```
gccagctttt tcctccgcag ccatgtcctg gtctccgatc ctaccatttt tgtcccttct       60
gcttctgctg ttcccactcg aggttcccag agcagccact gcgtcccttt cgcaagcatc      120
ctccgaaggc acaaccacct gcaaggtcca cgatgtgtgc ctcttggggc cacgcccatt      180
gccccctcca ccacctgtca gagtcagcct gtattatgag tccctgtgtg gagcttgtcg      240
ctacttcctc gtccgggatt tgttcccaac ctggctgatg gtgatggaaa tcatgaacat      300
caccctggtg ccctacggga atgcacagga gagaaatgtc agcggtacgt gggagttcac      360
gtgccagcac ggggagctgg agtgtagact gaacatggtg gaggcctgtc tgctggataa      420
gctggaaaag gaggcagcgt tcctaaccat cgtctgtatg gaggagatgg atgatatgga      480
gaagaaactg ggaccgtgcc tgcaggtgta tgctcctgag gtgtcaccag agagtatcat      540
ggagtgcgcc acaggaaaac ggggcacaca gctcatgcat gagaatgccc agctcacaga      600
tgccctacac ccacccacg agtatgtgcc ctgggtgctg gtcaatgaga aacctttgaa      660
ggaccccagc gagctcctga gcatagtctg tcagctggac·cagggaacgg agaagccaga      720
catctgctcc tccattgccg actcccccag gaaggtctgc tataagtaaa ggcataacct      780
caaactcgtc ccagaaaact gcccagcttc ttcaaattgc caacctgcaa gagctgctgc      840
ctcgctatga aaaccttgca catgtcccac aaagcccaga ctccagactt ctcagagaca      900
aggatcttgc cttattttca aatggtgcta aatttaaatt catagaataa atcatctata      960
ctcctgtgat tcctttttcc taaaaaaaaa aaaaaaaa                             999
```

<210> 18
<211> 2123
<212> DNA
<213> Mouse

<400> 18
```
gctgtcccgt gtcctgctgt ggaaactgct gcttcttcag agctctgcag tcctgtcctc       60
agggccttca gggaccgcag cagccagcaa ctctctggtg tctgagtctg tggtgagctt      120
ggcagccgga acccaggctg tgctacgctg ccagagcccc cgcatggtgt ggacccaaga      180
ccggctgcat gatcgccagc gcgtggtcca ctgggacctc agcggggacc cgggcagcca      240
acggcgccga cttgtggata tgtattcggc gggtgaacag cgcgtgtacg agccgcgcga      300
tcgcgaccgc ctcctgctgt cgccttctgc tttccacgac ggcaacttct cgctgctcat      360
tcgcgctgtg gagagaggcg atgaaggggt gtacacctgc aacctgcacc atcactactg      420
ccacctcgat gagagcctgg ctgtgcgcct cgaggttaca gacgatcccc tattaagtcg      480
cgcatactgg gacggtgaga aggaagtgtt ggtggtggcc catggcgcgc ggcactgat      540
gacctgcatc aaccgtgcgc acgtgtggac tgaccgccat ttagaggagg cgcagcaggt      600
ggtccattgg gaccgacagc tacctggagt gtcacacgac cgcgccgacc gcctgcttga      660
cctgtatgca tctggcgagc gccgcgccta tgggccgccc ttcctgcgtg atcgcgtgtc      720
agtgaacacc aacgcttttg cacgcggtga cttctcccta cgcatcgatg agctggagcg      780
agctgatgag ggcatctatt cctgccacct gcaccatcac tactgtggcc tccacgagcg      840
ccgagtcttc cacctacagg tcacagagcc tgcctttgag ccaccagctc gtgcttctcc      900
tgcaatgggg tctggtcaca gcagtgctcc tagcccagat cccaccctga cccgaggcca      960
cagcatcatc aatgtcattg tcccagagga ccacacacat ttcttccagc aactgggcta      1020
cgtgttggcc acgctgctgc tcttcatctt gctgctcatc actgtagtcc tggctacacg      1080
acatcgtcac agcggaggat gcaagacgtc ggacaaaaaa gctgggaagt caaagggaa       1140
ggatgtgaac atggtggagt ttgctgtagc cacaagggat caggctccat ataggactga      1200
```

```
ggacatccag ctagattaca aaaacaacat cctgaaggag agggctgagc tggcccatag        1260
tcctctgcct gccaaggatg tggatctgga taaagagttc aggaaggagt actgcaaata        1320
aatggaccct gagcttctgg ctgggccagc agctctgtat caaaggacat ctccctgacc        1380
ctcctgcggt attcctggct cttctcagcg gctggtccga cttacctaga aacttggcct        1440
aaacttggca gagcagctgc ctgtactttg cccttcctag aatcgccacc cctcatcttg        1500
gtgagcaact gtgggttccc tagagactct ggtatagtac gattgctgcc cttcagtcac        1560
ctgtgcccac tgatggtcgg acccccaact taaacacaac aaagatccct tgttaatatc        1620
caccaaatgc aaagtccctc gtggcctctt actgctaggg tcaggaagac acttaaaaat        1680
tccaggtaaa actccctagc caccagttaa acacattagc cattgtcctg ggggggggg         1740
ggtcttcctg agctgcatcg tgcctgtgtc ctgctcagag ccctgctgtt ataggttgtg        1800
actcatgggc ccgccttgct gctttgggca acttgaggct agcccagggc cctttctctg        1860
cttctgattc ctttctgccc aatgcctccc aagagctaca ccagcagttt ctgggtaccg        1920
tatgacccct ggccttgaca tccctcccta ggctggagtc tggggttggg gccccatttg        1980
tcctctgttt tggctgaaga tggggtgaag atttggctga .gtggcctatg ctgtcacatc        2040
aaacagctat catttactcc tacttggaaa gttgtcatgt gacaataaaa gatacatttg        2100
actttttaaaa aaaaaaaaaa aaa                                                2123
```

```
<210>  19
<211>  1391
<212>  DNA
<213>  Mouse

<400>  19
gctggcaggc tgctgtgcag tccacgagga aggcttcggt cgacaggaca ggcgtgcaga        60
cttcaggagg gaccctgggc agcagacatt ccctggaagg gcaggttgca ttgcatggtt        120
ggctcatgga ggcagcagag gtggcctcag ccaggcctgg gcagcatcag cccccggcag        180
cagcaagacg ctggctgttc cacctgccca caagaacagc caccaccagt acccagggga        240
tgactagcgg ccggaccaca ggccacaaaa agaagaaggc taccccactt acagatgcag        300
accatgtggg gctccggaga actgcttgta gcatggtttc tagtgttggc agcagatggt        360
actactgagc atgtctacag acccagccgt agagtgtgta ctgtggggat ttccggaggt        420
tccatctcgg agacctttgt gcagcgtgta taccagcctt acctcaccac ttgcgacgga        480
cacagagcct gcagcaccta ccgaaccatc taccggactg cctatcgccg tagccctggg        540
gtgactcccg caaggcctcg ctatgcttgc tgccctggtt ggaagaggac cagtgggctc        600
cctgggcctt gtggagcagc aatatgccag cctccatgtg ggaatggagg gagttgcatc        660
cgcccaggac actgccgctg ccctgtggga tggcagggag atacttgcca gacagatgtt        720
gatgaatgca gtacaggaga ggccagttgt ccccagcgct gtgtcaatac tgtgggaagt        780
tactggtgcc agggatggga gggacaaagc ccatctgcag atgggacgcg ctgcctgtct        840
aaggaggggc cctcccccggt ggccccaaac cccacagcag gagtggacag catggcgaga        900
gaggaggtgt acaggctgca ggctcgggtt gatgtgctag aacagaaact gcagttggtg        960
ctggccccac tgcacagcct ggcctctcgg tccacagagc atgggctaca agatcctggc        1020
agcctgctgg cccattcctt ccagcagctg gaccgaattg attcactgag tgagcaggtg        1080
tccttcttgg aggaacatct ggggtcctgc tcctgcaaaa aagatctgtg ataacctctc        1140
accacccagg ctggatagag cagtcatccc tagatccctt gtagccagag ttcaggcgct        1200
gtctggtggt gcctatgagc agaaggccct gcctcattgt ccctctttct taggaggttc        1260
ctaggacttg ggcatgggga gtggggtctt gtgtgactct tcagtggggc tccctgtcta        1320
agtggtaagg tggggattgt ctccatcttt gtcataataa agctgagact tgaaaaaaaa        1380
aaaaaaaaaa a                                                              1391
```

```
<210>  20
<211>  1864
<212>  DNA
<213>  Mouse

<400>  20
ggcaccgcgc gggcggctat ggagcgagcc tgaggcccgc caggatatga attggctccc        60
tctgaccgcc atttcagtgc ttgtaagtgt gaggtcagca actgcagcct acagattgat        120
aactgtcgaa cccctggaat tgtggaggca ctgcagtgaa gaaatatgta atcatggaat        180
```

```
ctccttgcta atcgtcacca cctgttccct gtgataagcc agccaggacg tgggctgagg      240
agaaggaaaa gaggccacca tgaagctgaa gcagcgagtt gtgctgttag caatactcct      300
cgtcattttt atcttcacca aagttttcct gatagacaat ttagatacat cagctgccaa      360
ccgagaggac cagagggctt ttcaccgaat gatgactggc ttgcgggtgg agctggtgcc      420
caagttggac cataccctgc agtctccttg ggagattgca gcccagtggg tggtgccccg      480
ggaagtgtat cctgaagaga caccagagct gggagcaatc atgcatgcca tggccactaa      540
gaaaatcatt aaagctgacg tgggctataa agggacacag ctaaaagctt tactgattct      600
tgaaggagga cagaaagttg tctttaagcc taagcggtac agcagagact atgtggtaga      660
aggggagcca tacgctggtt atgacagaca caatgcagag gtggcggcct ccatttgga      720
caggattctg ggtttccgcc gagctccctt ggtggtgggc agatatgtta atctgcgaac      780
agaagttaag cctgttgcca cggagcagct gctgagcacc ttcctaactg tagggaacaa      840
tacttgtttc tatgggaagt gctactactg ccgagaaaca gagccagcat gtgctgacgg      900
tgacatgatg gagggctctg tcacactttg gcttccagat gtgtggcctc tgcagaaaca      960
tcgacatccc tggggcagga cctaccgaga aggcaaactg gccaggtggg aatatgatga     1020
gagctactgc gatgctgtga agaaaacatc cccctatgac tcaggcccgc gtctcctgga     1080
catcattgac acggctgtct ttgattactt gattggcaat gctgatcgcc atcactacga     1140
gagctttcaa gatgatgaag gcgcgagcat gcttattctt cttgataatg ccaaaagctt     1200
tggaaacccc tcgctggatg agagaagcat tcttgcccct ctctatcagt gttgcatcat     1260
tcgggtttca acctggaata gactgaatta tctaaagaat ggagtactaa agtctgcctt     1320
aaaatctgcc atggcccacg accccatctc ccctgtgctc tccgatccac acttggacac     1380
tgtggaccag cggcttctga atgtcttggc caccatcaag cagtgtactg accagtttgg     1440
gacggatact gtgctggtgg aagacaggat gccactctcc cacttgtaat tctcaatgcg     1500
aaacaagtgg aactgatttt acaaagatag agaaacagca caatcaattc cgaatggcat     1560
gcgatggtct gcaggtggcc acagtgggtg ctggtggcag aagacggtgg cggccctggg     1620
agtgctcggt gttttctgca gtgcaagcta cggaccacag ttcagctgcc tcacctctca     1680
ggctgccagc agcagctctg ctcagtcttt attcccacac cagagggcga gcaggtgtga     1740
cataggctaa ggaagtgttt ccagagtgtg cgtctcgggt gacccttgct gtctttctc     1800
tacacccatg gattctctga aaacactttg cagttccttg tgtcttaaaa aaaaaaaaaa     1860
aaaa                                                                  1864
```

<210> 21
<211> 2324
<212> DNA
<213> Mouse

<400> 21
```
gggtctgtac tccccgctcc tcgccacaca cacaccgaga ggatgaggct caccgtgggt       60
gccctgctgg cctgcgccgc cctggggctg tgtctggctg tccccgacaa aacggtcaaa      120
tggtgcgcag tgtcagagca cgagaatacc aaatgcatca gcttccgtga ccacatgaag      180
accgtccttc cgcctgatgg ccccccggctt gcctgtgtga agaaaacctc ctatccggat      240
tgcatcaagg ccatttctgc aagtgaagcc gatgctatga ccttggatgg gggttgggtg      300
tacgatgccg gcctgactcc gaacaacctg aagcccgtgg cggcggagtt ttatggatca      360
gtggaacatc cacagaccta ctactacgct gtggctgtgg taaagaaggg aacagacttc      420
cagctgaacc agctcgaagg caagaagtcc tgccacacag gcctgggaag gtctgcaggc      480
tgggtcatcc ccattggctt gctcttctgt aagctgtcgg agccccgcag tcctcttgag      540
aaagctgtgt ccagtttctt ctcgggcagt tgtgtcccct gtgcagatcc agtggccttc      600
cccaaactgt gtcaactgtg cccaggctgt ggctgctcct ccactcaacc gttctttggc      660
tacgtaggcg cattcaagtg tctgaaagat ggcggtgggg atgtggcctt tgtcaagcac      720
acaaccatat ttgaggtctt gccggagaag gctgacaggg accaatatga actgctctgc      780
cttgacaata cccgcaagcc agtggatcag tatgaggatt gctacctggc tcggatccct      840
tctcatgctg ttgtggctcg aaaaaacaat ggcaaggaag acttgatctg ggagattctc      900
aaagtggcac aggaacactt tggcaaaggc aaatcaaaag acttccaact gttcagctct      960
cctcttggga aagacctgct gtttaaagat tctgcctttg ggctgttaag ggtcccccca     1020
aggatggact acaggctgta ccttggccat aactatgtca ctgccattcg gaatcagcag     1080
gaaggcgtgt gccgggaggg ctcgatcgac aactcgccag tgaagtggtg tgcactgagt     1140
cacctggaga gaaccaagtg tgacgagtgg agcatcatca gtgagggaaa gatagagtgt     1200
gagtcagcag agaccactga ggactgcatt gaaaagattg tgaacggaga agcggacgcc     1260
```

```
atgactttgg atggaggaca tgcctacatt gcaggccagt gtggtctagt gcctgtcatg   1320
gcagagtact acgagagctc taattgtgcc atcccatcac aacaaggtat ctttcctaaa   1380
gggtattatg ccgtggctgt ggtgaaggca tcggacacta gcatcacctg gaacaacctg   1440
aaaggcaaga agtcctgcca cactggggta gacagaaccg ctggttggaa catccctatg   1500
ggcatgctgt acaacaggat caaccactgc aaattcgatg aattttcag tcaaggctgc   1560
gctcccgggt atgagaagaa ttccaccctc tgtgacctgt gtattggccc actcaaatgt   1620
gctccgaaca acaaagagga atataatggt tacacagggg ctttcaggtg tctcgttgag   1680
aaaggagatg tagcctttgt gaaacaccag actgtcctgg ataacaccga aggaaagaac   1740
cctgccgaat gggctaagaa tctgaagcag gaagacttcg agttgctctg ccctgatggc   1800
accaggaagc ctgtgaaaga ttttgccagc tgccacctgg cccaagctcc aaaccatgtt   1860
gtggtctcac gaaaagagaa ggcagcccgg gttaaggctg tactgactag ccaggagact   1920
ttatttgggg gaagtgactg caccggcaat ttctgtttgt tcaagtctac caccaaggac   1980
cttctgttca gggatgacac caaatgtttc gttaaacttc cagagggtac cacacctgaa   2040
aaatacttag gagcggagta catgcaatct gtcggtaaca tgaggaagtg ctcaacctca   2100
cgactcctgg aagcctgcac tttccacaaa cattaaaatc caagaggtgg gttgccactg   2160
tggtggagac agatgctccc tcccgtggcc catgggcttc tcttggtctt catgccctga   2220
ggggttgggg ctaactggtg tagtcttcgc tgctgtgcct taccacatac acagagcaca   2280
aaataaaaac gactgctgac tttaaaaaaa aaaaaaaaaa aaaa                     2324
```

```
<210> 22
<211> 1859
<212> DNA
<213> Mouse
```

```
<400> 22
ggcgcaccta ccccagccta tgtgcgctcc gcaaggagaa ccgagccgct cgccagcggg     60
gcgcgctccc ggctgtgcca gtgcagaagg gtgcctgcga ggaagcaggg accacaagag    120
cagggcggct ccggagaaag tacaacttca tcgccgcagt ggtggagaag gtggcgccgt    180
ctgtggtcca cttgcagctg ttccgcagat dacagacaca caggttccca cactgatcta    240
aaggaggaga caccatcctg gacccagatc tcagttgtgt tcagaaaaga tggccaggac    300
gagcttcagg cagctcacaa agcacatgga agtggatcac ctctcaccaa ccaggaaatc    360
ccttcctcca gcggctctgg gttcatagtg tctgaggatg ggctcattgt caccaatgcc    420
cacgtcctca ccaaccagca gaagatccag gtagagctcc agagcggggc ccggtatgaa    480
gccaccgtca aagacatcga ccataaactg gaccttgcac tgattaagat cgagccagat    540
actgagcttc cagtactgct gctgggccga tcctctgacc tccgggctgg agagtttgtg    600
gtagctttgg gcagcccatt ttctctgcag aacaccgtga ctgcagggat tgtcagcacc    660
acacagagag gcggcagaga gctgggactg aagaattcag acatagacta tatccagacg    720
gatgccatca ttaaccatgg aaattctggg ggtccgctgg tgaacttgga tggcgacgtg    780
attggtataa acactctgaa ggtgactgca gggatctctt ttgcgatccc ctctgatcgg    840
atcagacagt tcctggaaga ctatcatgag cgccagttga aaggcaaggc ccctttgcag    900
aagaaatacc tgggtcttcg aatgctgcct ctcactctga acctccttca ggaaatgaag    960
aggcaagatc cagagttccc tgatgtgagt tctggagttt ttgtatatga agtgattcag   1020
ggatcggctg ctgcaagctc ggggttgaga gaccatgatg taattgtcag cataaacggg   1080
caacctgtca ccaccacaac tgatgtcatt gaagctgtta aggacaatga ctttctctcc   1140
atcattgtgc ttcgaggaag tcaaaccttg tttctgacag tcacacctga ataatcaat   1200
taagtatctt actttgagaa actgcctagc aaaaccagtt atattacctg gttttgtatc   1260
gaagaggtgc cagagatggc agggtcttct ggagatcaag aaaaatggat gctttaaatg   1320
cagaagttca tgtttgtgtg catacatcaa cacacacaca cacacacaca cactcatgga   1380
tcctgaggtt gagagtgctc ttctgccgca aaaccttcct aactcaaatg gaaacagcta   1440
tggtgatctg ataaaacttg atgacagtaa gaactggaaa gcaggcaatt cctaactaaa   1500
tcttgatagg aaactttagt tacctcctat acagccacaa actggtatgt cacgcacatg   1560
tacacataat tacctaccaa atattaagaa cctgaatctg gagtaaagag gtaatcacat   1620
tttaaataat acccctttgt atactgaatt tcccaggtta tatccactct gggccagggt   1680
ttgtggatag aaaggtcatc acctataaga catcttggag ctgatgacat catactacca   1740
cacaggagtg tgatcatttt ggaggtagaa acaatttcgg acctttagag tttctgagaa   1800
tgtcttctat ttctattaaa ataatttttc gaaccgttaa aaaaaaaaaa aaaaaaaaa   1859
```

```
<210>  23
<211>  724
<212>  DNA
<213>  Mouse

<400>  23
atgcctgcct  gtcgcctctg  cttgctggcc  gctggcctcc  tactagggtt  gctactgttc      60
acccccatct  cagccacagg  caccgatgca  gagaaacccg  gcgagtgccc  ccagctcgaa     120
ccaattacgg  actgtgtgtt  ggagtgcact  ttggacaagg  actgtgcgga  caaccgcaag     180
tgctgccagg  cgggctgcag  ctctgtctgc  tccaagccta  atggaccgag  cgaaggagag     240
ctctcaggga  cagatactaa  actctcagag  actgggacta  ctactcaatc  agcgggcctt     300
gaccacacta  ctaaaccacc  gggaggtcaa  gtctccacga  agccaccggc  tgtgaccagg     360
gaaggcttag  gtgtccgaga  aaagcagggc  acctgcccca  gcgtggacat  acccaagctc     420
ggcctctgtg  aggaccagtg  tcaggtggac  agccagtgtt  ctggcaacat  gaaatgctgc     480
cgcaatggat  gtgggaagat  ggcctgcacc  acacccaaat  tctgagcttc  agcctccagc     540
agcctgagga  acggagagag  gttgtttctg  ccggactgtg  catctggagt  cgttcctgtg     600
gcctcctttc  tctctggtct  ttgcatttct  tcctggtccg  acgaaagcat  ctcctttttc     660
taaccaataa  agtgatcgtt  ttcagcaatg  gagaagctat  aaaaaaaaaa  aaaaaaaaaa     720
aaaa                                                                     724


<210>  24
<211>  2395
<212>  DNA
<213>  Mouse

<400>  24
gaaagaatag  agacagagaa  ggagtttctg  cattcttggg  atcacaaacc  agaccatgaa      60
agctggcatt  cagaatgcct  gcctaccaaa  agtctcagca  aggcccagca  agctccacag     120
gatgcttttc  aagggtggct  ctgtggtgtg  ggtacggcca  aaggtgggga  aagccagtct     180
ttgggagcag  actctttgta  ggagtctgcc  cttccctctt  ccctgccca   ctccactctg     240
acagccacag  gtggaatgat  gagggcccaa  atgtgggaca  tctatgctca  gatattaaac     300
ctaagctcac  gtaagaagtg  ggcaaagact  ggccctggtt  tgtctgtaag  agacccagag     360
tttcccaacc  ccctgccat   gagctaggtc  atcacactaa  tttgttgatg  tttgctcctg     420
tttgccttaa  ggatagtgac  ccttgcctga  cgcagatgtc  atgtttaggc  attaagtgtc     480
cataggtcat  tccgtagggc  atctagtaca  cgtcggttca  caaatctact  tccaagaccc     540
tcagaatcct  tcattaaagg  gctgggcctg  ggtgtctgaa  tttctgatga  gctccctgca     600
atatggttaa  atgcactata  actggaggtc  agagccttag  aaccggggggg  agcagagcca     660
ccttgtaaat  gttatcaggc  taatcacaat  gagatggccc  cactgctagc  tacgtctcag     720
cctccatcag  ctcttgctgc  ctcttccaca  gctgcttaca  tctgggacac  ttgtgcccca     780
ttcccaggcc  atacaagcct  ggaaggtggg  ctggacagcc  tcctccctga  cctacatggg     840
aaggtctctc  cttttcttcc  cgccctttt   tctaatgtgg  atgcttccat  taatcctctg     900
tttctggagc  cttggaagat  ctgtcttcca  ttcattcatc  cacccatcca  tcattcaaca     960
tgaatgggtc  atgtcacgtg  ttgggtgcaa  gggatactct  ttcaaaacaa  tccctcacga    1020
gactcacagt  ctagtgaaga  gcacacgcca  gaaaccaatt  agagaagcta  ccaaccacga    1080
tggaacatca  gggattcaaa  acctcggggt  gagagggagc  ctactttctc  tgtgttcttc    1140
taagagccct  gatggctctc  gattgctctg  aacagaggtc  cacttggtcc  agtgctatca    1200
tgggtagtgc  ccacgaggtt  tccccagaga  atactactgt  agagcattct  atactcccca    1260
cagggagaca  ggaaaggatt  cccagagcca  tggctcttaa  gatggtcctc  gaaggaaaat    1320
ccagtcattt  ccaagtgggc  cctgaaccct  gaggctatgg  ggaggtcttc  agaagtcctg    1380
gaagagtgac  aacacccgag  tcccaggagc  tctgtgatgg  caaccttctc  ccttgaacac    1440
ccttttccat  ttttgagcat  cgagttggag  aggtgattct  gggacagggt  gtgtatattt    1500
gtgttgttta  aacacattca  catgtaagct  gcctgagggg  aggggatgtt  tgcctctagc    1560
tcagtcccag  tggagctggg  gggatgatga  gtctgagtgg  ctttagggcc  atcattgaca    1620
ccacctcagt  acaaacggac  tcccctccct  tcctccctct  cttctatcct  cctttccttc    1680
cttcccttag  cagggctgcc  aaggtgatat  gggacagcga  caggcaaac   gatcacctgt    1740
tgccttaatg  aactttccac  agctcactgc  tggctaggtc  gtagagtttc  tccttgtctt    1800
gtgaggccca  aggaaggagg  ccaatctaaa  gtgtcctcca  taccttcccc  ttgggggctt    1860
```

```
ttctgtaata cttgtttaaa aattgttctg atgatcatga tggaaacaga cagaccacct    1920
tagaaccaga ggcctgaaag cctgacctga ccagcacaga ttcccacttc agaaccccag    1980
ggctatggaa gtgcccttgt ccaacgctat gggaatagtc ctgtgggttg tctctgcttg    2040
ccactgtggc cagcattcca gtgcctacag ccacctgtgc ctacagccac ctgtgccatg    2100
agaagtgcct ctcctgctct atgccctgca tttgggatgc taagaagagg tgagggtgtg    2160
agcgagaaca gatccaccct tctcctaggt aggatcagct ctcaattggt gcttatcact    2220
agttatcaaa gaacagcaga gacagctgcg ttatccaaga agcaagtatt aggaccaaaa    2280
cctgttactg tatttaaagg aactttagtt tgcgtatctt acattttat aaagtactgt    2340
aattcagggg gtggggtatg caacagagac agactaaccc atgtttgtca tttgc         2395
```

<210> 25
<211> 881
<212> DNA
<213> Mouse

<400> 25
```
gtgaggaatg gcgacctttt ttttaaaaag gtgcaggtcg aggatggggg tgtgtatacc      60
tgttacgcca tgggggagac tttcaacgag acactgtctg tggagttgaa agtgtataac     120
ttcaccttgc acggacacca tgacaccctc aacacagcct acactaccct ggtgggctgt     180
atcctcagtg tggttctggt cctcatatac ttgtacctca ccccttgccg ctgctggtgt     240
cggggtgtgg agaaaccttc cagccaccaa ggagatagcc tcagctcttc tatgctcagt     300
accacaccca accacgaccc tatggctggt ggggacaaag atgatggttt tgaccggcgg     360
gtggccttcc tggaacctgc tggacccggg cagggtcaaa atggcaaact caagccaggc     420
aacactctgc cggtgcccga agctacaggc aagggccaac ggaggatgtc cgatccagag     480
tcggtcagct cggtcttttc tgatacaccc attgtggtgt gagcagcgta ggctgatggg     540
gaggttctgc cccaggagag gtacccctga gggatatgac agggtggaag agagggctgg     600
atgcccaagg gagtgggttc ctcctgacca ccagggaatc ggtcacaggc gccggaggag     660
gcaagacccc agtgagggtg tggatgctgc gagtttcacc tatggatatc ctcaggcaga     720
tgccacaccc ctacccaaag ccttggctat tctcagtgtg ggggaggggg acaggaacga     780
ggaaagggcg gaggggagga gcaaattccc taaacttttt tgaggtcatc cctagctcct     840
taagagaaaa ccatttgaaa aacaaaaaaa aaaaaaaaaa a                         881
```

<210> 26
<211> 556
<212> DNA
<213> Mouse

<400> 26
```
gcaccactcc cctggctcga gtcatctccc gggacactga aacacagaga tattacctgc      60
taagtcacac acctgcctgc agtctcaccc tgggtcctga tatggaggaa atcacctgtg     120
cctttctcct gctgctagca ggtctgccgg ccttggaagc cagtgaccca gttgataaag     180
acagtccctt ctactatgac tgggagagcc tgcagctggg aggattgatt tttggagggc     240
tcctgtgcat cgctggaatt gccatggccc tgagtggcaa gtgcaaatgt aggcgtaccc     300
ataagcccag ttccttacct ggaaaagcca ctccactcat cattccaggc ctgccaata      360
cctgctgaac tgaacacagg accaagtttg gaggcaggtt tttgacaact ttctgccgta     420
cttctcctct ggagaccttc ctctccagga tggcttccct agaacatact gttaagtctt     480
cattgacagg aaagggtgtg gcaaagctga ttttatatta aactggtctt gctgctcaaa     540
aaaaaaaaaa aaaaaa                                                     556
```

<210> 27
<211> 750
<212> DNA
<213> Mouse

<400> 27
```
gctgagtgtg gttctgggtg gaaccctcta cataggccat tatttagcca tgtattccga      60
aggcgccccc ttctggactg ggatcgtggc tatgctggct ggagctgttg ccttccttca     120
```

```
caagaaacgg ggtggtacct gctgggccct gatgaggacc cttcttgtgc tggcaagttt      180
ctgcaccgct gtggctgcca tcgttattgg gtctcgtgag ttgaattatt actggtattt      240
tctcggagat gatgtctgtc aaagagactc ttcatatgga tggtccacca tgcctagaac      300
cactccagtt cccgaagaag ctgataggat tgccttgtgc atatactaca caagcatgct      360
aaagaccctg ctcatgagcc tccaagctat gctcttgggt atctgggtgc tgctgctcct      420
ggcttctctc accctgtat  gtgtctacat ctggaaaaga tttttcacaa aggcggaaac      480
agaggagaag aaactgctgg gtgcagctgt gatctagcct ttcctcttgc tccgggcgtc      540
cctcctactg aagcctgaaa gaagaatcag gcaggactaa gaagaccctc ccccactagc      600
agggccatgg ccactgcctg gttctgccca gcaccacagc agctctcagc agcacttgct      660
tgtctctcca tccttcaccg tcctatatcc ctcctcaggc agcaacttga taataaactc      720
tcctgttatt gctggcaaaa aaaaaaaaaa                                       750
```

```
<210> 28
<211> 1896
<212> DNA
<213> Mouse
```

```
<400> 28
gtgaacatct gtctcccntta ctgcgggtgg ccagccacag tgccccggag ggatctgcac      60
aatgctccag cacactagcc tggtgttact cctcgcctct atttggacca ctaggcaccc      120
agtccaaggt gccgacctcg tgcaagacct ttccatttct acatgcagaa tcatgggcgt      180
tgcccttgtg ggcagaaaca aaaacccaca gatgaatttc acagaagcca acgaggcctg      240
taagatgctg ggactgactc tggccagcag ggaccaggta gagtcagcgc agaaatctgg      300
ctttgagact tgcagctatg gatgggttgg agaacagttc tctgtcatcc ctcggatttt      360
ctcaaacccc aggtgtggga agaatggcaa aggtgtcctg atttggaatg ctccctccag      420
ccaaaagttc aaagcctatt gccacaactc atccgacacc tgggttaact cctgcattcc      480
agaaatcgtt accacatttt accccgtgtt ggacactcaa acacccgcaa cagagttttc      540
tgtcagcagc agcgcctact ggcttcatc  ccctgactcc acaacacctg tttctgccac      600
cacccgggct ccacctttga cctccatggc acggaagaca aaaaagattt gtatcacgga      660
agtttataca gaacctatca ccatggctac agaaacagaa gcatttgttg caagtggagc      720
agcattcaag aacgaagcag ctgggtttgg aggtgtcccc accgccctgc tggtgctggc      780
tctcctcttc tttggtgctg ccgctgtgct ggctgtttgc tacgtgaaaa ggtatgtgaa      840
ggccttccct ttcacaacca agaatcaaca gaaggaaatg atcgaaacca aggttgtaaa      900
ggaagagaag gctgatgacg tcaacgctaa tgaagaatca aagaaaacca ttaaaaaccc      960
agaggaggcc aagagtccac ccaaaactac ggtgcgatgc ttagaagctg aagtttagat      1020
gcaagagagt ggagaaggtg cacacgaggc aagtttcatg ccccgggaac caaagaagca      1080
agccactgtc agttcctgca gaaaaagact gcagagttca ccagaaggag ccctctcctt      1140
actgcagtct tctctggact ctaccctctg gcctccaacc ttcccacagc ctccctaacc      1200
cttctgtggc tcacagcaga ccagagagta gagggagctt tcaaagtacc aggtcctaaa      1260
acagctccta agctcacact cagagacagg cttccaggtt gcctgacccc catgaaaggc      1320
cagagtccct gagacatggc cagccccata gttcaaaatc ttcccacagg gaaatacacc      1380
acctggccgt gctctttgga accaggcaca tgtaaaataa ggaaggaaa  acaacagaag      1440
gtcatggaga gcctgggtga cttgagactt aatctctgga aagccaaaat aaacagagca      1500
tgagatggga gctggggcca cagatagcag ccttgttggc tgagactgta aatacaggct      1560
ggggctgaga agcctctcgg ttaattgatc tgcagcacgt agacagactt tcttttcttt      1620
ttactgttgc tggtgttctc tagagacaaa tacacgttta taagaaacct aaaagcagga      1680
gagcccagga gctgactcag tggtaaagca cttgcccggc atgtacaaac aaggcttcca      1740
gtccaatccc cagaatccac tgaccccaca cacacaaaga aacaaacaca agtatgcatt      1800
tccatttttt acttgaatta caggacccat ggctgagaaa ataactgtgt taaaaggtta      1860
aaaaaagga gaaagtaca  aaaaaaaaaa aaaaa                                  1896
```

```
<210> 29
<211> 1854
<212> DNA
<213> Mouse
```

```
<400> 29
```

```
gcccacatgg tctgggccaa cttggctgtg tttgtcatct gcttcctgcc cttgcatgtg      60
gtcctgaccg tgcaggtctc cctgaacctc aatacctgtg ctgcccgaga caccttcagc     120
cgtgccctgt ccatcacagg taaactctca gacaccaact gctgcctgga tgccatctgt     180
tactactaca tggccagaga gttccaggaa gcgtccaagc cagccacgtc ttccaacaca     240
ccccacaaga gccaagattc ccagatcctg agcctcacct agaagaagtg aacacatgcc     300
aagggccaga ggaacctgtg atgtgagcaa ggagccctgg atcagcctga acctcctgtg     360
gggtctgagc actctaggag acccagttgg actagagagg ctgcatctgc tcccctgaaa     420
ggaccagagg actcaggctc taacgtccga cctgagggac cctggaacaa gaccacatat     480
ctcccattcc agatctagaa accctgggca ccagaatggg gccttgatgg ctagccactg     540
agtttaggat acacccctcc ccagagttgg tcctggcaag gtcctctgtc acctagatgc     600
aagtgatgag agataaagga cagacatacg gctcagagaa ccaggagaca tctttccaga     660
ggaccctcaa atggcttctt ccttttagga cctttaaact tcatgccaca tgtaggggtg     720
ggcaaaaggg cagcagctgt ggtctggcag gctgtcctcc aaggcccatg actgtcactg     780
ttgctccagc tctgtattat gagggttcca gctcaggaga cccagtggtc ataacatcat     840
gttgagcaat cggacctgag cctcttctgg ttatttccat tctatagtgg gactgttgat     900
tcctgaggac agtggctatg gtagaggtct ctggagttta ttgtgaggaa gattgctgtt     960
tggtattcat gctctctgag gatgtggccc caggcttcga ggatctctgg agtaaaggat    1020
gagccacaaa gccagctttg agtcaggagc acatttggag atgtggtagc cctgggcttc    1080
cccctcaatg ctttgatttt tgtcttggtc caaatgctac agctgtaccc agagccagag    1140
cccctccagc tcaggggagg ggggtactgg ctctccctac tctctacccc tacttcatcc    1200
aaggcctact gcctaactga cccctttttt tgtatgacct tttctacaaa aaccaaaaat    1260
ctgttcatcc ttcagacacc agagaaagga ttccactcaa gtataaattg gtgaactgat    1320
ttcctggagt tacttacaaa agcacggtga ctcttgggtg ctcagtcact gaaaagcctc    1380
actcagcata gataacaatc cccaaactgc accgctagat taccaatccc cactaaactt    1440
ccacctcaca cacacacttg gacacctgac ctgctccaga caaaaatgtg cctagggtgt    1500
gaggaagctg tggctgcgac ccaaggtgtg ctgaccctct tcgctctgcc aaggactact    1560
aacagcttca tgatcatcag cctattcgcc acagccgtat tttgcttgtt tcactggcat    1620
gactgtaggc cgagctgttc tgtggatcag agcagcgctt ttcctgttca ctgctgatga    1680
tcatcctaag ccagagaaat ggcttctctg ccacactggc ccactctccc tccagttctc    1740
acatcccctc caccctctgt tctgcagtat tatctaaacc ttcaccttgg aaggaaggga    1800
tggtgtatct atataatatc aagatatagg atccacaaaa aaaaaaaaaa aaaa          1854
```

```
<210> 30
<211> 2866
<212> DNA
<213> Mouse

<400> 30
ggtttcggag agataaggcg cttggccgtt actaactgga ctacaaagag ctggatcgga      60
ccggaaccac atggctcaac tcgcccgagc caccgctcc ccgctgtcat ggctgctgct     120
gctgttctgc tatgcactcc ggaaagcggg tggggatata cgtgtgctgg tgccctacaa     180
ttcgacaggc gtcttgggag ggtcgaccac cttgcactgt agtctgactt ctaatgagaa     240
tgtgactatc actcaaataa cctggatgaa gaaggattca ggtggatccc acgctcttgt     300
ggctgtcttc caccccaaga aggggcccaa catcaaagag ccagagaggg tgaaattctt     360
ggctgcccaa caggatctga ggaacgcatc tctggccatc tcgaacttaa gtgtagaaga     420
cgaaggcatc tatgaatgtc agattgccac attccccaga ggcagtagaa gcaccaatgc     480
ctggctgaag gtgcaagccc gacctaagaa cactgcagag gccctggagc cctctcccac     540
cttgatactg caggatgtgg ctaaatgcat ctctgccaat ggtcaccctc ctggacgaat     600
ctcttggccc tcgaatgtga atggaagtca ccgtgaaatg aaggaaccag ggtcccagcc     660
gggcaccacc acagttacca gctacctctc catggtacct tctcgccagg cagacggcaa     720
gaacatcacc tgcacggtgg agcatgaaag cttacaggag ctggaccagc tgctggtgac     780
cctttcccaa ccctatccac ctgaaaacgt gtccatctct ggctatgacg gcaactggta     840
tgttggcctc actaacttga ccctgacctg tgaagctcac agcaaaccag cgcctgacat     900
ggctggatat aactggagca cgaacacggg tgactttccc aactctgtta agcgccaggg     960
caatatgctt ctaatctcca ccgtagagga tggtctcaat aacacggtca ttgtgtgcga    1020
agtcaccaat gccctagggt ctgggcaggg ccaagtgcac atcattgtta aagagaaacc    1080
tgagaatatg cagcaaaata caagattaca cctaggctac atctttctta tcgtctttgt    1140
```

```
cctcgctgta gtcatcatca tcgcagcact atacactata cgaagatgca ggcatggtcg    1200
tgctctgcag tccaatccct cagagaggga gaacgtccag tattcatctg tgaacggcga    1260
ctgtagactg aacatggagc caaacagcac aaggtgacgg tgctgggtag acagaactaa    1320
ggaacttgaa ggcatagcaa ctggaaccct actctcataa atgaagaagc ctccagagag    1380
actggctgct cagtgtgatg agcatagcaa gtttgggggg tctcccagga tgctgccgaa    1440
ttccacgttg tcaaaaggac ccatggaggc cagtgtgttg gctcactctt gacatctcag    1500
caagctgggg ggggggggg gagcataaag caaggttgag tctagcttgg gctatagagc     1560
aaagccctgt ccatacacaa acaagctaag gggctttgag acggtcagaa actgaagtct    1620
tgctttgggt aaggtaaatc ctctaccgca tgtatgtgct agacttgaaa gacttccaca    1680
cagacctctt tataagttga ctccattggg gctatccct cctctctgga caaggtctct     1740
gtatgtagcc aaggctaggc tcaaactcac agagatatgt ctgcttctac ctccccagtg    1800
ctagagttga aagtatttgt gccactgcac ttttctaggt cttcttttaa tgaagtaaag    1860
tatatattta taaaaagcta tttagttata tatatatata tttttgagac tatttcatag    1920
agcccaagct aacctcaaac ttactatgta gccaagagtg atggtaaact aatttatttt    1980
aatttatttg tcttcaattt taaccatcac ccaacccctg ctcccttcca tatcttcttt    2040
caatccattt cattgtcttt ttcttcccag acactattct gacttacgtc tccattacaa    2100
acattttatt gaactacata aaaatgtgtg aaccacaaaa aaaaaatgta tttgtcaaaa    2160
ttgtagttgt ctttctgagg ctgacctgag ttctctgata ccattctctc cagttgtatc    2220
cagtttcctg taaacaatgt gactttgttt ttctcagtag ctaaaacatc ccaattatgt    2280
gagtgtacac tttctttact cattcctctg tgggccacca gctgggttgg ttccatatct    2340
gagctattgt gcatggaatt gtctctgtgg tgggtttagt aaactcccag gaatgcctgt    2400
acatgtttgt agaggccaga agaaggcaca aaatcttgag ccaggcttac atgcacttgt    2460
gagtagcccc acataggtgc taagaaccca gttcaggtcc tctgctgtgg gatggtgggc    2520
tgtgcacaga aagcctggtc ccggtctagc aaaggtctgg aactccggag ccggtgggct    2580
gtgatttaca ccagcatggg atggaaggag ttggacctcg cctcctgggc acctggctcc    2640
tgtcacatag ctacagcctc ccacagcccc cctataggga ggtatgcagc atcaatcaca    2700
tagtagctgc actaagccct cccacatgca aataaggttt ccccaaactc tcagtccaag    2760
ccaatgaaaa gtacctgctg tcaaacccta aatcatcccc aaaactctgt aagtcctatc    2820
agggaataaa atgtgtgtga aaactaaaaa aaaaaaaaa aaaaaa              2866
```

```
<210> 31
<211> 1093
<212> DNA
<213> Mouse
```

```
<400> 31
gcgaccactg agaccttgag actcagacac caagagagat gtttctagtt gggagcctcg    60
ttgtcctctg tgggctgctg gcccacagca cagcacagct ggcaggcttg ccattgcccc    120
tgggccaggg tccacccttg ccactgaacc agggcccacc gttgccactg aaccagggcc    180
agctgttgcc cctggctcag ggtctgcctt tggctgtaag cccagcactg ccttcaaatc    240
ccacagatct tcttgctgga aaattcacag atgctctcag cggtggcctg ctgtctgggg    300
ggctgctggg cattttggaa aatattccac tcctggatgt tataaagtct ggaggaggca    360
attctaatgg ccttgttggg ggcctgctgg gaaaactgac gtcatcagtt cctctcctga    420
acaacatcct cgacataaaa atcactgatc cgcagctgct agaacttggt cttgtgcaga    480
gtcctgatgg ccatcgtctc tatgtcacca tccctctggg cttgacactc aacgtaaata    540
tgcccgtagt tggaagtctt ttgcaattgg ctgtgaagct gaacattact gcagaagtct    600
tagccgtgaa agacaatcag gggaggattc atctggttct tggtgactgc acccactccc    660
ctggcagcct gaaaatcagc ttgctcaatg gagtcactcc tgttcaaagc tttttagaca    720
acctcacagg gatattgact aaagtccttc ctgagctgat ccagggcaag gtatgtcctc    780
tggtcaatgg gattctcagc ggtttggatg tcaccctggt gcacaacatt gctgaattac    840
tgatccatgg actacagttt gtcatcaaag tttaggcatc ccaggaagga aggctatctt    900
ggctgagctg aatcatttct tgctgctcag tctcctgcct cttgcccagt ctcccatggc    960
tcacagaaag gggcccacat cctggaaaat tatgtcttcc ttctcctcac ggagcctgat    1020
ctcttcccat caggcacgat taatcctgtg atcctcacta aataaaatag ctcttcatct    1080
gcaaaaaaaa aaa                                                    1093
```

```
<210> 32
```

<211> 1353
<212> DNA
<213> Mouse

<400> 32
```
gaaacagtat gagcaaacac tgagctgagg ggagcttctg attaagagcg ctccccagcg    60
aggccccgagg ccgtgaacct tcccagcaag agggtggtgg ttgctcctgg aagcctgcgc   120
ccagcagctg aagccatggc caccaccacg tgccaggtgg tagggcttct cctgtccctc   180
ctgggtctgg ccggctgcat agccgccact gggatggaca tgtggagcac tcaagacctg   240
tatgacaacc cagtcaccgc cgtgttccag catgaagggc tctggaggag ttgcgtgcaa   300
cagagctcgg ggttcaccga gtgccggcca tacttcacca tcctgggcct tccagccatg   360
ctgcaagctg tacgagccct gatgatcgtg ggcattgttc tgggggtcat cggtatcctc   420
gtgtccatct tcgccctgaa gtgcattcgc attggtagca tggatgactc tgccaaggcc   480
aagatgactc tgacttctgg gatcttgttc atcatctccg gcatctgtgc aatcattggt   540
gtgtctgtgt ttgccaacat gctggtgacc aacttctgga tgtccacagc taacatgtac   600
agcggcatgg gcggcatggg tggcatggtg cagaccgttc agaccaggta caccttcggt   660
gcagctctgt tcgtgggctg ggttgctgga ggcctcaccc tgattggggg agtgatgatg   720
tgcatcgcct gccgtggcct gacaccagat gacagcaact caaagctgt gtcttaccat   780
gcctctggcc aaaatgttgc ctacaggcct ggaggcttta aggccagcac tggctttggg   840
tccaacacca gaaacaagaa gatctacgat gggggtgccc gcacagaaga cgatgaacag   900
tctcatccta ccaagtatga ctatgtgtag tgctctaaga cccgccaacc tgtgtgcagg   960
aggaacccctt ccccaagaag agctcacccc aaagcaacgg gagtctacct tgttcccttg  1020
ttgatttcaa ctgacatctg aaagttggta aagcctgatt ttcatccata gggaggctag  1080
acagtcttgg ccacatgtgt ctgcctctaa atatcccatc acaaaacagc tgagttatcg  1140
tttatgagtt agaggccata acactcactt tagcccaacc ctctgctttt taccgtagac  1200
tttcttttca tctggtgatg gaatggaatt tgactcacag actaatactt taatggttta  1260
gagaaacttt ccttcctcgt acttaataag cctgctgatg gtcgattttc cagcttgacc  1320
accaagggaa attttaaaaa aaaaaaaaaa aaa                                 1353
```

<210> 33
<211> 1046
<212> DNA
<213> Mouse

<400> 33
```
gcctcagtcc acagctgtct ccccagctgc ttccagtgaa caccccggca gtctaggctc    60
ccacagcaat gagttggtgg agggacaact tctggatcat cttagctatg tccatcatct   120
tcatctccct ggtcctgggt ctcatcctgt actgtgtctg caggtggcag cttagacaag   180
gcaggaactg ggaaattgct aagccctcaa aacaggatgg aagagatgaa gaaaagatgt   240
atgagaatgt tcttaattct tcaccaggcc agttacctgc tctgccaccc aggggttcac   300
cttttccagg agacctagcc ccacaggaag ctccaagaca accctcagct tggtactcat   360
cagtgaagaa agttaggaac aagaaggtct ttgctatctc gggctccacc gagccagaaa   420
atgattatga tgatgttgag attccagcaa ccaccgaaac ccagcactct aaaaccacac   480
cttttggca gctgaagtg ggtttacaca gctcgtttta gaatactcta gaatagccgg   540
attataacac aagcacttcc taatccccag aggaagccac ctcagccatg tgaagctac   600
agcagaagac aggacagctt gatgttcccg aggctccaga tgtttctgtt gctccagatg   660
tttctgctgc tccagatgtt tctgttgctc caaatatttc tgctgctcca gatgtttctg   720
ttgctccaga tgtttctgtt gctccagatg ctcctgttgc tccagatgct cctgatgttt   780
ctgacactgc agaagctcta ccccaagatt ctgaggatgt ggccttggca cctttgtgga   840
ggaagtttcc ttagtgcaga ccactgggcc tgtgagaact gactcatttc tcaacatttt   900
cttttcgttcc ctgggtgaat gtagctgtaa ggcagtgact ctcaaccttc ctaatgcagg   960
gatccttcaa tacaattcct tatttgtggt gatcctcaac cataaaatta ttttgttgct  1020
acttcaaaaa aaaaaaaaaa aaaaaa                                         1046
```

<210> 34
<211> 1261
<212> DNA

<213> Mouse

<400> 34

```
gcacagacgg gtaaaccgct tgggaacctc gaggaaaaag aggctacgaa aaccttttcc     60
taagaggcta caaatttgga agcagggaaa acccagacat gagatgtttt tagtttattt    120
ctccagaagg gggcactgta tcaattatgt gaagggacat gcagacagcc tagctccatg    180
gtgctgtggg gtaggactga ggagccctct ggccagaccc cagcacggcc atgtctctcc    240
caaggatcat gttcctggag gtcacgcccc tggtccttct cataagtggc tgtgcacagc    300
agctctctgg aggtatttgg aacattctgc tgtcacacat gggactgctc ttcctgaagc    360
ccacgctgtt cgtgggaaac atgggaagaa aggaagacgt gttgtgtgct gctcagtaga    420
cttcccacaa gccacctctc tcttctgaaa cgtcactgaa tggactggag aggactgcgg    480
gtttataaaa ctgctttta tctgagaaca atgggtttgg aaactagtct cttttcttcc    540
cactttaca gagcttctca aatcattcct ccaggccctg acttggacag gtaggggggc    600
agaccctggg tcccaaggtg cactgtccag gcacactgcc cacattgcta agagaagagg    660
ccctgctgcc agtggaccct tcaccccaca cgagacacct gtcttgcctt taggacaccc    720
tcctctagag agtggtgttg gaaggagggg acctatgtaa ggagttgggg caggcatgaa    780
tctgccaaat actggatatg gatccaaggc tggcccaggc acctgcacct ccagtgagtg    840
gtcagcaggt ggcgctgctg cccgccaggc ttcacagagt ccctttaggg agtctgctcc    900
cagatccctt ctggtgcaca cttactggat gtcactgcaa gctctaccct ctgagcaggt    960
gttgcaccac agtggcgctg accctggccc cgcaacggca actgctgaag gcagccattg   1020
cctcagccat tctcaagacc cttcaatttt taaaagcagt tcgattctgt aatatttatt   1080
tttcttttttg aggatgtttc gttgccccgc agactgactg cagtgtgcac cattgcatga   1140
gccctgcctc agtgccctgt ggctccctgg gcactgctgc ccctctgtct aaagctgact   1200
gtggcagcac tgcccaacaa taaagctgac ctaaaagctg aaaaaaaaaa aaaaaaaaa    1260
a                                                                   1261
```

<210> 35
<211> 995
<212> DNA
<213> Mouse

<400> 35

```
gctcacccgc gtccgggcgc gcgcaggccc cgtctccttg ccttccaggc ctcatgcgct     60
cccgcgcctg gctcccgcga ccgctgcccg gaggagggg gcccgcgttg tctgcgcgtc    120
tacgcaggcc tcataggcac cgtggtcacc cccaactacc tggacaacgt gagcgcgcgc    180
gttgcgccct ggtgcggctg tgcggccagt ggaaaccggc gcgaagaatg cgaagccttc    240
cgcaagctct ttacaaggaa cccctgcttg gatggtgcca tacaagcctt tgacagcttg    300
cagccatcag ttctgcagga ccagactgct gggtgctgtt cccgcgggt gtcctggctg    360
tatgcactca ctgccctggc tctccaggcc ctgctctgat taggaacatg aaccgtggac    420
gacacagctg actgccatgt ctcccgatga ctgctcactg agctgaaact cccttgccct    480
caggtctgct gccctttgca ggcctggacc cttgtgtggc tgtcctctgg attgggggct    540
ggaggctagg gtctgactga aaagcctgtg ttcccctgtc agtaggcatc ttgtccgttt    600
tcttccccat cctagagctg agcacccata gatgaggcct cattgggtcc cctgggctta    660
cagagcagga cagagactag ccccgctcc tagaattcgg aactgtcctt ttccaagatg    720
acaaggcact aaggagatca tatgaacagg ctgacagaca aggctgccta aatacctcc     780
cagttagcca ttattcacca ttaagcttac ccgtgtcaca gcactgacgt ggcttgtcac    840
ctatgacaca gtgtgtagac attaaggaga gactgaggtc cctcctgctc agcacccac    900
tggcttccca ggctttccct gccatggttt ccccagcacc tgcaggggct caataaaccc    960
atgtgcactg agaaaaaaaa aaaaaaaaaa aaaaa                               995
```

<210> 36
<211> 747
<212> PRT
<213> Rat

<400> 36
Glu Ala Thr Val Ile Thr Thr Glu Lys Arg Glu Arg Pro Ala Pro Pro

```
  1                    5                        10                       15
Arg Glu Leu Leu Val Pro Gln Ala Glu Val Thr Ala Arg Ser Leu Arg
                  20              25                      30
Leu Gln Trp Val Pro Gly Ser Asp Gly Ala Ser Pro Ile Arg Tyr Phe
            35              40                      45
Thr Val Gln Val Arg Glu Leu Pro Gly Gly Glu Trp Gln Thr Tyr Ser
      50              55                      60
Ser Ser Ile Ser His Glu Ala Thr Leu Cys Ala Val Glu Arg Leu Arg
65                  70                      75                      80
Pro Phe Thr Ser Tyr Lys Leu Arg Leu Lys Ala Thr Asn Asp Ile Gly
                  85                      90                      95
Asp Ser Asp Phe Ser Ala Glu Thr Glu Ala Val Thr Thr Leu Gln Asp
              100                     105                     110
Val Pro Gly Glu Pro Pro Gly Ser Val Ser Ala Thr Pro His Thr Thr
              115                     120                     125
Ser Ser Val Leu Ile Gln Trp Gln Pro Pro Arg Asp Glu Ser Leu Asn
      130                     135                     140
Gly Leu Leu Gln Gly Tyr Arg Ile Tyr Tyr Arg Glu Leu Glu Ser Glu
145                     150                     155                     160
Thr Gly Leu Ser Pro Glu Pro Lys Thr Leu Lys Ser Pro Ser Ala Leu
              165                     170                     175
Arg Ala Glu Leu Thr Ala Gln Ser Ser Phe Lys Thr Val Asn Ser Ser
              180                     185                     190
Ser Thr Leu Thr Thr Tyr Glu Leu Thr His Leu Lys Lys Tyr Arg Arg
      195                     200                     205
Tyr Glu Val Ile Met Thr Ala Tyr Asn Ile Ile Gly Glu Ser Pro Ala
      210                     215                     220
Ser Val Pro Val Glu Val Phe Val Gly Glu Ala Ala Pro Ala Met Ala
225                     230                     235                     240
Pro Gln Asn Ile Gln Val Thr Pro Leu Thr Ala Ser Gln Leu Glu Val
              245                     250                     255
Thr Trp Asp Pro Pro Pro Pro Glu Ser Gln Asn Gly Asn Ile Gln Gly
              260                     265                     270
Tyr Lys Val Tyr Tyr Trp Glu Ala Asp Ser Arg Asn Glu Thr Glu Lys
              275                     280                     285
Met Lys Val Leu Phe Leu Pro Glu Pro Val Val Lys Ile Lys Asp Leu
      290                     295                     300
Thr Ser His Thr Lys Tyr Leu Val Ser Ile Ser Ala Phe Asn Ala Ala
305                     310                     315                     320
Gly Asp Gly Pro Arg Ser Asp Pro Cys Gln Gly Arg Thr His Gln Ala
              325                     330                     335
Ala Pro Gly Pro Pro Ser Phe Leu Glu Phe Ser Glu Ile Thr Ser Thr
              340                     345                     350
Thr Leu Asn Val Ser Trp Gly Glu Pro Ser Ala Ala Asn Gly Ile Leu
              355                     360                     365
Gln Gly Tyr Arg Val Val Tyr Glu Pro Leu Ala Pro Val Gln Gly Val
      370                     375                     380
Ser Lys Val Val Thr Val Asp Val Lys Gly Asn Trp Gln Arg Trp Leu
385                     390                     395                     400
Lys Val Arg Asp Leu Thr Lys Gly Val Thr Tyr Phe Phe Arg Val Gln
              405                     410                     415
Ala Arg Thr Ile Ala Tyr Gly Pro Glu Leu Gln Ala Asn Val Thr Ala
              420                     425                     430
Gly Pro Ala Glu Gly Ser Pro Gly Ser Pro Arg Asn Val Leu Val Thr
              435                     440                     445
Lys Ser Ala Ser Glu Leu Thr Leu Gln Trp Thr Glu Gly Asn Thr Gly
      450                     455                     460
```

```
Asn Thr Pro Thr Thr Gly Tyr Val Ile Glu Ala Arg Pro Ser Asp Glu
465             470             475             480
Gly Leu Trp Asp Met Phe Ala Lys Asp Ile Pro Arg Ser Ala Thr Ser
            485             490             495
Tyr Thr Val Gly Leu Asp Lys Leu Arg Gln Gly Val Thr Tyr Glu Phe
        500             505             510
Arg Val Val Ala Val Asn Lys Ala Gly Phe Gly Glu Pro Ser Arg Pro
    515             520             525
Ser Ile Ala Val Ser Ala Gln Ala Glu Ala Pro Phe Tyr Glu Glu Trp
    530             535             540
Trp Phe Leu Leu Val Ile Ala Leu Ser Ser Leu Leu Leu Val Leu Leu
545             550             555             560
Val Val Phe Val Leu Val Leu His Gly Gln Ser Lys Lys Tyr Lys Asn
            565             570             575
Cys Gly Ser Gly Lys Gly Ile Ser Asn Met Glu Glu Thr Val Thr Leu
        580             585             590
Asp Asn Gly Gly Phe Ala Ala Leu Glu Leu Asn Ser Arg His Leu Asn
    595             600             605
Val Lys Ser Thr Phe Ser Lys Lys Asn Gly Thr Arg Ser Pro Pro Arg
    610             615             620
Pro Ser Pro Gly Gly Leu His Tyr Ser Asp Glu Asp Ile Cys Asn Lys
625             630             635             640
Tyr Asn Gly Ala Val Leu Thr Glu Ser Val Asn Leu Lys Glu Lys Ser
            645             650             655
Val Asp Gly Ser Glu Ser Glu Ala Ser Asp Ser Asp Tyr Glu Glu Ala
        660             665             670
Leu Pro Lys His Ser Phe Val Asn His Tyr Met Ser Asp Pro Thr Tyr
    675             680             685
Tyr Asn Phe Trp Lys Arg Arg Pro Pro Ala Ala Ala Pro His Arg Tyr
    690             695             700
Glu Ala Val Ala Gly Ala Glu Ala Gly Pro His Leu His Thr Val Ile
705             710             715             720
Thr Thr Gln Ser Ala Gly Gly Val Tyr Thr Pro Ala Gly Pro Gly Ala
            725             730             735
Arg Ala Pro Leu Thr Gly Phe Ser Ser Phe Val
            740             745
```

<210> 37
<211> 205
<212> PRT
<213> Mouse

<400> 37
```
Met Leu Gly Thr Leu Val Trp Met Leu Ala Val Gly Phe Leu Leu Ala
1           5           10              15
Leu Ala Pro Gly Arg Ala Ala Gly Ala Leu Arg Thr Gly Arg Arg Pro
            20              25              30
Ala Arg Pro Arg Asp Cys Ala Asp Arg Pro Glu Glu Leu Leu Glu Gln
        35              40              45
Leu Tyr Gly Arg Leu Ala Ala Gly Val Leu Ser Ala Phe His His Thr
    50              55              60
Leu Gln Leu Gly Pro Arg Glu Gln Ala Arg Asn Ala Ser Cys Pro Ala
65              70              75              80
Gly Gly Arg Ala Ala Asp Arg Arg Phe Arg Pro Pro Thr Asn Leu Arg
            85              90              95
Ser Val Ser Pro Trp Ala Tyr Arg Ile Ser Tyr Asp Pro Ala Arg Phe
        100             105             110
```

```
Pro Arg Tyr Leu Pro Glu Ala Tyr Cys Leu Cys Arg Gly Cys Leu Thr
        115             120             125
Gly Leu Tyr Gly Glu Glu Asp Phe Arg Phe Arg Ser Thr Pro Val Phe
        130             135             140
Ser Pro Ala Val Val Leu Arg Arg Thr Ala Ala Cys Ala Gly Gly Arg
145             150             155             160
Ser Val Tyr Ala Glu His Tyr Ile Thr Ile Pro Val Gly Cys Thr Cys
            165             170             175
Val Pro Glu Pro Asp Lys Ser Ala Asp Ser Ala Asn Ser Ser Met Asp
            180             185             190
Lys Leu Leu Leu Gly Pro Ala Asp Arg Pro Ala Gly Arg
        195             200             205


<210> 38
<211> 238
<212> PRT
<213> Mouse


<400> 38
Met Leu Cys Phe Leu Arg Gly Met Ala Phe Val Pro Phe Leu Leu Val
1               5               10              15
Thr Trp Ser Ser Ala Ala Phe Ile Ile Ser Tyr Val Val Ala Val Leu
            20              25              30
Ser Gly His Val Asn Pro Phe Leu Pro Tyr Ile Ser Asp Thr Gly Thr
            35              40              45
Thr Pro Pro Glu Ser Gly Ile Phe Gly Phe Met Ile Asn Phe Ser Ala
    50              55              60
Phe Leu Gly Ala Ala Thr Met Tyr Thr Arg Tyr Lys Ile Val Glu Lys
65              70              75              80
Gln Asn Glu Thr Cys Tyr Phe Ser Thr Pro Val Phe Asn Leu Val Ser
            85              90              95
Leu Ala Leu Gly Leu Val Gly Cys Ile Gly Met Gly Ile Val Ala Asn
        100             105             110
Phe Gln Glu Leu Ala Val Pro Val Val His Asp Gly Gly Ala Leu Leu
        115             120             125
Ala Phe Val Cys Gly Val Val Tyr Thr Leu Leu Gln Ser Ile Ile Ser
    130             135             140
Tyr Lys Ser Cys Pro Gln Trp Asn Ser Leu Thr Thr Cys His Val Arg
145             150             155             160
Met Ala Ile Ser Ala Val Ser Cys Ala Ala Val Val Pro Met Ile Ala
            165             170             175
Cys Ala Ser Leu Ile Ser Ile Thr Lys Leu Glu Trp Asn Pro Lys Glu
        180             185             190
Lys Asp Tyr Ile Tyr His Val Val Ser Ala Ile Cys Glu Trp Thr Val
        195             200             205
Ala Phe Gly Phe Ile Phe Tyr Phe Leu Thr Phe Ile Gln Asp Phe Gln
    210             215             220
Ser Val Thr Leu Arg Ile Ser Thr Glu Ile Asn Asp Asp Phe
225             230             235


<210> 39
<211> 492
<212> PRT
<213> Mouse


<400> 39
Leu Arg Leu Leu Leu Ala Trp Val Ala Ala Val Pro Ala Leu Gly Gln
```

```
1                     5                        10                        15
Val Pro Trp Thr Pro Glu Pro Arg Ala Ala Cys Gly Pro Ser Ser Cys
            20                      25                  30
Tyr Ala Leu Phe Pro Arg Arg Arg Thr Phe Leu Glu Ala Trp Arg Ala
            35                      40                  45
Cys Arg Glu Leu Gly Gly Asn Leu Ala Thr Pro Arg Thr Pro Glu Glu
        50                  55                  60
Ala Gln Arg Val Asp Ser Leu Val Gly Val Gly Pro Ala Asn Gly Leu
65                  70                  75                      80
Leu Trp Ile Gly Leu Gln Arg Gln Ala Arg Gln Cys Gln Pro Gln Arg
                85                  90                  95
Pro Leu Arg Gly Phe Ile Trp Thr Thr Gly Asp Gln Asp Thr Ala Phe
            100                 105                 110
Thr Asn Trp Ala Gln Pro Ala Thr Glu Gly Pro Cys Pro Ala Gln Arg
        115                 120                 125
Cys Ala Ala Leu Glu Ala Ser Gly Glu His Arg Trp Leu Glu Gly Ser
    130                 135                 140
Cys Thr Leu Ala Val Asp Gly Tyr Leu Cys Gln Phe Gly Phe Glu Gly
145                 150                 155                 160
Ala Cys Pro Ala Leu Pro Leu Glu Val Gly Gln Ala Gly Pro Ala Val
            165                 170                 175
Tyr Thr Thr Pro Phe Asn Leu Val Ser Ser Glu Phe Glu Trp Leu Pro
            180                 185                 190
Phe Gly Ser Val Ala Ala Val Gln Cys Gln Ala Gly Arg Gly Ala Ser
        195                 200                 205
Leu Leu Cys Val Lys Gln Pro Ser Gly Gly Val Gly Trp Ser Gln Thr
    210                 215                 220
Gly Pro Leu Cys Pro Gly Thr Gly Cys Gly Pro Asp Asn Gly Gly Cys
225                 230                 235                 240
Glu His Glu Cys Val Glu Glu Val Asp Gly Ala Val Ser Cys Arg Cys
            245                 250                 255
Ser Glu Gly Phe Arg Leu Ala Ala Asp Gly His Ser Cys Glu Asp Pro
        260                 265                 270
Cys Ala Gln Ala Pro Cys Glu Gln Gln Cys Glu Pro Gly Gly Pro Gln
    275                 280                 285
Gly Tyr Ser Cys His Cys Arg Leu Gly Phe Arg Pro Ala Glu Asp Asp
    290                 295                 300
Pro His Arg Cys Val Asp Thr Asp Glu Cys Gln Ile Ala Gly Val Cys
305                 310                 315                 320
Gln Gln Met Cys Val Asn Tyr Val Gly Gly Phe Glu Cys Tyr Cys Ser
            325                 330                 335
Glu Gly His Glu Leu Glu Ala Asp Gly Ile Ser Cys Ser Pro Ala Gly
        340                 345                 350
Ala Met Gly Ala Gln Ala Ser Gln Asp Leu Arg Asp Glu Leu Leu Asp
        355                 360                 365
Asp Gly Glu Glu Gly Glu Asp Glu Glu Glu Pro Trp Glu Asp Phe Asp
    370                 375                 380
Gly Thr Trp Thr Glu Glu Gln Gly Ile Leu Trp Leu Ala Pro Thr His
385                 390                 395                 400
Pro Pro Asp Phe Gly Leu Pro Tyr Arg Pro Asn Phe Pro Gln Asp Gly
            405                 410                 415
Glu Pro Gln Arg Leu His Leu Glu Pro Thr Trp Pro Pro Pro Leu Lys
        420                 425                 430
Ala Pro Lys Gly Pro Gln Gln Pro Pro Arg Gly Ala Ala Lys Thr Pro
        435                 440                 445
Lys Gly Asn Pro Ala Asn Pro Thr His Thr Thr Phe Cys Pro Gln Asp
    450                 455                 460
```

```
Leu Cys Tyr Phe Ser Tyr Thr Pro Thr Pro Glu Pro Cys Pro Pro Thr
465                 470             475                     480
Cys His Gly Pro Cys His Thr Ser Ser Cys Val Leu
                485                 490
```

<210> 40
<211> 464
<212> PRT
<213> Mouse

<400> 40
```
Met Gly Arg Ala Trp Gly Leu Leu Val Gly Leu Leu Gly Val Val Trp
 1               5               10                  15
Leu Leu Arg Leu Gly His Gly Glu Glu Arg Arg Pro Glu Thr Ala Ala
            20              25                  30
Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys
        35              40                  45
Asp Val Glu Thr Ile Asp Lys Phe Asn Asn Tyr Arg Leu Phe Pro Arg
    50              55                  60
Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn
65              70                  75                      80
Leu Lys Lys Pro Cys Pro Phe Trp Asn Asp Ile Asn Gln Cys Gly Arg
            85                  90                      95
Arg Asp Cys Ala Val Lys Pro Cys His Ser Asp Glu Val Pro Asp Gly
            100             105                 110
Ile Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Arg Ile Glu
        115             120                 125
Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu Ser
    130             135                 140
Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp Ser
145             150             155                     160
Ser Asp Ser Phe Cys Glu Ile Asp Asp Ile Gln Ser Pro Asp Ala Glu
            165             170                     175
Tyr Val Asp Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly
            180             185                 190
Pro Asp Ala Trp Arg Ile Trp Ser Val Ile Tyr Glu Glu Asn Cys Phe
        195             200                 205
Lys Pro Gln Thr Ile Gln Arg Pro Leu Ala Ser Gly Arg Gly Lys Ser
    210             215                 220
Lys Glu Asn Thr Phe Tyr Asn Trp Leu Glu Gly Leu Cys Val Glu Lys
225             230             235                     240
Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala Ser Ile Asn Val
            245             250                 255
His Leu Ser Ala Arg Tyr Leu Leu Gln Asp Thr Trp Leu Glu Lys Lys
            260             265                 270
Trp Gly His Asn Val Thr Glu Phe Gln Gln Arg Phe Asp Gly Ile Leu
        275             280                 285
Thr Glu Gly Glu Gly Pro Arg Arg Leu Arg Asn Leu Tyr Phe Leu Tyr
    290             295                 300
Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro Phe Phe Glu Arg
305             310                 315                     320
Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Val Gln Asp Ala Glu Asn
            325             330                 335
Lys Ala Leu Leu Leu Glu Ile Leu His Glu Ile Lys Ser Phe Pro Leu
            340             345                 350
His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys Asn Glu Ala His
        355             360                 365
```

```
Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg Ile
    370             375             380
Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln
385             390             395             400
Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu
            405             410             415
Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe Gln Leu Thr
            420             425             430
Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr
        435             440             445
Ser Val Arg Glu Leu Glu Asn Phe Arg His Leu Leu Gln Asn Val His
    450             455             460
```

<210> 41
<211> 148
<212> PRT
<213> Rat

<400> 41
```
Leu Asn Trp Gln Ile Lys Lys Tyr Asp Thr Lys Ala Ala Tyr Cys Gln
  1             5               10              15
Ser Lys Leu Ala Val Val Leu Phe Thr Lys Glu Leu Ser Arg Arg Leu
            20              25              30
Gln Gly Thr Gly Val Thr Val Asn Ala Leu His Pro Gly Val Ala Arg
        35              40              45
Thr Glu Leu Gly Arg His Thr Gly Met His Asn Ser Ala Phe Ser Gly
    50              55              60
Phe Met Leu Gly Pro Phe Phe Trp Leu Leu Phe Lys Ser Pro Gln Leu
65              70              75              80
Ala Ala Gln Pro Ser Thr Tyr Leu Ala Val Ala Glu Glu Leu Glu Ser
            85              90              95
Val Ser Gly Lys Tyr Phe Asp Gly Leu Arg Glu Lys Ala Pro Ser Pro
            100             105             110
Glu Ala Glu Asp Glu Glu Val Ala Arg Arg Leu Trp Thr Glu Ser Ala
        115             120             125
His Leu Val Gly Leu Asp Met Ala His Gly Ser Ser Gly Arg Gly His
    130             135             140
Ser Ile Ser Arg
145
```

<210> 42
<211> 228
<212> PRT
<213> Mouse

<400> 42
```
Met Gly Phe Leu Leu Leu Leu Leu Leu His Ala Ala Ile Ala Gly His
  1             5               10              15
Lys Asn Tyr Gly Thr His Asn His Cys Trp Leu Ser Leu His Arg Gly
            20              25              30
Phe Ile Trp Ser Phe Leu Gly Pro Ala Ala Ala Ile Ile Leu Ile Asn
        35              40              45
Leu Val Phe Tyr Phe Leu Ile Ile Trp Ile Leu Arg Ser Lys Leu Ser
    50              55              60
Ser Leu Asn Lys Glu Val Ser Thr Leu Gln Asp Thr Lys Val Met Thr
65              70              75              80
Phe Lys Ala Ile Val Gln Leu Phe Val Leu Gly Cys Ser Trp Gly Ile
```

```
                            85                    90                    95
Gly Leu Phe Ile Phe Ile Glu Val Gly Lys Thr Val Arg Leu Ile Val
            100                   105                   110
Ala Tyr Leu Phe Thr Ile Ile Asn Val Leu Gln Gly Val Leu Ile Phe
        115                   120                   125
Met Val His Cys Leu Leu Asn Arg Gln Val Arg Met Glu Tyr Lys Lys
    130                   135                   140
Trp Phe His Arg Leu Arg Lys Glu Val Glu Ser Glu Ser Thr Glu Val
145                   150                   155                   160
Ser His Ser Thr Thr His Thr Lys Met Gly Leu Ser Leu Asn Leu Glu
                165                   170                   175
Asn Phe Cys Pro Thr Gly Asn Leu His Asp Pro Ser Asp Ser Ile Leu
            180                   185                   190
Pro Ser Thr Glu Val Ala Gly Val Tyr Leu Ser Thr Pro Arg Ser His
        195                   200                   205
Met Gly Ala Glu Asp Val Asn Ser Gly Thr His Ala Tyr Trp Ser Arg
    210                   215                   220
Thr Ile Ser Asp
225


<210> 43
<211> 373
<212> PRT
<213> Mouse


<400> 43
Met Lys Glu Tyr Val Met Leu Leu Leu Leu Ala Val Cys Ser Ala Lys
1                   5                   10                  15
Pro Phe Phe Ser Pro Ser His Thr Ala Leu Lys Asn Met Met Leu Lys
                20                  25                  30
Asp Met Glu Asp Thr Asp Asp Asp Asn Asp Asp Asp Asp Asn Ser
        35                  40                  45
Leu Phe Pro Thr Lys Glu Pro Val Asn Pro Phe Phe Pro Phe Asp Leu
    50                  55                  60
Phe Pro Thr Cys Pro Phe Gly Cys Gln Cys Tyr Ser Arg Val Val His
65                  70                  75                  80
Cys Ser Asp Leu Gly Leu Thr Ser Val Pro Asn Asn Ile Pro Phe Asp
            85                  90                  95
Thr Arg Met Val Asp Leu Gln Asn Asn Lys Ile Lys Glu Ile Lys Glu
            100                 105                 110
Asn Asp Phe Lys Gly Leu Thr Ser Leu Tyr Ala Leu Ile Leu Asn Asn
        115                 120                 125
Asn Lys Leu Thr Lys Ile His Pro Lys Thr Phe Leu Thr Thr Lys Lys
    130                 135                 140
Leu Arg Arg Leu Tyr Leu Ser His Asn Gln Leu Ser Glu Ile Pro Leu
145                 150                 155                 160
Asn Leu Pro Lys Ser Leu Ala Glu Leu Arg Ile His Asp Asn Lys Val
            165                 170                 175
Lys Lys Ile Gln Lys Asp Thr Phe Lys Gly Met Asn Ala Leu His Val
        180                 185                 190
Leu Glu Met Ser Ala Asn Pro Leu Glu Asn Asn Gly Ile Glu Pro Gly
    195                 200                 205
Ala Phe Glu Gly Val Thr Val Phe His Ile Arg Ile Ala Glu Ala Lys
    210                 215                 220
Leu Thr Ser Ile Pro Lys Gly Leu Pro Pro Thr Leu Leu Glu Leu His
225                 230                 235                 240
Leu Asp Phe Asn Lys Ile Ser Thr Val Glu Leu Glu Asp Leu Lys Arg
```

```
                 245                      250                      255
Tyr Arg Glu Leu Gln Arg Leu Gly Leu Gly Asn Asn Arg Ile Thr Asp
            260                      265                      270
Ile Glu Asn Gly Thr Phe Ala Asn Ile Pro Arg Val Arg Glu Ile His
        275                      280                      285
Leu Glu His Asn Lys Leu Lys Lys Ile Pro Ser Gly Leu Gln Glu Leu
    290                      295                      300
Lys Tyr Leu Gln Ile Ile Phe Leu His Tyr Asn Ser Ile Ala Lys Val
305                      310                      315                      320
Gly Val Asn Asp Phe Cys Pro Thr Val Pro Lys Met Lys Lys Ser Leu
                325                      330                      335
Tyr Ser Ala Ile Ser Leu Phe Asn Asn Pro Met Lys Tyr Trp Glu Ile
            340                      345                      350
Gln Pro Ala Thr Phe Arg Cys Val Leu Gly Arg Met Ser Val Gln Leu
        355                      360                      365
Gly Asn Val Gly Lys
    370


<210> 44
<211> 466
<212> PRT
<213> Mouse

<400> 44
Met Trp Gly Cys Trp Leu Gly Leu Leu Leu Leu Leu Leu Ala Gly Gln
1               5                   10                      15
Ala Ala Leu Glu Ala Arg Arg Ser Arg Trp Arg Arg Glu Leu Ala Pro
            20                  25                      30
Gly Leu His Leu Arg Gly Ile Arg Asp Ala Gly Gly Arg Tyr Cys Gln
        35                  40                      45
Glu Gln Asp Met Cys Cys Arg Gly Arg Ala Asp Glu Cys Ala Leu Pro
    50                  55                      60
Tyr Leu Gly Ala Thr Cys Tyr Cys Asp Leu Phe Cys Asn Arg Thr Val
65                  70                  75                      80
Ser Asp Cys Cys Pro Asp Phe Trp Asp Phe Cys Leu Gly Ile Pro Pro
                85                  90                      95
Pro Phe Pro Pro Val Gln Gly Cys Met His Gly Gly Arg Ile Tyr Pro
            100                 105                     110
Val Phe Gly Thr Tyr Trp Asp Asn Cys Asn Arg Cys Thr Cys His Glu
        115                 120                     125
Gly Gly His Trp Glu Cys Asp Gln Glu Pro Cys Leu Val Asp Pro Asp
    130                     135                 140
Met Ile Lys Ala Ile Asn Arg Gly Asn Tyr Gly Trp Gln Ala Gly Asn
145                 150                     155                     160
His Ser Ala Phe Trp Gly Met Thr Leu Asp Glu Gly Ile Arg Tyr Arg
                165                 170                     175
Leu Gly Thr Ile Arg Pro Ser Ser Thr Val Met Asn Met Asn Glu Ile
            180                     185                 190
Tyr Thr Val Leu Gly Gln Gly Glu Val Leu Pro Thr Ala Phe Glu Ala
        195                     200                 205
Ser Glu Lys Trp Pro Asn Leu Ile His Glu Pro Leu Asp Gln Gly Asn
    210                     215                 220
Cys Ala Gly Ser Trp Ala Phe Ser Thr Ala Ala Val Ala Ser Asp Arg
225                 230                     235                     240
Val Ser Ile His Ser Leu Gly His Met Thr Pro Ile Leu Ser Pro Gln
                245                     250                     255
Asn Leu Leu Ser Cys Asp Thr His His Gln Gln Gly Cys Arg Gly Gly
```

```
                 260                    265                     270
Arg Leu Asp Gly Ala Trp Trp Phe Leu Arg Arg Arg Gly Val Val Ser
        275                    280                285
Asp Asn Cys Tyr Pro Phe Ser Gly Arg Glu Gln Asn Glu Ala Ser Pro
    290                    295                300
Thr Pro Arg Cys Met Met His Ser Arg Ala Met Gly Arg Gly Lys Arg
305                    310                315                320
Gln Ala Thr Ser Arg Cys Pro Asn Gly Gln Val Asp Ser Asn Asp Ile
            325                    330                335
Tyr Gln Val Thr Pro Ala Tyr Arg Leu Gly Ser Asp Glu Lys Glu Ile
            340                    345                350
Met Lys Glu Leu Met Glu Asn Gly Pro Val Gln Ala Leu Met Glu Val
        355                    360                365
His Glu Asp Phe Phe Leu Tyr Gln Arg Gly Ile Tyr Ser His Thr Pro
    370                    375                380
Val Ser Gln Gly Arg Pro Glu Gln Tyr Arg Arg His Gly Thr His Ser
385                    390                    395                400
Val Lys Ile Thr Gly Trp Gly Glu Glu Thr Leu Pro Asp Gly Arg Thr
            405                    410                415
Ile Lys Tyr Trp Thr Ala Ala Asn Ser Trp Gly Pro Trp Trp Gly Glu
            420                    425                430
Arg Gly His Phe Arg Ile Val Arg Gly Thr Asn Glu Cys Asp Ile Glu
        435                    440                445
Thr Phe Val Leu Gly Val Trp Gly Arg Val Gly Met Glu Asp Met Gly
    450                    455                460
His His
465
```

```
<210> 45
<211> 422
<212> PRT
<213> Mouse
```

```
<400> 45
Met Asp Phe Trp Leu Trp Leu Leu Tyr Phe Leu Pro Val Ser Gly Ala
1               5                   10                15
Leu Arg Val Leu Pro Glu Val Gln Leu Asn Val Glu Trp Gly Gly Ser
            20                  25                  30
Ile Ile Ile Glu Cys Pro Leu Pro Gln Leu His Val Arg Met Tyr Leu
        35                  40                  45
Cys Arg Gln Met Ala Lys Pro Gly Ile Cys Ser Thr Val Val Ser Asn
    50                  55                  60
Thr Phe Val Lys Lys Glu Tyr Glu Arg Arg Val Thr Leu Thr Pro Cys
65                  70                  75                  80
Leu Asp Lys Lys Leu Phe Leu Val Glu Met Thr Gln Leu Thr Glu Asn
            85                  90                  95
Asp Asp Gly Ile Tyr Ala Cys Gly Val Gly Met Lys Thr Asp Lys Gly
            100                 105                 110
Lys Thr Gln Lys Ile Thr Leu Asn Val His Asn Glu Tyr Pro Glu Pro
        115                 120                 125
Phe Trp Glu Asp Glu Trp Thr Ser Glu Arg Pro Arg Trp Leu His Arg
    130                 135                 140
Phe Leu Gln His Gln Met Pro Trp Leu His Gly Ser Glu His Pro Ser
145                 150                 155                 160
Ser Ser Gly Val Ile Ala Lys Val Thr Thr Pro Ala Ser Lys Thr Glu
            165                 170                 175
Ala Pro Pro Val His Gln Pro Ser Ser Ile Thr Ser Val Thr Gln His
```

```
                    180                 185                 190
Pro Arg Val Tyr Arg Ala Phe Ser Val Ser Ala Thr Lys Ser Pro Ala
        195                 200                 205
Leu Leu Pro Ala Thr Thr Ala Ser Lys Thr Ser Thr Gln Gln Ala Ile
    210                 215                 220
Arg Pro Leu Glu Ala Ser Tyr Ser His His Thr Arg Leu His Glu Gln
225                 230                 235                 240
Arg Thr Arg His His Gly Pro His Tyr Gly Arg Glu Asp Arg Gly Leu
            245                 250                 255
His Ile Pro Ile Pro Glu Phe His Ile Leu Ile Pro Thr Phe Leu Gly
            260                 265                 270
Phe Leu Leu Leu Val Leu Leu Gly Leu Val Val Lys Arg Ala Ile Gln
        275                 280                 285
Arg Arg Arg Ala Ser Ser Arg Arg Ala Gly Arg Leu Ala Met Arg Arg
    290                 295                 300
Arg Gly Arg Gly Ala Ser Arg Pro Phe Pro Thr Gln Arg Arg Asp Ala
305                 310                 315                 320
Pro Gln Arg Pro Arg Ser Gln Asn Asn Val Tyr Ser Ala Cys Pro Arg
            325                 330                 335
Arg Ala Arg Gly Pro Asp Ser Leu Gly Pro Ala Glu Ala Pro Leu Leu
            340                 345                 350
Asn Ala Pro Ala Ser Ala Ser Pro Ala Ser Pro Gln Val Leu Glu Ala
            355                 360                 365
Pro Trp Pro His Thr Pro Ser Leu Lys Met Ser Cys Glu Tyr Val Ser
    370                 375                 380
Leu Gly Tyr Gln Pro Ala Val Asn Leu Glu Asp Pro Asp Ser Asp Asp
385                 390                 395                 400
Tyr Ile Asn Ile Pro Asp Pro Ser His Leu Pro Ser Tyr Ala Pro Gly
            405                 410                 415
Pro Arg Ser Ser Cys Gln
            420

<210> 46
<211> 228
<212> PRT
<213> Mouse

<400> 46
Met Lys Ala Leu Arg Ala Val Leu Leu Ile Leu Leu Leu Ser Gly Gln
1               5                   10                  15
Pro Gly Ser Gly Trp Ala Gln Glu Asp Gly Asp Ala Asp Pro Glu Pro
            20                  25                  30
Glu Asn Tyr Asn Tyr Asp Asp Asp Asp Glu Glu Glu Glu Glu Glu Glu
        35                  40                  45
Thr Asn Met Ile Pro Gly Ser Arg Asp Arg Ala Pro Leu Gln Cys Tyr
    50                  55                  60
Phe Cys Gln Val Leu His Ser Gly Glu Ser Cys Asn Gln Thr Gln Ser
65              70                  75                  80
Cys Ser Ser Ser Lys Pro Phe Cys Ile Thr Leu Val Ser His Ser Gly
            85                  90                  95
Thr Asp Lys Gly Tyr Leu Thr Thr Tyr Ser Met Trp Cys Thr Asp Thr
            100                 105                 110
Cys Gln Pro Ile Ile Lys Thr Val Gly Gly Thr Gln Met Thr Gln Thr
        115                 120                 125
Cys Cys Gln Ser Thr Leu Cys Asn Ile Pro Pro Trp Gln Asn Pro Gln
    130                 135                 140
Val Gln Asn Pro Leu Gly Gly Arg Ala Asp Ser Pro Leu Glu Ser Gly
```

```
145                     150                     155                     160
Thr Arg His Pro Gln Gly Gly Lys Phe Ser His Pro Gln Val Val Lys
                165                     170                     175
Ala Ala His Pro Gln Ser Asp Gly Ala Asn Leu Pro Lys Ser Gly Lys
                180                     185                     190
Ala Asn Gln Pro Gln Gly Ser Gly Ala Gly Tyr Pro Ser Gly Trp Thr
                195                     200                     205
Lys Phe Gly Asn Ile Ala Leu Leu Leu Ser Phe Phe Thr Cys Leu Trp
        210                     215                     220
Ala Ser Gly Ala
225


<210> 47
<211> 269
<212> PRT
<213> Mouse

<400> 47
Gly Cys Ser Asp Gly Glu Asn Gln Arg Ser Gly His Leu Ser Val Ser
  1                 5                  10                      15
Leu Gln Leu Ser Leu Lys Val Leu Leu Ile Arg Met Ala Ser Gly Trp
                20                      25                      30
Phe Tyr Leu Ser Cys Met Val Leu Gly Ser Leu Gly Ser Met Cys Ile
        35                      40                      45
Leu Phe Thr Ala Tyr Trp Met Gln Tyr Trp Arg Gly Gly Phe Ala Trp
        50                      55                      60
Asp Gly Thr Val Leu Met Phe Asn Trp His Pro Val Leu Met Val Ala
65                      70                      75                      80
Gly Met Val Val Leu Tyr Gly Ala Ala Ser Leu Val Tyr Arg Leu Pro
                85                      90                      95
Ser Ser Trp Val Gly Pro Arg Leu Pro Trp Lys Val Leu His Ala Ala
                100                     105                     110
Leu His Leu Leu Ala Phe Thr Cys Thr Val Val Gly Leu Ile Ala Val
        115                     120                     125
Phe Arg Phe His Asn His Ser Arg Ile Ala His Leu Tyr Ser Leu His
        130                     135                     140
Ser Trp Leu Gly Ile Thr Thr Val Val Leu Phe Ala Cys Gln Trp Phe
145                     150                     155                     160
Leu Gly Phe Ala Val Phe Leu Leu Pro Trp Ala Ser Gln Trp Leu Arg
                165                     170                     175
Ser Leu Leu Lys Pro Leu His Val Phe Phe Gly Ala Cys Ile Leu Ser
                180                     185                     190
Leu Ser Ile Thr Ser Val Ile Ser Gly Ile Asn Glu Lys Leu Phe Phe
                195                     200                     205
Val Leu Lys Asn Ala Thr Lys Pro Tyr Ser Ser Leu Pro Gly Glu Ala
        210                     215                     220
Val Phe Ala Asn Ser Thr Gly Leu Leu Val Val Ala Phe Gly Leu Leu
225                     230                     235                     240
Val Leu Tyr Val Leu Leu Ala Ser Ser Trp Lys Arg Pro Asp Pro Gly
                245                     250                     255
Ala Leu Thr Asp Arg Gln Pro Leu Leu His Asp Arg Glu
                260                     265


<210> 48
<211> 188
<212> PRT
<213> Mouse
```

<400> 48
Met Arg Leu Pro Leu Pro Leu Leu Leu Leu Phe Gly Cys Arg Ala Ile
1   5   10   15
Leu Gly Ser Ala Gly Asp Arg Val Ser Leu Ser Ala Ser Ala Pro Thr
        20   25   30
Leu Asp Asp Glu Glu Lys Tyr Ser Ala His Met Pro Ala His Leu Arg
        35   40   45
Cys Asp Ala Cys Arg Ala Val Ala Phe Gln Met Gly Gln Arg Leu Ala
    50   55   60
Lys Ala Glu Ala Lys Ser His Thr Pro Asp Ala Ser Gly Leu Gln Glu
65   70   75   80
Leu Ser Glu Ser Thr Tyr Thr Asp Val Leu Asp Gln Thr Cys Ser Gln
            85   90   95
Asn Trp Gln Ser Tyr Gly Val His Glu Val Asn Gln Met Lys Arg Leu
            100   105   110
Thr Gly Pro Gly Leu Ser Lys Gly Pro Glu Pro Arg Ile Ser Val Met
        115   120   125
Ile Ser Gly Gly Pro Trp Pro Asn Arg Leu Ser Lys Thr Cys Phe His
    130   135   140
Tyr Leu Gly Glu Phe Gly Glu Asp Gln Ile Tyr Glu Ala Tyr Arg Gln
145   150   155   160
Gly Gln Ala Asn Leu Glu Ala Leu Leu Cys Gly Gly Thr His Gly Pro
            165   170   175
Cys Ser Gln Glu Ile Leu Ala Gln Arg Glu Glu Leu
            180   185

<210> 49
<211> 247
<212> PRT
<213> Mouse

<400> 49
Met Ile Pro Gln Val Val Thr Ser Glu Thr Val Thr Val Ile Ser Pro
1   5   10   15
Asn Gly Ile Ser Phe Pro Gln Thr Asp Lys Pro Gln Pro Ser His Gln
        20   25   30
Ser Gln Asp Arg Leu Lys Lys His Leu Lys Ala Glu Ile Lys Val Met
        35   40   45
Ala Ala Ile Gln Ile Met Cys Ala Val Met Val Leu Ser Leu Gly Ile
    50   55   60
Ile Leu Ala Ser Val Pro Ser Asn Leu His Phe Thr Ser Val Phe Ser
65   70   75   80
Ile Leu Leu Glu Ser Gly Tyr Pro Phe Val Gly Ala Leu Phe Phe Ala
            85   90   95
Ile Ser Gly Ile Leu Ser Ile Val Thr Glu Lys Lys Met Thr Lys Pro
            100   105   110
Leu Val His Ser Ser Leu Ala Leu Ser Ile Leu Ser Val Leu Ser Ala
        115   120   125
Leu Thr Gly Ile Ala Ile Leu Ser Val Ser Leu Ala Ala Leu Glu Pro
    130   135   140
Ala Leu Gln Gln Cys Lys Leu Ala Phe Thr Gln Leu Asp Thr Thr Gln
145   150   155   160
Asp Ala Tyr His Phe Phe Ser Pro Glu Pro Leu Asn Ser Cys Phe Val
            165   170   175
Ala Lys Ala Ala Leu Thr Gly Val Phe Ser Leu Met Leu Ile Ser Ser
        180   185   190

```
Val Leu Glu Leu Gly Leu Ala Val Leu Thr Ala Thr Leu Trp Trp Lys
        195             200             205
Gln Ser Ser Ser Ala Phe Ser Gly Asn Val Ile Phe Leu Ser Gln Asn
    210             215             220
Ser Lys Asn Lys Ser Ser Val Ser Ser Glu Ser Leu Cys Asn Pro Thr
225             230             235             240
Tyr Glu Asn Ile Leu Thr Ser
            245
```

```
<210> 50
<211> 182
<212> PRT
<213> Mouse

<400> 50
Pro Phe His Cys His Val Trp Ser Leu Cys Leu Gln Gly Ser Lys Gln
 1               5              10              15
Ser Gly Leu Cys Gln Val Gln Arg Asp Leu Gly Arg Asp Asp Arg Ser
        20              25              30
Val Arg Gly Ser Lys Ala Ala Val Val Ala Gly Ala Val Val Gly Thr
        35              40              45
Phe Val Gly Leu Val Leu Ile Ala Gly Leu Val Leu Leu Tyr Gln Arg
    50              55              60
Arg Ser Lys Thr Leu Glu Glu Leu Ala Asn Asp Ile Lys Glu Asp Ala
65              70              75              80
Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser Asp Thr Ile Ser
            85              90              95
Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg Pro
        100             105             110
Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr Pro Thr Pro Ser
        115             120             125
Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro Arg Val Asp Glu
        130             135             140
Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly Val Ser Ser Ser
145             150             155             160
Ala Leu Ser Arg Met Gly Ala Val Pro Val Met Val Pro Ala Gln Ser
            165             170             175
Gln Ala Gly Ser Leu Val
        180
```

```
<210> 51
<211> 248
<212> PRT
<213> Mouse

<400> 51
Met Ser Trp Ser Pro Ile Leu Pro Phe Leu Ser Leu Leu Leu Leu Leu
 1               5              10              15
Phe Pro Leu Glu Val Pro Arg Ala Ala Thr Ala Ser Leu Ser Gln Ala
        20              25              30
Ser Ser Glu Gly Thr Thr Thr Cys Lys Val His Asp Val Cys Leu Leu
        35              40              45
Gly Pro Arg Pro Leu Pro Pro Ser Pro Pro Val Arg Val Ser Leu Tyr
    50              55              60
Tyr Glu Ser Leu Cys Gly Ala Cys Arg Tyr Phe Leu Val Arg Asp Leu
65              70              75              80
Phe Pro Thr Trp Leu Met Val Met Glu Ile Met Asn Ile Thr Leu Val
```

```
                      85                  90                  95
Pro Tyr Gly Asn Ala Gln Glu Arg Asn Val Ser Gly Thr Trp Glu Phe
            100                 105                 110
Thr Cys Gln His Gly Glu Leu Glu Cys Arg Leu Asn Met Val Glu Ala
            115                 120                 125
Cys Leu Leu Asp Lys Leu Glu Lys Glu Ala Ala Phe Leu Thr Ile Val
            130                 135                 140
Cys Met Glu Glu Met Asp Asp Met Glu Lys Lys Leu Gly Pro Cys Leu
145                 150                 155                 160
Gln Val Tyr Ala Pro Glu Val Ser Pro Glu Ser Ile Met Glu Cys Ala
            165                 170                 175
Thr Gly Lys Arg Gly Thr Gln Leu Met His Glu Asn Ala Gln Leu Thr
            180                 185                 190
Asp Ala Leu His Pro Pro His Glu Tyr Val Pro Trp Val Leu Val Asn
            195                 200                 205
Glu Lys Pro Leu Lys Asp Pro Ser Glu Leu Leu Ser Ile Val Cys Gln
    210                 215                 220
Leu Asp Gln Gly Thr Glu Lys Pro Asp Ile Cys Ser Ser Ile Ala Asp
225                 230                 235                 240
Ser Pro Arg Lys Val Cys Tyr Lys
            245


<210> 52
<211> 278
<212> PRT
<213> Mouse


<400> 52
Met Gln Thr Met Trp Gly Ser Gly Glu Leu Leu Val Ala Trp Phe Leu
1               5                   10                  15
Val Leu Ala Ala Asp Gly Thr Thr Glu His Val Tyr Arg Pro Ser Arg
            20                  25                  30
Arg Val Cys Thr Val Gly Ile Ser Gly Gly Ser Ile Ser Glu Thr Phe
            35                  40                  45
Val Gln Arg Val Tyr Gln Pro Tyr Leu Thr Thr Cys Asp Gly His Arg
    50                  55                  60
Ala Cys Ser Thr Tyr Arg Thr Ile Tyr Arg Thr Ala Tyr Arg Arg Ser
65                  70                  75                  80
Pro Gly Val Thr Pro Ala Arg Pro Arg Tyr Ala Cys Cys Pro Gly Trp
            85                  90                  95
Lys Arg Thr Ser Gly Leu Pro Gly Ala Cys Gly Ala Ala Ile Cys Gln
            100                 105                 110
Pro Pro Cys Gly Asn Gly Gly Ser Cys Ile Arg Pro Gly His Cys Arg
            115                 120                 125
Cys Pro Val Gly Trp Gln Gly Asp Thr Cys Gln Thr Asp Val Asp Glu
    130                 135                 140
Cys Ser Thr Gly Glu Ala Ser Cys Pro Gln Arg Cys Val Asn Thr Val
145                 150                 155                 160
Gly Ser Tyr Trp Cys Gln Gly Trp Glu Gly Gln Ser Pro Ser Ala Asp
            165                 170                 175
Gly Thr Arg Cys Leu Ser Lys Glu Gly Pro Ser Pro Val Ala Pro Asn
            180                 185                 190
Pro Thr Ala Gly Val Asp Ser Met Ala Arg Glu Glu Val Tyr Arg Leu
            195                 200                 205
Gln Ala Arg Val Asp Val Leu Glu Gln Lys Leu Gln Leu Val Leu Ala
    210                 215                 220
Pro Leu His Ser Leu Ala Ser Arg Ser Thr Glu His Gly Leu Gln Asp
```

```
                    225                    230                    235                    240
Pro Gly Ser Leu Leu Ala His Ser Phe Gln Gln Leu Asp Arg Ile Asp
                        245                    250                    255
Ser Leu Ser Glu Gln Val Ser Phe Leu Glu Glu His Leu Gly Ser Cys
                260                    265                    270
Ser Cys Lys Lys Asp Leu
            275
```

```
<210> 53
<211> 409
<212> PRT
<213> Mouse
```

```
<400> 53
Met Lys Leu Lys Gln Arg Val Val Leu Leu Ala Ile Leu Leu Val Ile
1               5                   10                  15
Phe Ile Phe Thr Lys Val Phe Leu Ile Asp Asn Leu Asp Thr Ser Ala
            20                  25                  30
Ala Asn Arg Glu Asp Gln Arg Ala Phe His Arg Met Met Thr Gly Leu
        35                  40                  45
Arg Val Glu Leu Val Pro Lys Leu Asp His Thr Leu Gln Ser Pro Trp
    50                  55                  60
Glu Ile Ala Ala Gln Trp Val Val Pro Arg Glu Val Tyr Pro Glu Glu
65                  70                  75                  80
Thr Pro Glu Leu Gly Ala Ile Met His Ala Met Ala Thr Lys Lys Ile
                85                  90                  95
Ile Lys Ala Asp Val Gly Tyr Lys Gly Thr Gln Leu Lys Ala Leu Leu
            100                 105                 110
Ile Leu Glu Gly Gly Gln Lys Val Val Phe Lys Pro Lys Arg Tyr Ser
        115                 120                 125
Arg Asp Tyr Val Val Glu Gly Glu Pro Tyr Ala Gly Tyr Asp Arg His
    130                 135                 140
Asn Ala Glu Val Ala Ala Phe His Leu Asp Arg Ile Leu Gly Phe Arg
145                 150                 155                 160
Arg Ala Pro Leu Val Val Gly Arg Tyr Val Asn Leu Arg Thr Glu Val
                165                 170                 175
Lys Pro Val Ala Thr Glu Gln Leu Leu Ser Thr Phe Leu Thr Val Gly
            180                 185                 190
Asn Asn Thr Cys Phe Tyr Gly Lys Cys Tyr Tyr Cys Arg Glu Thr Glu
        195                 200                 205
Pro Ala Cys Ala Asp Gly Asp Met Met Glu Gly Ser Val Thr Leu Trp
    210                 215                 220
Leu Pro Asp Val Trp Pro Leu Gln Lys His Arg His Pro Trp Gly Arg
225                 230                 235                 240
Thr Tyr Arg Glu Gly Lys Leu Ala Arg Trp Glu Tyr Asp Glu Ser Tyr
                245                 250                 255
Cys Asp Ala Val Lys Lys Thr Ser Pro Tyr Asp Ser Gly Pro Arg Leu
            260                 265                 270
Leu Asp Ile Ile Asp Thr Ala Val Phe Asp Tyr Leu Ile Gly Asn Ala
        275                 280                 285
Asp Arg His His Tyr Glu Ser Phe Gln Asp Asp Glu Gly Ala Ser Met
    290                 295                 300
Leu Ile Leu Leu Asp Asn Ala Lys Ser Phe Gly Asn Pro Ser Leu Asp
305                 310                 315                 320
Glu Arg Ser Ile Leu Ala Pro Leu Tyr Gln Cys Cys Ile Ile Arg Val
                325                 330                 335
Ser Thr Trp Asn Arg Leu Asn Tyr Leu Lys Asn Gly Val Leu Lys Ser
```

```
                340                      345                   350
Ala Leu Lys Ser Ala Met Ala His Asp Pro Ile Ser Pro Val Leu Ser
            355                   360               365
Asp Pro His Leu Asp Thr Val Asp Gln Arg Leu Leu Asn Val Leu Ala
        370                   375               380
Thr Ile Lys Gln Cys Thr Asp Gln Phe Gly Thr Asp Thr Val Leu Val
385                   390               395                   400
Glu Asp Arg Met Pro Leu Ser His Leu
                405
```

```
<210> 54
<211> 697
<212> PRT
<213> Mouse
```

```
<400> 54
Met Arg Leu Thr Val Gly Ala Leu Leu Ala Cys Ala Ala Leu Gly Leu
  1                 5                   10                  15
Cys Leu Ala Val Pro Asp Lys Thr Val Lys Trp Cys Ala Val Ser Glu
            20                  25                  30
His Glu Asn Thr Lys Cys Ile Ser Phe Arg Asp His Met Lys Thr Val
            35                  40                  45
Leu Pro Pro Asp Gly Pro Arg Leu Ala Cys Val Lys Lys Thr Ser Tyr
    50                  55                  60
Pro Asp Cys Ile Lys Ala Ile Ser Ala Ser Glu Ala Asp Ala Met Thr
65                  70                  75                  80
Leu Asp Gly Gly Trp Val Tyr Asp Ala Gly Leu Thr Pro Asn Asn Leu
                85                  90                  95
Lys Pro Val Ala Ala Glu Phe Tyr Gly Ser Val Glu His Pro Gln Thr
            100                 105                 110
Tyr Tyr Tyr Ala Val Ala Val Val Lys Lys Gly Thr Asp Phe Gln Leu
        115                 120                 125
Asn Gln Leu Glu Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg Ser
    130                 135                 140
Ala Gly Trp Val Ile Pro Ile Gly Leu Leu Phe Cys Lys Leu Ser Glu
145                 150                 155                 160
Pro Arg Ser Pro Leu Glu Lys Ala Val Ser Ser Phe Phe Ser Gly Ser
                165                 170                 175
Cys Val Pro Cys Ala Asp Pro Val Ala Phe Pro Lys Leu Cys Gln Leu
            180                 185                 190
Cys Pro Gly Cys Gly Cys Ser Ser Thr Gln Pro Phe Phe Gly Tyr Val
        195                 200                 205
Gly Ala Phe Lys Cys Leu Lys Asp Gly Gly Gly Asp Val Ala Phe Val
    210                 215                 220
Lys His Thr Thr Ile Phe Glu Val Leu Pro Glu Lys Ala Asp Arg Asp
225                 230                 235                 240
Gln Tyr Glu Leu Leu Cys Leu Asp Asn Thr Arg Lys Pro Val Asp Gln
                245                 250                 255
Tyr Glu Asp Cys Tyr Leu Ala Arg Ile Pro Ser His Ala Val Val Ala
            260                 265                 270
Arg Lys Asn Asn Gly Lys Glu Asp Leu Ile Trp Glu Ile Leu Lys Val
        275                 280                 285
Ala Gln Glu His Phe Gly Lys Gly Lys Ser Lys Asp Phe Gln Leu Phe
        290                 295                 300
Ser Ser Pro Leu Gly Lys Asp Leu Leu Phe Lys Asp Ser Ala Phe Gly
305                 310                 315                 320
Leu Leu Arg Val Pro Pro Arg Met Asp Tyr Arg Leu Tyr Leu Gly His
```

```
                        325                        330                        335
Asn Tyr Val Thr Ala Ile Arg Asn Gln Gln Glu Gly Val Cys Pro Glu
            340                    345                    350
Gly Ser Ile Asp Asn Ser Pro Val Lys Trp Cys Ala Leu Ser His Leu
            355                    360                    365
Glu Arg Thr Lys Cys Asp Glu Trp Ser Ile Ile Ser Glu Gly Lys Ile
            370                    375                    380
Glu Cys Glu Ser Ala Glu Thr Thr Glu Asp Cys Ile Glu Lys Ile Val
385                    390                    395                    400
Asn Gly Glu Ala Asp Ala Met Thr Leu Asp Gly Gly His Ala Tyr Ile
            405                    410                    415
Ala Gly Gln Cys Gly Leu Val Pro Val Met Ala Glu Tyr Tyr Glu Ser
            420                    425                    430
Ser Asn Cys Ala Ile Pro Ser Gln Gln Gly Ile Phe Pro Lys Gly Tyr
            435                    440                    445
Tyr Ala Val Ala Val Val Lys Ala Ser Asp Thr Ser Ile Thr Trp Asn
            450                    455                    460
Asn Leu Lys Gly Lys Lys Ser Cys His Thr Gly Val Asp Arg Thr Ala
465                    470                    475                    480
Gly Trp Asn Ile Pro Met Gly Met Leu Tyr Asn Arg Ile Asn His Cys
            485                    490                    495
Lys Phe Asp Glu Phe Phe Ser Gln Gly Cys Ala Pro Gly Tyr Glu Lys
            500                    505                    510
Asn Ser Thr Leu Cys Asp Leu Cys Ile Gly Pro Leu Lys Cys Ala Pro
            515                    520                    525
Asn Asn Lys Glu Glu Tyr Asn Gly Tyr Thr Gly Ala Phe Arg Cys Leu
            530                    535                    540
Val Glu Lys Gly Asp Val Ala Phe Val Lys His Gln Thr Val Leu Asp
545                    550                    555                    560
Asn Thr Glu Gly Lys Asn Pro Ala Glu Trp Ala Lys Asn Leu Lys Gln
            565                    570                    575
Glu Asp Phe Glu Leu Leu Cys Pro Asp Gly Thr Arg Lys Pro Val Lys
            580                    585                    590
Asp Phe Ala Ser Cys His Leu Ala Gln Ala Pro Asn His Val Val Val
            595                    600                    605
Ser Arg Lys Glu Lys Ala Ala Arg Val Lys Ala Val Leu Thr Ser Gln
610                    615                    620
Glu Thr Leu Phe Gly Gly Ser Asp Cys Thr Gly Asn Phe Cys Leu Phe
625                    630                    635                    640
Lys Ser Thr Thr Lys Asp Leu Leu Phe Arg Asp Asp Thr Lys Cys Phe
            645                    650                    655
Val Lys Leu Pro Glu Gly Thr Thr Pro Glu Lys Tyr Leu Gly Ala Glu
            660                    665                    670
Tyr Met Gln Ser Val Gly Asn Met Arg Lys Cys Ser Thr Ser Arg Leu
            675                    680                    685
Leu Glu Ala Cys Thr Phe His Lys His
            690                    695
```

```
<210> 55
<211> 400
<212> PRT
<213> Mouse

<400> 55
Gly Ala Pro Thr Pro Ala Tyr Val Arg Ser Ala Arg Arg Thr Glu Pro
  1               5                   10                  15
Leu Ala Ser Gly Ala Arg Ser Arg Leu Cys Gln Cys Arg Arg Val Pro
```

```
                   20                    25                    30
Ala Arg Lys Gln Gly Pro Gln Glu Gln Gly Gly Ser Gly Glu Ser Thr
        35                    40                    45
Thr Ser Ser Pro Gln Trp Trp Arg Arg Trp Arg Arg Leu Trp Ser Thr
        50                    55                    60
Cys Ser Cys Ser Ala Asp Asp Arg His Thr Gly Ser His Thr Asp Leu
65                        70                    75                    80
Lys Glu Glu Thr Pro Ser Trp Thr Gln Ile Ser Val Val Phe Arg Lys
                85                    90                    95
Asp Gly Gln Asp Glu Leu Gln Ala Ala His Lys Ala His Gly Ser Gly
            100                   105                   110
Ser Pro Leu Thr Asn Gln Glu Ile Pro Ser Ser Ser Gly Ser Gly Phe
        115                   120                   125
Ile Val Ser Glu Asp Gly Leu Ile Val Thr Asn Ala His Val Leu Thr
        130                   135                   140
Asn Gln Gln Lys Ile Gln Val Glu Leu Gln Ser Gly Ala Arg Tyr Glu
145                   150                   155                   160
Ala Thr Val Lys Asp Ile Asp His Lys Leu Asp Leu Ala Leu Ile Lys
                165                   170                   175
Ile Glu Pro Asp Thr Glu Leu Pro Val Leu Leu Leu Gly Arg Ser Ser
            180                   185                   190
Asp Leu Arg Ala Gly Glu Phe Val Val Ala Leu Gly Ser Pro Phe Ser
        195                   200                   205
Leu Gln Asn Thr Val Thr Ala Gly Ile Val Ser Thr Thr Gln Arg Gly
        210                   215                   220
Gly Arg Glu Leu Gly Leu Lys Asn Ser Asp Ile Asp Tyr Ile Gln Thr
225                   230                   235                   240
Asp Ala Ile Ile Asn His Gly Asn Ser Gly Gly Pro Leu Val Asn Leu
                245                   250                   255
Asp Gly Asp Val Ile Gly Ile Asn Thr Leu Lys Val Thr Ala Gly Ile
            260                   265                   270
Ser Phe Ala Ile Pro Ser Asp Arg Ile Arg Gln Phe Leu Glu Asp Tyr
        275                   280                   285
His Glu Arg Gln Leu Lys Gly Lys Ala Pro Leu Gln Lys Lys Tyr Leu
        290                   295                   300
Gly Leu Arg Met Leu Pro Leu Thr Leu Asn Leu Leu Gln Glu Met Lys
305                   310                   315                   320
Arg Gln Asp Pro Glu Phe Pro Asp Val Ser Ser Gly Val Phe Val Tyr
                325                   330                   335
Glu Val Ile Gln Gly Ser Ala Ala Ala Ser Ser Gly Leu Arg Asp His
            340                   345                   350
Asp Val Ile Val Ser Ile Asn Gly Gln Pro Val Thr Thr Thr Thr Asp
        355                   360                   365
Val Ile Glu Ala Val Lys Asp Asn Asp Phe Leu Ser Ile Ile Val Leu
        370                   375                   380
Arg Gly Ser Gln Thr Leu Phe Leu Thr Val Thr Pro Glu Ile Ile Asn
385                   390                   395                   400
```

<210> 56
<211> 174
<212> PRT
<213> Mouse

<400> 56
```
Met Pro Ala Cys Arg Leu Cys Leu Leu Ala Ala Gly Leu Leu Leu Gly
  1           5                   10                  15
Leu Leu Leu Phe Thr Pro Ile Ser Ala Thr Gly Thr Asp Ala Glu Lys
```

```
                  20                    25                    30
Pro Gly Glu Cys Pro Gln Leu Glu Pro Ile Thr Asp Cys Val Leu Glu
            35                    40                    45
Cys Thr Leu Asp Lys Asp Cys Ala Asp Asn Arg Lys Cys Cys Gln Ala
        50                    55                    60
Gly Cys Ser Ser Val Cys Ser Lys Pro Asn Gly Pro Ser Glu Gly Glu
65                    70                    75                    80
Leu Ser Gly Thr Asp Thr Lys Leu Ser Glu Thr Gly Thr Thr Thr Gln
                85                    90                    95
Ser Ala Gly Leu Asp His Thr Thr Lys Pro Pro Gly Gly Gln Val Ser
            100                   105                   110
Thr Lys Pro Pro Ala Val Thr Arg Glu Gly Leu Gly Val Arg Glu Lys
            115                   120                   125
Gln Gly Thr Cys Pro Ser Val Asp Ile Pro Lys Leu Gly Leu Cys Glu
            130                   135                   140
Asp Gln Cys Gln Val Asp Ser Gln Cys Ser Gly Asn Met Lys Cys Cys
145                   150                   155                   160
Arg Asn Gly Cys Gly Lys Met Ala Cys Thr Thr Pro Lys Phe
                165                   170
```

```
<210> 57
<211> 173
<212> PRT
<213> Mouse
```

```
<400> 57
Val Arg Asn Gly Asp Leu Phe Phe Lys Lys Val Gln Val Glu Asp Gly
1               5               10                    15
Gly Val Tyr Thr Cys Tyr Ala Met Gly Glu Thr Phe Asn Glu Thr Leu
            20                    25                    30
Ser Val Glu Leu Lys Val Tyr Asn Phe Thr Leu His Gly His His Asp
            35                    40                    45
Thr Leu Asn Thr Ala Tyr Thr Thr Leu Val Gly Cys Ile Leu Ser Val
        50                    55                    60
Val Leu Val Leu Ile Tyr Leu Tyr Leu Thr Pro Cys Arg Cys Trp Cys
65                    70                    75                    80
Arg Gly Val Glu Lys Pro Ser Ser His Gln Gly Asp Ser Leu Ser Ser
                85                    90                    95
Ser Met Leu Ser Thr Thr Pro Asn His Asp Pro Met Ala Gly Gly Asp
            100                   105                   110
Lys Asp Asp Gly Phe Asp Arg Arg Val Ala Phe Leu Glu Pro Ala Gly
            115                   120                   125
Pro Gly Gln Gly Gln Asn Gly Lys Leu Lys Pro Gly Asn Thr Leu Pro
            130                   135                   140
Val Pro Glu Ala Thr Gly Lys Gly Gln Arg Arg Met Ser Asp Pro Glu
145                   150                   155                   160
Ser Val Ser Ser Val Phe Ser Asp Thr Pro Ile Val Val
                165                   170
```

```
<210> 58
<211> 88
<212> PRT
<213> Mouse
```

```
<400> 58
Met Glu Glu Ile Thr Cys Ala Phe Leu Leu Leu Leu Ala Gly Leu Pro
1               5               10                    15
```

```
Ala Leu Glu Ala Ser Asp Pro Val Asp Lys Asp Ser Pro Phe Tyr Tyr
            20                  25              30
Asp Trp Glu Ser Leu Gln Leu Gly Gly Leu Ile Phe Gly Gly Leu Leu
            35              40              45
Cys Ile Ala Gly Ile Ala Met Ala Leu Ser Gly Lys Cys Lys Cys Arg
        50              55              60
Arg Thr His Lys Pro Ser Ser Leu Pro Gly Lys Ala Thr Pro Leu Ile
65              70              75              80
Ile Pro Gly Ser Ala Asn Thr Cys
                85
```

```
<210> 59
<211> 171
<212> PRT
<213> Mouse
```

```
<400> 59
Leu Ser Val Val Leu Gly Gly Thr Leu Tyr Ile Gly His Tyr Leu Ala
 1               5                  10                  15
Met Tyr Ser Glu Gly Ala Pro Phe Trp Thr Gly Ile Val Ala Met Leu
            20                  25              30
Ala Gly Ala Val Ala Phe Leu His Lys Lys Arg Gly Gly Thr Cys Trp
            35              40              45
Ala Leu Met Arg Thr Leu Leu Val Leu Ala Ser Phe Cys Thr Ala Val
        50              55              60
Ala Ala Ile Val Ile Gly Ser Arg Glu Leu Asn Tyr Tyr Trp Tyr Phe
65              70              75              80
Leu Gly Asp Asp Val Cys Gln Arg Asp Ser Ser Tyr Gly Trp Ser Thr
            85                  90                  95
Met Pro Arg Thr Thr Pro Val Pro Glu Glu Ala Asp Arg Ile Ala Leu
            100                 105                 110
Cys Ile Tyr Tyr Thr Ser Met Leu Lys Thr Leu Leu Met Ser Leu Gln
        115                 120                 125
Ala Met Leu Leu Gly Ile Trp Val Leu Leu Leu Ala Ser Leu Thr
        130             135             140
Pro Val Cys Val Tyr Ile Trp Lys Arg Phe Phe Thr Lys Ala Glu Thr
145                 150                 155                 160
Glu Glu Lys Lys Leu Leu Gly Ala Ala Val Ile
                165             170
```

```
<210> 60
<211> 318
<212> PRT
<213> Mouse
```

```
<400> 60
Met Leu Gln His Thr Ser Leu Val Leu Leu Leu Ala Ser Ile Trp Thr
 1               5                  10                  15
Thr Arg His Pro Val Gln Gly Ala Asp Leu Val Gln Asp Leu Ser Ile
            20                  25              30
Ser Thr Cys Arg Ile Met Gly Val Ala Leu Val Gly Arg Asn Lys Asn
        35              40              45
Pro Gln Met Asn Phe Thr Glu Ala Asn Glu Ala Cys Lys Met Leu Gly
        50              55              60
Leu Thr Leu Ala Ser Arg Asp Gln Val Glu Ser Ala Gln Lys Ser Gly
65              70              75              80
Phe Glu Thr Cys Ser Tyr Gly Trp Val Gly Glu Gln Phe Ser Val Ile
```

```
                     85                   90                   95
Pro Arg Ile Phe Ser Asn Pro Arg Cys Gly Lys Asn Gly Lys Gly Val
                100                 105                 110
Leu Ile Trp Asn Ala Pro Ser Ser Gln Lys Phe Lys Ala Tyr Cys His
                115                 120                 125
Asn Ser Ser Asp Thr Trp Val Asn Ser Cys Ile Pro Glu Ile Val Thr
                130                 135                 140
Thr Phe Tyr Pro Val Leu Asp Thr Gln Thr Pro Ala Thr Glu Phe Ser
145                 150                 155                 160
Val Ser Ser Ser Ala Tyr Leu Ala Ser Ser Pro Asp Ser Thr Thr Pro
                165                 170                 175
Val Ser Ala Thr Thr Arg Ala Pro Pro Leu Thr Ser Met Ala Arg Lys
                180                 185                 190
Thr Lys Lys Ile Cys Ile Thr Glu Val Tyr Thr Glu Pro Ile Thr Met
                195                 200                 205
Ala Thr Glu Thr Glu Ala Phe Val Ala Ser Gly Ala Ala Phe Lys Asn
210                 215                 220
Glu Ala Ala Gly Phe Gly Gly Val Pro Thr Ala Leu Leu Val Leu Ala
225                 230                 235                 240
Leu Leu Phe Phe Gly Ala Ala Ala Val Leu Ala Val Cys Tyr Val Lys
                245                 250                 255
Arg Tyr Val Lys Ala Phe Pro Phe Thr Thr Lys Asn Gln Gln Lys Glu
                260                 265                 270
Met Ile Glu Thr Lys Val Val Lys Glu Glu Lys Ala Asp Asp Val Asn
                275                 280                 285
Ala Asn Glu Glu Ser Lys Lys Thr Ile Lys Asn Pro Glu Glu Ala Lys
                290                 295                 300
Ser Pro Pro Lys Thr Thr Val Arg Cys Leu Glu Ala Glu Val
305                 310                 315
```

```
<210> 61
<211> 93
<212> PRT
<213> Mouse

<400> 61
Ala His Met Val Trp Ala Asn Leu Ala Val Phe Val Ile Cys Phe Leu
  1               5                  10                  15
Pro Leu His Val Val Leu Thr Val Gln Val Ser Leu Asn Leu Asn Thr
                20                  25                  30
Cys Ala Ala Arg Asp Thr Phe Ser Arg Ala Leu Ser Ile Thr Gly Lys
      35                  40                  45
Leu Ser Asp Thr Asn Cys Cys Leu Asp Ala Ile Cys Tyr Tyr Tyr Met
      50                  55                  60
Ala Arg Glu Phe Gln Glu Ala Ser Lys Pro Ala Thr Ser Ser Asn Thr
65                  70                  75                  80
Pro His Lys Ser Gln Asp Ser Gln Ile Leu Ser Leu Thr
                85                  90
```

```
<210> 62
<211> 408
<212> PRT
<213> Mouse

<400> 62
Met Ala Gln Leu Ala Arg Ala Thr Arg Ser Pro Leu Ser Trp Leu Leu
  1               5                  10                  15
```

```
Leu Leu Phe Cys Tyr Ala Leu Arg Lys Ala Gly Gly Asp Ile Arg Val
            20                  25                  30
Leu Val Pro Tyr Asn Ser Thr Gly Val Leu Gly Gly Ser Thr Thr Leu
        35                  40                  45
His Cys Ser Leu Thr Ser Asn Glu Asn Val Thr Ile Thr Gln Ile Thr
    50                  55                  60
Trp Met Lys Lys Asp Ser Gly Gly Ser His Ala Leu Val Ala Val Phe
65                  70                  75                  80
His Pro Lys Lys Gly Pro Asn Ile Lys Glu Pro Glu Arg Val Lys Phe
                85                  90                  95
Leu Ala Ala Gln Gln Asp Leu Arg Asn Ala Ser Leu Ala Ile Ser Asn
            100                 105                 110
Leu Ser Val Glu Asp Glu Gly Ile Tyr Glu Cys Gln Ile Ala Thr Phe
        115                 120                 125
Pro Arg Gly Ser Arg Ser Thr Asn Ala Trp Leu Lys Val Gln Ala Arg
    130                 135                 140
Pro Lys Asn Thr Ala Glu Ala Leu Glu Pro Ser Pro Thr Leu Ile Leu
145                 150                 155                 160
Gln Asp Val Ala Lys Cys Ile Ser Ala Asn Gly His Pro Pro Gly Arg
                165                 170                 175
Ile Ser Trp Pro Ser Asn Val Asn Gly Ser His Arg Glu Met Lys Glu
            180                 185                 190
Pro Gly Ser Gln Pro Gly Thr Thr Thr Val Thr Ser Tyr Leu Ser Met
        195                 200                 205
Val Pro Ser Arg Gln Ala Asp Gly Lys Asn Ile Thr Cys Thr Val Glu
    210                 215                 220
His Glu Ser Leu Gln Glu Leu Asp Gln Leu Leu Val Thr Leu Ser Gln
225                 230                 235                 240
Pro Tyr Pro Pro Glu Asn Val Ser Ile Ser Gly Tyr Asp Gly Asn Trp
                245                 250                 255
Tyr Val Gly Leu Thr Asn Leu Thr Leu Thr Cys Glu Ala His Ser Lys
            260                 265                 270
Pro Ala Pro Asp Met Ala Gly Tyr Asn Trp Ser Thr Asn Thr Gly Asp
        275                 280                 285
Phe Pro Asn Ser Val Lys Arg Gln Gly Asn Met Leu Leu Ile Ser Thr
    290                 295                 300
Val Glu Asp Gly Leu Asn Asn Thr Val Ile Val Cys Glu Val Thr Asn
305                 310                 315                 320
Ala Leu Gly Ser Gly Gln Gly Gln Val His Ile Ile Val Lys Glu Lys
                325                 330                 335
Pro Glu Asn Met Gln Gln Asn Thr Arg Leu His Leu Gly Tyr Ile Phe
            340                 345                 350
Leu Ile Val Phe Val Leu Ala Val Val Ile Ile Ile Ala Ala Leu Tyr
        355                 360                 365
Thr Ile Arg Arg Cys Arg His Gly Arg Ala Leu Gln Ser Asn Pro Ser
    370                 375                 380
Glu Arg Glu Asn Val Gln Tyr Ser Ser Val Asn Gly Asp Cys Arg Leu
385                 390                 395                 400
Asn Met Glu Pro Asn Ser Thr Arg
                405
```

<210> 63
<211> 278
<212> PRT
<213> Mouse

<400> 63

```
Met Phe Leu Val Gly Ser Leu Val Val Leu Cys Gly Leu Leu Ala His
1             5                 10                15
Ser Thr Ala Gln Leu Ala Gly Leu Pro Leu Pro Leu Gly Gln Gly Pro
            20              25                30
Pro Leu Pro Leu Asn Gln Gly Pro Pro Leu Pro Leu Asn Gln Gly Gln
        35              40              45
Leu Leu Pro Leu Ala Gln Gly Leu Pro Leu Ala Val Ser Pro Ala Leu
    50              55              60
Pro Ser Asn Pro Thr Asp Leu Leu Ala Gly Lys Phe Thr Asp Ala Leu
65              70              75              80
Ser Gly Gly Leu Leu Ser Gly Gly Leu Leu Gly Ile Leu Glu Asn Ile
            85              90              95
Pro Leu Leu Asp Val Ile Lys Ser Gly Gly Gly Asn Ser Asn Gly Leu
        100             105             110
Val Gly Gly Leu Leu Gly Lys Leu Thr Ser Ser Val Pro Leu Leu Asn
        115             120             125
Asn Ile Leu Asp Ile Lys Ile Thr Asp Pro Gln Leu Leu Glu Leu Gly
    130             135             140
Leu Val Gln Ser Pro Asp Gly His Arg Leu Tyr Val Thr Ile Pro Leu
145             150             155             160
Gly Leu Thr Leu Asn Val Asn Met Pro Val Val Gly Ser Leu Leu Gln
            165             170             175
Leu Ala Val Lys Leu Asn Ile Thr Ala Glu Val Leu Ala Val Lys Asp
            180             185             190
Asn Gln Gly Arg Ile His Leu Val Leu Gly Asp Cys Thr His Ser Pro
        195             200             205
Gly Ser Leu Lys Ile Ser Leu Leu Asn Gly Val Thr Pro Val Gln Ser
    210             215             220
Phe Leu Asp Asn Leu Thr Gly Ile Leu Thr Lys Val Leu Pro Glu Leu
225             230             235             240
Ile Gln Gly Lys Val Cys Pro Leu Val Asn Gly Ile Leu Ser Gly Leu
            245             250             255
Asp Val Thr Leu Val His Asn Ile Ala Glu Leu Leu Ile His Gly Leu
            260             265             270
Gln Phe Val Ile Lys Val
            275
```

```
<210>  64
<211>  264
<212>  PRT
<213>  Mouse
```

```
<400>  64
Met Ala Thr Thr Thr Cys Gln Val Val Gly Leu Leu Leu Ser Leu Leu
1             5                 10                15
Gly Leu Ala Gly Cys Ile Ala Ala Thr Gly Met Asp Met Trp Ser Thr
            20              25                30
Gln Asp Leu Tyr Asp Asn Pro Val Thr Ala Val Phe Gln His Glu Gly
        35              40              45
Leu Trp Arg Ser Cys Val Gln Gln Ser Ser Gly Phe Thr Glu Cys Arg
    50              55              60
Pro Tyr Phe Thr Ile Leu Gly Leu Pro Ala Met Leu Gln Ala Val Arg
65              70              75              80
Ala Leu Met Ile Val Gly Ile Val Leu Gly Val Ile Gly Ile Leu Val
            85              90              95
Ser Ile Phe Ala Leu Lys Cys Ile Arg Ile Gly Ser Met Asp Asp Ser
        100             105             110
```

```
Ala Lys Ala Lys Met Thr Leu Thr Ser Gly Ile Leu Phe Ile Ile Ser
        115             120             125
Gly Ile Cys Ala Ile Ile Gly Val Ser Val Phe Ala Asn Met Leu Val
        130             135             140
Thr Asn Phe Trp Met Ser Thr Ala Asn Met Tyr Ser Gly Met Gly Gly
145             150             155             160
Met Gly Gly Met Val Gln Thr Val Gln Thr Arg Tyr Thr Phe Gly Ala
                165             170             175
Ala Leu Phe Val Gly Trp Val Ala Gly Gly Leu Thr Leu Ile Gly Gly
            180             185             190
Val Met Met Cys Ile Ala Cys Arg Gly Leu Thr Pro Asp Asp Ser Asn
        195             200             205
Phe Lys Ala Val Ser Tyr His Ala Ser Gly Gln Asn Val Ala Tyr Arg
    210             215             220
Pro Gly Gly Phe Lys Ala Ser Thr Gly Phe Gly Ser Asn Thr Arg Asn
225             230             235             240
Lys Lys Ile Tyr Asp Gly Gly Ala Arg Thr Glu Asp Asp Glu Gln Ser
            245             250             255
His Pro Thr Lys Tyr Asp Tyr Val
            260
```

```
<210> 65
<211> 132
<212> PRT
<213> Mouse

<400> 65
Ala His Pro Arg Pro Gly Ala Arg Arg Pro Arg Leu Leu Ala Phe Gln
 1           5               10              15
Ala Ser Cys Ala Pro Ala Pro Gly Ser Arg Asp Arg·Cys Pro Glu Glu
        20              25              30
Gly Gly Pro Arg Cys Leu Arg Val Tyr Ala Gly Leu Ile Gly Thr Val
        35              40              45
Val Thr Pro Asn Tyr Leu Asp Asn Val Ser Ala Arg Val Ala Pro Trp
    50              55              60
Cys Gly Cys Ala Ala Ser Gly Asn Arg Arg Glu Glu Cys Glu Ala Phe
65              70              75              80
Arg Lys Leu Phe Thr Arg Asn Pro Cys Leu Asp Gly Ala Ile Gln Ala
            85              90              95
Phe Asp Ser Leu Gln Pro Ser Val Leu Gln Asp Gln Thr Ala Gly Cys
            100             105             110
Cys Phe Pro Arg Val Ser Trp Leu Tyr Ala Leu Thr Ala Leu Ala Leu
        115             120             125
Gln Ala Leu Leu
        130
```

```
<210> 66
<211> 764
<212> DNA
<213> Mouse

<400> 66
gcagcaccca gcgccaagcg caccaggcac cgcgacagac ggcaggagca cccatcgacg      60
ggcgtactgg agcgagccga gcagagcaga gagaggcgtg cttgaaaccg agaaccaagc     120
cgggcggcat cccccggccg ccgcacgcac aggccggcgc cctccttgcc tccctgctcc     180
ccaccgcgcc cctccggcca gcatgaggct cctggcggcc gcgctgctcc tgctgctcct     240
ggcgctgtgc gcctcgcgcg tggacgggtc caagtgtaag tgttcccgga aggggcccaa     300
```

```
gatccgctac agcgacgtga agaagctgga aatgaagcca aagtacccac actgcgagga      360
gaagatggtt atcgtcacca ccaagagcat gtccaggtac cggggccagg agcactgcct      420
gcaccctaag ctgcagagca ccaaacgctt catcaagtgg tacaatgcct ggaacgagaa      480
gcgcagggtc tacgaagaat agggtggacg atcatggaaa gaaaaactcc aggccagttg      540
agagacttca gcagaggact ttgcagatta aaataaaagc cctttctttc tcacaagcat      600
aagacaaatt atatattgct atgaagctct tcttaccagg gtcagttttt acattttata      660
gctgtgtgtg aaaggcttcc agatgtgaga tccagctcgc ctgcgcacca gacttcatta      720
caagtggctt tttgctgggc ggttggcggg gggcggggggg acct                       764
```

<210> 67
<211> 288
<212> DNA
<213> Human

<400> 67
```
gcggccgcgc tgctcctgct gctgctggcg ctgtacaccg cgcgtgtgga cgggtccaaa       60
tgcaagtgct cccggaaggg acccaagatc cgctacagcg acgtgaagaa gctggaaatg      120
aagccaaagt acccgcactg cgaggagaag atggttatca tcaccaccaa gagcgtgtcc      180
aggtaccgag gtcaggagca ctgcctgcac cccaagctgc agagcaccaa gcgcttcatc      240
aagtggtaca acgcctggaa cgagaagcgc agggtctacg aagaatag                    288
```

<210> 68
<211> 95
<212> PRT
<213> Human

<400> 68
```
Ala Ala Ala Leu Leu Leu Leu Leu Leu Ala Leu Tyr Thr Ala Arg Val
1               5                   10                  15
Asp Gly Ser Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr
            20                  25                  30
Ser Asp Val Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu
        35                  40                  45
Glu Lys Met Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly
    50                  55                  60
Gln Glu His Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile
65                  70                  75                  80
Lys Trp Tyr Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu
            85                  90                  95
```

<210> 69
<211> 234
<212> DNA
<213> Mouse

<400> 69
```
tccaagtgta agtgttcccg gaaggggccc aagatccgct acagcgacgt gaagaagctg       60
gaaatgaagc caaagtaccc acactgcgag gagaagatgg ttatcgtcac caccaagagc      120
atgtccaggt accggggcca ggagcactgc ctgcacccta agctgcagag caccaaacgc      180
ttcatcaagt ggtacaatgc ctggaacgag aagcgcaggg tctacgaaga atag            234
```

<210> 70
<211> 77
<212> PRT
<213> Mouse

<400> 70
```
```

```
Ser Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp
1               5               10              15
Val Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys
            20              25              30
Met Val Ile Val Thr Thr Lys Ser Met Ser Arg Tyr Arg Gly Gln Glu
        35              40              45
His Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp
    50              55              60
Tyr Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu
65              70              75
```

<210> 71
<211> 234
<212> DNA
<213> Human

<400> 71
```
tccaaatgca agtgctcccg gaagggaccc aagatccgct acagcgacgt gaagaagctg      60
gaaatgaagc caaagtaccc gcactgcgag gagaagatgg ttatcatcac caccaagagc     120
gtgtccaggt accgaggtca ggagcactgc ctgcacccca agctgcagag caccaagcgc     180
ttcatcaagt ggtacaacgc ctggaacgag aagcgcaggg tctacgaaga atag           234
```

<210> 72
<211> 77
<212> PRT
<213> Human

<400> 72
```
Ser Lys Cys Lys Cys Ser Arg Lys Gly Pro Lys Ile Arg Tyr Ser Asp
1               5               10              15
Val Lys Lys Leu Glu Met Lys Pro Lys Tyr Pro His Cys Glu Glu Lys
            20              25              30
Met Val Ile Ile Thr Thr Lys Ser Val Ser Arg Tyr Arg Gly Gln Glu
        35              40              45
His Cys Leu His Pro Lys Leu Gln Ser Thr Lys Arg Phe Ile Lys Trp
    50              55              60
Tyr Asn Ala Trp Asn Glu Lys Arg Arg Val Tyr Glu Glu
65              70              75
```

<210> 73
<211> 1460
<212> DNA
<213> Pinus radiata

<400> 73
```
aaaacgtcca tagcttcctt gccaactgca agcaatacag tacaagagcc agacgatcga      60
atcctgtgaa gtggttctga agtgatggga agcttggaat ctgaaaaaac tgttacagga     120
tatgcagctc gggactccag tggccacttg tcccccttaca cttacaatct cagaaagaaa    180
ggacctgagg atgtaattgt aaaggtcatt tactgcggaa tctgccactc tgatttagtt     240
caaatgcgta atgaaatgga catgtctcat tacccaatgg tccctgggca tgaagtggtg     300
gggattgtaa cagagattgg cagcgaggtg aagaaattca aagtgggaga gcatgtaggg     360
gttggttgca ttgttgggtc ctgtcgcagt tgcggtaatt gcaatcagag catggaacaa     420
tactgcagca gaggatttg gacctacaat gatgtgaacc atgacggcac acctactcag      480
ggcggatttg caagcagtat ggtggttgat cagatgtttg tggttcgaat cccggagaat     540
cttcctctgg aacaagcggc ccctctgtta tgtgcagggg ttacagtttt cagcccaatg     600
aagcatttcg ccatgacaga gcccgggaag aaatgtggga ttttgggttt aggaggcgtg     660
gggcacatgg gtgtcaagat tgccaaagcc tttggactcc acgtgacggt tatcagttcg     720
```

```
tctgataaaa agaaagaaga agccatggaa gtcctcggcg ccgatgctta tcttgttagc    780
aaggatactg aaaagatgat ggaagcagca gagagcctag attacataat ggacaccatt    840
ccagttgctc atcctctgga accatatctt gcccttctga agacaaatgg aaagctagtg    900
atgctgggcg ttgttccaga gccgttgcac ttcgtgactc ctctcttaat acttgggaga    960
aggagcatag ctggaagttt cattggcagc atggaggaaa cacaggaaac tctagatttc   1020
tgtgcagaga agaaggtatc atcgatgatt gaggttgtgg gcctggacta catcaacacg   1080
gccatggaaa ggttggagaa gaacgatgtc cgttacagat ttgtggtgga tgttgctaga   1140
agcaagttgg ataattagtc tgcaatcaat caatcagatc aatgcctgca tgcaagatga   1200
atagatctgg actagtagct taacatgaaa gggaaattaa atttttattt aggaactcga   1260
tactggtttt tgttactttа gtttagcttt tgtgaggttg aaacaattca gatgtttttt   1320
taacttgtat atgtaaagat caatttctcg tgacagtaaa taataatcca atgtcttctg   1380
ccaaattaat atatgtattc gtattttat atgaaaaaaa aaaaaaaaaa aaaaaaaaaa   1440
aaaaaaaaaa aaaaaaaaaa                                               1460
```

<210> 74
<211> 363
<212> DNA
<213> Eucalyptus grandis

<400> 74
```
aaagcaacac attgaactct ctctctctct ctctctctct ctctctctct ccccccacccc     60
cccttcccaa ccccacccac atacagacaa gtagatacgc gcacacagaa gaagaaaaga    120
tgggggtttc aatgcagtca atcgcactag cgacggttct ggccgtccta acgacatggg    180
cgtggagggc ggtgaactgg gtgtggctga ggccgaagag gctcgagagg cttctgagac    240
agcaaggtct ctccggcaag tcctacacct tcctggtcgg cgacctcaag gagaacctgc    300
ggatgctcaa ggaagccaag tccaagccca tcgccgtctc cgatgacatc aagcctcgtc    360
tct                                                                 363
```

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ00/00256

A.	**CLASSIFICATION OF SUBJECT MATTER**

Int. Cl. [7]:   C12N 15/11

According to International Patent Classification (IPC) or to both national classification and IPC

B.	**FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)
SEE ELECTRONIC DATA BASES

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
SEE ELECTRONIC DATA BASES

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EMBL, GenBank, PIR , GenePept: Sequence IDs 1, 36, 2, 37, 3, 38, 4, 39, 5, 40

C.	**DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenBank Accession No. AL034558 28 July 1999 Whole Sequence w.r.t. Sequence ID 3	1 - 14
X	GenPept Accession No. CAA29045 21 March 1995 Whole Seqence Frame +2 w.r.t. Sequence ID 4	1 - 14
X	GenBank Accession No. AR018857 5 December 1998 & US 5783182 Whole Sequence w.r.t. Seqence ID 5	1 - 14

[X] Further documents are listed in the continuation of Box C	[X] See patent family annex

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
28 March 2001	**29.03.2001**

Name and mailing address of the ISA/AU	Authorized officer
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	**CRAIG ALLATT** Telephone No : (02) 6283 2414

C (Continuation).	DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenPept Accession No. CAB40181 14 December 1999 Whole Seqeunce w.r.t. Sequence ID 40	1 - 14

Box I	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :

   because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos :

   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos :

   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

   See Supplemental Box

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

   Claims 1 - 14 partially.(See Supplemental Box)

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ00/00256

Supplemental Box
(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

In the present application, the feature that all sequences come from "mammalian sources" does not provide a special technical feature. Genes and their expressed proteins from "mammalian sources" have been sequenced. Cells from "mammalian sources" comprise a variety of different animals and cell types. Moreover the applicant has provided no evidence that the nucleotide sequences of the present application, and the peptides they express, form a unique group of protein types. On the contrary, putative peptides derived from the nucleotide sequences of the application have functions assigned on the basis of their similarity to known proteins expressed by a variety of cell types.

The applicant has grouped the polynucleotides of the application into activity categories according to putative functions of the proteins they encode. However, most of the applicants' groupings do not form a homogenous set of proteins either in structure or function. Moreover, it is noted that most of the peptides encoded by the polynucleotides are assigned to more than one activity category.

The ISA considers that each nucleotide/peptide sequence pair (defined in Table 1 pages 8 - 19) comprises one invention and that there are 35 different inventions (the inventions being numbered sequentially).

However, as a service to the applicants, the ISA will search the first five inventions without inviting additional search fees.

Therefore the ISA has searched SEQ IDs 1, 36, 2, 37, 3, 38, 4, 39, 5, and 40.

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
US	5783182	AU	11609/97	CA	2237929	EP	870057
		WO	9718454				

END OF ANNEX